1 00:01:03,850 --> 00:01:06,619 >> I WOULD LIKE TO INTRODUCE THE 2 00:01:06,619 --> 00:01:09,922 SESSION CHAIR IS A COLLEAGUE OF 3 00:01:09,922 --> 00:01:11,324 MINE ALSO FROM NIBIB. 4 00:01:11,324 --> 00:01:21,501 >> OKAY. 5 00:01:21,801 --> 00:01:23,736 >> THANK YOU, OUR FIRST SPEAKER 6 00:01:23,736 --> 00:01:26,339 THIS MORNING IS DR. TATIANA 7 00:01:26,339 --> 00:01:29,008 COHEN, SCIENTIFIC REVIEW OFFICER 8 00:01:29,008 --> 00:01:32,512 FOR TECHNOLOGIES WHICH IS ONE OF 9 00:01:32,512 --> 00:01:34,113 PREDOMINANT SYNTHETIC BIOLOGY 10 00:01:34,113 --> 00:01:37,884 STUDY SESSIONS AND SHE'S HERE TO 11 00:01:37,884 --> 00:01:48,428 ASSESS THE CRC REVIEW. MORNING 12 00:01:49,729 --> 00:01:51,330 CAN YOU HEAR ME, MORNING AND 13 00:01:51,330 --> 00:01:52,865 THANK YOU FOR INVITING ME TO 14 00:01:52,865 --> 00:01:54,100 PARTICIPATE IN THIS MEETING AND 15 00:01:54,100 --> 00:01:59,372 TELL YOU ABOUT NIH PEER REVIEW. 16 00:01:59,372 --> 00:02:03,209 SO THE MISSION OF NIH IS TO 17 00:02:03,209 --> 00:02:05,344 PROMOTE FUNDAMENTAL KNOWLEDGE OF 18 00:02:05,344 --> 00:02:07,880 LIVING THINGS. AND TO USE THAT 19 00:02:07,880 --> 00:02:10,316 KNOWLEDGE TO ADVANCE HEALTH. 20 00:02:10,316 --> 00:02:12,251 AND SO THIS MISSION IS 21 00:02:12,251 --> 00:02:13,753 ACCOMPLISHED THROUGH FUNDING 22 00:02:13,753 --> 00:02:19,258 THAT'S OFFERED TO 27 NIH 23 00:02:19,258 --> 00:02:29,101 INSTITUTES. MY -- OF THESE 27 24 00:02:29,101 --> 00:02:29,735 INSTITUTES AND CENTERS THERE ARE 25 00:02:29,735 --> 00:02:30,736 24 THAT ACTUALLY PROVIDE 26 00:02:30,736 --> 00:02:33,172 FUNDING. SO THOSE ARE HERE. IN 27 00:02:33,172 --> 00:02:34,340 BLUE. BUT THERE'S ALSO THREE 28 00:02:34,340 --> 00:02:37,043 THAT DID NOT PROVIDE FUNDING BUT 29 00:02:37,043 --> 00:02:38,678 ARE INVOLVED IN OTHER THINGS AND 30 00:02:38,678 --> 00:02:40,646 SO ONE OF THESE IS THE CENTER 31 00:02:40,646 --> 00:02:44,383 FOR SCIENTIFIC REVIEW. SO 32 00:02:44,383 --> 00:02:47,320 THAT'S WHERE I'M FROM. SO THE 33 00:02:47,320 --> 00:02:51,524 MEGS MISSION OF CSR CENTER FOR 34 00:02:51,524 --> 00:03:00,032 SCIENTIFIC REVIEW IS TO INSHURE 35 00:03:00,032 --> 00:03:07,073 AND WE ACCOMPLISH THROUGH THE 36 00:03:07,073 --> 00:03:08,674 APPLICATIONS. WE REVIEW 37 00:03:08,674 --> 00:03:12,378 ABOUT -- WE CONDUCT ABOUT 2,000 38 00:03:12,378 --> 00:03:15,314 OF MEETINGS. TO THE THREE 39 00:03:15,314 --> 00:03:16,816 CYCLES AND THIS REVIEW IS 40 00:03:16,816 --> 00:03:18,551 ACCOMPLISHED THROUGH THE HELP OF 41 00:03:18,551 --> 00:03:22,522 ABOUT 270 SCIENTIFIC REVIEW 42 00:03:22,522 --> 00:03:25,525 OFFICERS. SUCH AS MYSELF. SO 43 00:03:25,525 --> 00:03:27,326 THIS IS KIND OF A BREAKDOWN OF 44 00:03:27,326 --> 00:03:29,562 THE TYPES OF APPLICATIONS THAT 45 00:03:29,562 --> 00:03:35,902 WE REVIEW THE MAJORITY ARE WE 46 00:03:35,902 --> 00:03:37,169 ARE FAMILIAR W. THESE ARE 47 00:03:37,169 --> 00:03:40,439 TYPICAL FOUR OR FIVE YEAR GRANTS 48 00:03:40,439 --> 00:03:43,309 250K BUDGET ANABOLIC. WE DO 49 00:03:43,309 --> 00:03:44,844 ALSO REVIEW OTHER GRANT 50 00:03:44,844 --> 00:03:49,415 MECHANISMS. SO OF THESE, A GRAY 51 00:03:49,415 --> 00:03:55,221 PROPORTION IS RO 21, R 03 AND 52 00:03:55,221 --> 00:03:57,256 TRAINING GRANTS WE ALSO REVIEW 53 00:03:57,256 --> 00:03:58,858 FELLOWSHIP APPLICATION FOR 54 00:03:58,858 --> 00:04:03,362 GRADUATE STUDENTS OR POSTDOCS 55 00:04:03,362 --> 00:04:07,900 AND ALSO APPLICATIONS WE TALKED 56 00:04:07,900 --> 00:04:11,270 THE OTHER DAY ABOUT THE 57 00:04:11,270 --> 00:04:13,539 POSSIBILITY OF INVOLVING SMALLER 58 00:04:13,539 --> 00:04:14,540 BUSINESSES. I WOULD LIKE TO 59 00:04:14,540 --> 00:04:15,775 TALK TO YOU ABOUT IT AFTERWARDS 60 00:04:15,775 --> 00:04:17,076 IF YOU WOULD LIKE. THERE'S A 61 00:04:17,076 --> 00:04:19,845 LOT OF NICE OPPORTUNITIES THERE 62 00:04:19,845 --> 00:04:22,848 FOR SMALL BUSINESS, SOMEWHERE 63 00:04:22,848 --> 00:04:28,854 PHASE ONE APPLICATIONS, AND THE 64 00:04:28,854 --> 00:04:30,723 COMMERCIALIZATION READINESS 65 00:04:30,723 --> 00:04:34,927 PROGRAM. SO THIS IS THE TYPICAL 66 00:04:34,927 --> 00:04:38,598 CYCLE FOR HOW THE REVIEW 67 00:04:38,598 --> 00:04:39,298 MEETINGS ARE SET UP. THIS KIND 68 00:04:39,298 --> 00:04:41,133 OF GIVES YOU A PERSPECTIVE ON 69 00:04:41,133 --> 00:04:42,902 THE TIMELINES THAT ARE INVOLVED. 70 00:04:42,902 --> 00:04:47,807 SO YOU CAN SEE A STTYPICAL CYCL 71 00:04:47,807 --> 00:04:49,408 MIGHT TAKE A YEAR. FROM THE 72 00:04:49,408 --> 00:04:51,110 ONSET OF WHEN THE APPLICATIONS 73 00:04:51,110 --> 00:04:56,415 ARE FIRST RECEIVED AND ASSIGNED 74 00:04:56,415 --> 00:04:59,318 TO SICIENTIICIENTIFIC REVIEW GR 75 00:04:59,318 --> 00:05:00,653 AN OPPORTUNITY FOR THE REVIEWERS 76 00:05:00,653 --> 00:05:02,288 TO BE ASSEMBLED INTO A PANEL TO 77 00:05:02,288 --> 00:05:04,523 REVIEW THE APPLICATIONS. 78 00:05:04,523 --> 00:05:06,125 TYPICALLY THAT TAKES SEVERAL 79 00:05:06,125 --> 00:05:08,594 MONTHS. AND THEN ONCE WE ARE 80 00:05:08,594 --> 00:05:11,297 DONE WITH THE REVIEW, THE TWO 81 00:05:11,297 --> 00:05:16,502 PHASE NIH REVIEW ALLOWS FOR THE 82 00:05:16,502 --> 00:05:19,038 NEXT PHASE TO COME IN SO WE ARE 83 00:05:19,038 --> 00:05:20,673 PHASE ONE WHERE APPLICATIONS ARE 84 00:05:20,673 --> 00:05:22,675 REVIEWED FOR SCIENTIFIC MERIT 85 00:05:22,675 --> 00:05:26,879 AND THAT IS OUR ONLY JOB AND 86 00:05:26,879 --> 00:05:28,314 AFTER THE REVIEW IT GOES ONTO 87 00:05:28,314 --> 00:05:31,150 THE NIC WHERE THAT APPLICATION 88 00:05:31,150 --> 00:05:32,652 AND ITS FORE IS THEN CONSIDERED 89 00:05:32,652 --> 00:05:34,687 FOR FUNDING. SO WE DON'T HAVE 90 00:05:34,687 --> 00:05:36,222 ANYTHING TO DO WITH FUNDING. 91 00:05:36,222 --> 00:05:38,190 AND THEN TO BREAK THIS UP INTO 92 00:05:38,190 --> 00:05:42,595 SORT OF WHERE THIS GOES, THE 93 00:05:42,595 --> 00:05:43,329 FIRST PART OF THIS IS 94 00:05:43,329 --> 00:05:47,133 APPLICATIONS COMING IN TO THE 95 00:05:47,133 --> 00:05:47,800 DIVISION OF RECEIPT AND REFERRAL 96 00:05:47,800 --> 00:05:49,869 SO THIS THE IS FIRST SORT OF SET 97 00:05:49,869 --> 00:05:52,071 OF EYES THAT SEIZE THESE 98 00:05:52,071 --> 00:05:52,972 APPLICATIONS. AND DETERMINES 99 00:05:52,972 --> 00:05:55,307 HOW TO ASSIGN THE APPLICATION TO 100 00:05:55,307 --> 00:05:58,344 THE IC, AND THEN MAKES INITIAL 101 00:05:58,344 --> 00:06:00,312 DETERMINATIONS AS TO THE 102 00:06:00,312 --> 00:06:01,313 SCIENTIFIC DISCIPLINE INTO WHICH 103 00:06:01,313 --> 00:06:02,481 THIS APPLICATION MIGHT FALL 104 00:06:02,481 --> 00:06:03,449 INTO. SO WHICH SCIENTIFIC GROUP 105 00:06:03,449 --> 00:06:07,286 TO ASSIGN IT TO. THEN ONCE IT'S 106 00:06:07,286 --> 00:06:11,190 ASSIGNED THEN THE SRO THEN 107 00:06:11,190 --> 00:06:12,491 STARTS LOOKING OVER THE 108 00:06:12,491 --> 00:06:14,326 APPLICATION AND MAKING A 109 00:06:14,326 --> 00:06:15,294 DETERMINATION OF WHAT KIND OF 110 00:06:15,294 --> 00:06:23,602 EXPERTISE IS NEEDED. IF IT'S A 111 00:06:23,602 --> 00:06:25,404 STANDING PANEL A LARGE 112 00:06:25,404 --> 00:06:27,173 PROPORTION OF THE REVIEWERS ARE 113 00:06:27,173 --> 00:06:28,441 STANDING MEMBERS THAT ARE 114 00:06:28,441 --> 00:06:29,542 NOMINATED AND ELECTED TO BE -- 115 00:06:29,542 --> 00:06:31,310 THEY USED TO BE CALLED PERMANENT 116 00:06:31,310 --> 00:06:32,945 MEMBERS BUT THEY ACTUALLY SERVE 117 00:06:32,945 --> 00:06:36,482 ANYWHERE BETWEEN 4-6 YEARS AND 118 00:06:36,482 --> 00:06:39,318 THEY COME TO EVERY MEETING AND 119 00:06:39,318 --> 00:06:41,020 ANOTHER SMALLER LESS THAN HALF 120 00:06:41,020 --> 00:06:42,488 PROPORTION OF THEM WILL BE AD 121 00:06:42,488 --> 00:06:44,690 HOCS, REVIEWERS THAT COME IN TO 122 00:06:44,690 --> 00:06:46,459 PROVIDE ADDITIONAL EXPERTISE AND 123 00:06:46,459 --> 00:06:49,829 FINISH THE REVIEW OF THE 124 00:06:49,829 --> 00:06:53,632 APPLICATIONS. SO WE WILL ASSIGN 125 00:06:53,632 --> 00:06:54,900 THESE APPLICATIONS. AND GIVE 126 00:06:54,900 --> 00:06:58,304 THE REVIEWERS ABOUT TWO MONTHS 127 00:06:58,304 --> 00:07:05,544 TO REVIEW THEN THE MEETING TAKES 128 00:07:05,544 --> 00:07:06,912 PLACE OVER TWO DAYS AFTER WHICH 129 00:07:06,912 --> 00:07:08,481 50% OF THE APPLICATIONS ARE 130 00:07:08,481 --> 00:07:09,749 DISCUSSED SO WE NEVER DISCUSS 131 00:07:09,749 --> 00:07:11,550 100% OF THE APPLICATIONS. THE 132 00:07:11,550 --> 00:07:13,552 APPLICATIONS ARE SORTED FROM 133 00:07:13,552 --> 00:07:15,121 BEST TO WORST AND THEN THE TOP 134 00:07:15,121 --> 00:07:17,790 50% TYPICALLY ARE DISCUSSED. 135 00:07:17,790 --> 00:07:20,659 AND THEN AFTER THAT DISCUSSION, 136 00:07:20,659 --> 00:07:24,230 THEN THE SRO WRITES THE RESUME 137 00:07:24,230 --> 00:07:26,165 AND THE SUMMARY OF DISCUSSION. 138 00:07:26,165 --> 00:07:29,001 SO THE REVIEWERS PROVIDE THE 139 00:07:29,001 --> 00:07:30,536 CRITIQUES, THEY PROVIDE THE 140 00:07:30,536 --> 00:07:32,304 INDIVIDUAL CRITIQUES FOR EACH 141 00:07:32,304 --> 00:07:34,440 APPLICATION AND THEN THE 142 00:07:34,440 --> 00:07:36,041 DISCUSSION SUMMARY IS PROVIDE BY 143 00:07:36,041 --> 00:07:38,377 THE SRO, AFTER THAT, THE 144 00:07:38,377 --> 00:07:41,313 APPLICATION'S RELEASED TO THE -- 145 00:07:41,313 --> 00:07:43,115 OR THE SUMMARY STATE IS RELEASED 146 00:07:43,115 --> 00:07:45,985 TO THE APPLICANT AND THE IC AND 147 00:07:45,985 --> 00:07:47,520 THAT'S WHERE THE SECOND PHASE 148 00:07:47,520 --> 00:07:50,089 OCCURS WHERE THE IC MAKES A 149 00:07:50,089 --> 00:07:50,856 DETERMINATION BASED ON THEIR PAY 150 00:07:50,856 --> 00:07:55,995 LINES OR OTHER CONSIDERATIONS. 151 00:07:55,995 --> 00:07:57,129 LET'S BREAK THIS DOWN A LITTLE 152 00:07:57,129 --> 00:07:59,565 BIT FURTHER SO THE DIVISION OF 153 00:07:59,565 --> 00:08:01,000 RECEIPT AND REFERRAL, THIS 154 00:08:01,000 --> 00:08:04,737 OFFICE DETERMINES WHETHER THE 155 00:08:04,737 --> 00:08:06,505 APPLICATION IS ACTUALLY ELIGIBLE 156 00:08:06,505 --> 00:08:08,808 FOR WHAT IT IS PROPOSING TO DO. 157 00:08:08,808 --> 00:08:10,209 IF IT'S SUBMITTED TO A 158 00:08:10,209 --> 00:08:12,912 PARTICULAR RFA OR A PARENT 159 00:08:12,912 --> 00:08:14,413 ANNOUNCEMENT, WHETHER ALL OF THE 160 00:08:14,413 --> 00:08:17,983 PARTS ARE IN PLACE SO THAT IT 161 00:08:17,983 --> 00:08:21,053 CAN BE ACCEPTED AND AS I 162 00:08:21,053 --> 00:08:23,656 MENTIONED JUST BEFORE, IT ALSO 163 00:08:23,656 --> 00:08:27,226 MAKES THE DETERMINATION OF WHICH 164 00:08:27,226 --> 00:08:30,629 IC THAT APPLICATION WILL BE 165 00:08:30,629 --> 00:08:33,332 REFERRED TO. SOMETIMES THEY 166 00:08:33,332 --> 00:08:34,934 RECOMMEND A PREFERRED IC THAT 167 00:08:34,934 --> 00:08:37,102 MAY OR MAY NOT ALWAYS COINCIDE 168 00:08:37,102 --> 00:08:41,807 WITH WHAT THAT MISSION IS AND SO 169 00:08:41,807 --> 00:08:43,909 DRR WILL NEGOTIATE TO MAKE THE 170 00:08:43,909 --> 00:08:44,510 DETERMINATION OF WHETHER THE 171 00:08:44,510 --> 00:08:46,812 APPLICATION FALLS INTO THAT IC'S 172 00:08:46,812 --> 00:08:49,081 PROBLEMATIC GOALS OR NOT. 173 00:08:49,081 --> 00:08:50,416 SOMETIMES A SECOND IC MIGHT BE 174 00:08:50,416 --> 00:08:53,485 ASSIGNED AS WELL IF THE FIRST IC 175 00:08:53,485 --> 00:08:54,587 FOR EXAMPLE DECLINES OR IF AFTER 176 00:08:54,587 --> 00:08:57,656 THE REVIEW, THERE IS A DECISION 177 00:08:57,656 --> 00:08:59,325 MADE THAT FUNDING NEEDS TO BE 178 00:08:59,325 --> 00:09:01,727 ALLOCATED DIFFERENTLY THAN A 179 00:09:01,727 --> 00:09:03,929 SECONDARY IC MIGHT PLAY A ROLE 180 00:09:03,929 --> 00:09:06,866 IN THAT CASE. AND THEN DRR ALSO 181 00:09:06,866 --> 00:09:09,301 ASSIGNS, IS ONE OF THE INITIAL 182 00:09:09,301 --> 00:09:10,836 ASSIGNMENTS TO THE SIDE REVIEW 183 00:09:10,836 --> 00:09:14,840 GROUP. OUR GROUPS ARE ORGANIZED 184 00:09:14,840 --> 00:09:16,742 INTO BRANCHES, AND DIVISIONS, SO 185 00:09:16,742 --> 00:09:19,411 AFTER THAT DETERMINATION IS 186 00:09:19,411 --> 00:09:21,714 MADE, THE APPLICATION THEN GOES 187 00:09:21,714 --> 00:09:24,083 TO THE BRANCH WHEN IT IS FURTHER 188 00:09:24,083 --> 00:09:25,451 CATEGORIZED. IF IT'S A 189 00:09:25,451 --> 00:09:26,952 RESUBMISSION THEN IT'S LIKELY TO 190 00:09:26,952 --> 00:09:28,687 JUST COME STRAIGHT TO THE STUDY 191 00:09:28,687 --> 00:09:31,724 SECTION WHERE IT WAS FIRST 192 00:09:31,724 --> 00:09:37,930 REVIEWED. SO THIS IS THE STUDY 193 00:09:37,930 --> 00:09:41,567 SECTION THAT I RUN THIS HAS 23 194 00:09:41,567 --> 00:09:43,302 STANDING REGULAR MEMBERS IF YOU 195 00:09:43,302 --> 00:09:47,239 WILL. AND THEN AS I MENTIONED 196 00:09:47,239 --> 00:09:48,807 THE REST ARE AD HOCS WE RECEIVE 197 00:09:48,807 --> 00:09:51,443 ABOUT 80-90 APPLICATIONS PER 198 00:09:51,443 --> 00:09:52,478 ROUND AND THAT'S APPEAR 199 00:09:52,478 --> 00:09:53,112 IMPORTANT NUMBER TO KEEP IN MIND 200 00:09:53,112 --> 00:09:54,914 IF YOU WANT TO THINK ABOUT HOW 201 00:09:54,914 --> 00:09:58,083 YOUR APPLICATION WILL BE 202 00:09:58,083 --> 00:10:03,355 EVALUATED AGAINST OTHERS. THERE 203 00:10:03,355 --> 00:10:05,557 MIGHT BE OTHER APPLICATIONS THAT 204 00:10:05,557 --> 00:10:10,095 ARE CONSIDERED AND IT MUST BE 205 00:10:10,095 --> 00:10:11,664 RELATIVE. IT'S HOW IT'S RELATED 206 00:10:11,664 --> 00:10:19,038 TO THE SCIENCE NOT TO LIST -- 207 00:10:19,038 --> 00:10:19,371 EACH OTHER. 208 00:10:19,371 --> 00:10:23,309 WE HAVE THE SYSTEMS, LIVING CELL 209 00:10:23,309 --> 00:10:25,878 DEVICES, ORGANOIDS, MICRO IF A 210 00:10:25,878 --> 00:10:29,348 LITTIC DEVICE FOR SELF CULTURE, 211 00:10:29,348 --> 00:10:31,250 PROBES FOR MOLECULAR PROCESSES, 212 00:10:31,250 --> 00:10:35,321 SO FLUORESCENT PROBES, PARTICLE, 213 00:10:35,321 --> 00:10:38,624 THINGS LIKE THAT. MUTUAL AND 214 00:10:38,624 --> 00:10:39,725 METHODS FOR CELL ENGINEER SO 215 00:10:39,725 --> 00:10:41,927 THIS IS RELEVANT FOR THIS 216 00:10:41,927 --> 00:10:44,797 CONFERENCE TODAY. SO SYNTHETIC 217 00:10:44,797 --> 00:10:46,332 BIOLOGY, AS WELL AS TOOLS FOR 218 00:10:46,332 --> 00:10:48,934 MEASURING CELLULAR FUNCTION, 219 00:10:48,934 --> 00:10:50,836 EXTRACELLULAR MANIPULATION AND 220 00:10:50,836 --> 00:10:55,774 THINGS LIKE THAT. MICROFLUIDIC 221 00:10:55,774 --> 00:10:56,408 TECHNOLOGIES. SO TECHNOLOGIES 222 00:10:56,408 --> 00:11:00,446 AND DEVICES FOR CAPTURING AND 223 00:11:00,446 --> 00:11:02,381 MANIPULATING CELLS, BIO 224 00:11:02,381 --> 00:11:04,149 PRINTING, CELL SORTING, THINGS 225 00:11:04,149 --> 00:11:07,319 LIKE THAT AND ALONG WITH CELL 226 00:11:07,319 --> 00:11:08,687 ALSO EXTRACELLULAR VESICLES 227 00:11:08,687 --> 00:11:11,623 WOULD FALL INTO THIS CATEGORY. 228 00:11:11,623 --> 00:11:14,493 NEW METHODS AND TECHNIQUES FOR 229 00:11:14,493 --> 00:11:16,362 PRESERVING CELLS THINGS LIKE BIO 230 00:11:16,362 --> 00:11:19,732 REACTORS, CRYO BIOLOGY, BIO 231 00:11:19,732 --> 00:11:21,166 STABILIZATION, BIO PRESERVATION 232 00:11:21,166 --> 00:11:22,835 AND OTHER TYPES OF METHODS. 233 00:11:22,835 --> 00:11:24,603 AND THEN DEVELOPMENT AND 234 00:11:24,603 --> 00:11:26,772 ADVANCEMENT OF MICROSCOPY AND 235 00:11:26,772 --> 00:11:28,273 HIGH RESOLUTION IMAGING SO 236 00:11:28,273 --> 00:11:30,843 THINGS LIKE SUPER RESOLUTION 237 00:11:30,843 --> 00:11:32,478 IMAGING TECHNIQUES, SOMETIMES 238 00:11:32,478 --> 00:11:36,248 OCT, OTHER TYPES OF HIGH 239 00:11:36,248 --> 00:11:44,823 RESOLUTION MICROSCOPY. THIS IS 240 00:11:44,823 --> 00:11:45,424 KIND OF A GENERAL GUIDELINE 241 00:11:45,424 --> 00:11:47,326 ALTHOUGH YOU CAN APPLY IT. SO 242 00:11:47,326 --> 00:11:49,528 THE MAKEUP OF REVIEW PANELS, 243 00:11:49,528 --> 00:11:51,597 SROS PUT A LOT OF THOUGHT INTO 244 00:11:51,597 --> 00:11:54,833 THE MAKEUP OF THESE PANELS. SO 245 00:11:54,833 --> 00:11:55,934 WE HAVE GENERAL GUIDELINES THAT 246 00:11:55,934 --> 00:11:59,038 WE HAVE TO GO BY. SO FIRST OF 247 00:11:59,038 --> 00:12:01,974 ALL, THE SCIENTISTS HAVE TO MEET 248 00:12:01,974 --> 00:12:02,775 THE REQUIREMENTS OF THE PANEL. 249 00:12:02,775 --> 00:12:04,009 THEY NEED TO MEET THE 250 00:12:04,009 --> 00:12:06,812 REQUIREMENTS OF THE EXPERTISE. 251 00:12:06,812 --> 00:12:09,314 THEY NEED TO BE VISIBLE 252 00:12:09,314 --> 00:12:11,316 SCIENTISTS, SCIENTISTS THAT ARE 253 00:12:11,316 --> 00:12:14,553 KNOWN IN THEIR AREA. AND THAT 254 00:12:14,553 --> 00:12:15,621 CAN AT LEAST ON PAPER, 255 00:12:15,621 --> 00:12:17,956 DEMONSTRATE THAT THEY HAVE THE 256 00:12:17,956 --> 00:12:22,194 EXPERTISE NEEDED TO EVALUATE THE 257 00:12:22,194 --> 00:12:23,162 APPLICATIONS. THE STUDY SECTION 258 00:12:23,162 --> 00:12:25,664 ALSO HAVE TO BALANCE. WE HAVE 259 00:12:25,664 --> 00:12:27,933 TO TAKE ALL KINDS OF DIVERSITY 260 00:12:27,933 --> 00:12:29,601 INTO CONSIDERATION. WE DON'T 261 00:12:29,601 --> 00:12:31,336 WANT REVIEWERS TO ALL BE IN THE 262 00:12:31,336 --> 00:12:34,006 SAME CITY SO WE HAVE TO, YOU 263 00:12:34,006 --> 00:12:35,441 KNOW, DISTRIBUTE THEM ACROSS THE 264 00:12:35,441 --> 00:12:37,209 U.S. SO PUT A LOT OF THOUGHT 265 00:12:37,209 --> 00:12:40,412 INTO THAT. OTHER TYPES OF 266 00:12:40,412 --> 00:12:43,048 DIVERSITY LIKE DEMOGRAPHIC, 267 00:12:43,048 --> 00:12:44,817 STATURE, YOU KNOW THE STATUS IN 268 00:12:44,817 --> 00:12:49,154 YOUR CAREER, ALL OF THOSE ARE 269 00:12:49,154 --> 00:12:50,522 IMPORTANT FOR US. YOU CAN, AT 270 00:12:50,522 --> 00:12:53,525 ANY GIVEN MEETING, THERE'S A 271 00:12:53,525 --> 00:12:55,327 LINK AND I HOPE THESE SLIDES 272 00:12:55,327 --> 00:12:58,230 WILL BE AVAILABLE FOR PEOPLE. 273 00:12:58,230 --> 00:12:59,031 BUT THERE'S A LINK THERE WHERE 274 00:12:59,031 --> 00:13:01,133 YOU CAN ACTUALLY GO TO THE STUDY 275 00:13:01,133 --> 00:13:04,736 SECTION DESCRIPTION AND SEE PAST 276 00:13:04,736 --> 00:13:06,271 ROSTERS OF COURSE IF YOU APPLY 277 00:13:06,271 --> 00:13:08,073 INTO THE STUDY SECTION APPLY FOR 278 00:13:08,073 --> 00:13:09,875 THE MEETING. THE SUMMARY 279 00:13:09,875 --> 00:13:11,310 STATEMENT ALSO LISTS THE ROSTER 280 00:13:11,310 --> 00:13:14,480 OF THAT PARTICULAR MEETING. WE 281 00:13:14,480 --> 00:13:16,648 PUT A LOT OF EFFORT INTO 282 00:13:16,648 --> 00:13:18,484 TRAINING OUR REVIEWERS. SO 283 00:13:18,484 --> 00:13:21,153 THESE REVIEWERS HAVE TO BE 284 00:13:21,153 --> 00:13:23,122 TRAINED. NOT ONLY IN SORT OF 285 00:13:23,122 --> 00:13:25,858 THE BASIC TENETS OF NIH REVIEW 286 00:13:25,858 --> 00:13:27,392 AND HOW IMPORTANT IT IS TO 287 00:13:27,392 --> 00:13:29,928 EVALUATE STRICTLY ON SCIENTIFIC 288 00:13:29,928 --> 00:13:32,097 MERIT. BUT THEY'RE ALSO TRAINED 289 00:13:32,097 --> 00:13:34,066 FOR WHAT WE CALL THE PILLARS OF 290 00:13:34,066 --> 00:13:36,335 REVIEW SO PILLARS OF REVIEW ARE, 291 00:13:36,335 --> 00:13:38,170 SO THINGS LIKE BIAS AWARENESS, 292 00:13:38,170 --> 00:13:39,872 WE WANT TO MAKE SURE THAT THE 293 00:13:39,872 --> 00:13:42,875 REVIEW IS FAIR AND UNBIASED AND 294 00:13:42,875 --> 00:13:44,776 BIAS CAN BE MANY THINGS TO 295 00:13:44,776 --> 00:13:45,644 DIFFERENT PEOPLE HERE. 296 00:13:45,644 --> 00:13:47,679 INCLUDING THINGS LIKE, YOU KNOW, 297 00:13:47,679 --> 00:13:50,616 BIAS AGAINST PARTICULAR 298 00:13:50,616 --> 00:13:51,383 INVESTIGATORS OR TRANSLATIONAL 299 00:13:51,383 --> 00:13:52,985 BIAS, DIFFERENT THINGS LIKE THAT 300 00:13:52,985 --> 00:13:55,220 SO ALL REVIEWERS HAVE A MANDATED 301 00:13:55,220 --> 00:13:56,588 TRAINING THAT THEY HAVE TO 302 00:13:56,588 --> 00:13:58,357 UNDERGO EVERY THREE YEARS FOR 303 00:13:58,357 --> 00:14:01,660 THAT. AND THEN ANOTHER OF THESE 304 00:14:01,660 --> 00:14:02,594 PILLARS IS THE REVIEW INTEGRITY. 305 00:14:02,594 --> 00:14:05,564 SO REVIEWERS HAVE TO UNDERSTAND 306 00:14:05,564 --> 00:14:06,765 THAT INFORMATION THAT IS 307 00:14:06,765 --> 00:14:09,935 PRESENTED IN THESE MEETINGS IS 308 00:14:09,935 --> 00:14:12,504 PRIVILEGED AND CONFIDENTIAL IT 309 00:14:12,504 --> 00:14:15,707 CANNOT BE DISCUSSED OUTSIDE THE 310 00:14:15,707 --> 00:14:17,075 STUDY SECTION THAT EVERY PIECE 311 00:14:17,075 --> 00:14:19,745 OF INFORMATION, EVERY PIECE OF 312 00:14:19,745 --> 00:14:20,746 DOCUMENT THAT THEY RECEIVE CAN 313 00:14:20,746 --> 00:14:24,583 ONLY BE DISCUSSED WITH THE GROUP 314 00:14:24,583 --> 00:14:28,654 AND NOT ANYWHERE ELSE. AND THEY 315 00:14:28,654 --> 00:14:31,123 HAVE TO PRESERVE THAT. THERE'S 316 00:14:31,123 --> 00:14:32,257 ANOTHER MODULE THEY HAVE TO TAKE 317 00:14:32,257 --> 00:14:33,825 TO HELP THEM GET TRAINED ABOUT 318 00:14:33,825 --> 00:14:36,995 THAT. ALONG WITH TRAINING A 319 00:14:36,995 --> 00:14:39,665 REGULAR PANEL, OUR REGULAR PANEL 320 00:14:39,665 --> 00:14:41,567 MEMBERS. WE ALSO STRIVE TO 321 00:14:41,567 --> 00:14:43,302 EXPAND THE POOL OF REVIEWERS. 322 00:14:43,302 --> 00:14:45,204 SO WE DON'T WANT REVIEWERS WHO 323 00:14:45,204 --> 00:14:46,905 HAVE BEEN, YOU KNOW, REVIEWING 324 00:14:46,905 --> 00:14:50,475 FOR NIH FOR 30 YEARS AND 325 00:14:50,475 --> 00:14:51,310 BASICALLY PRESENT UNDUE 326 00:14:51,310 --> 00:14:52,344 INFLUENCE FOR THAT STUDY 327 00:14:52,344 --> 00:14:53,679 SECTION. WE WANT TO MAKE SURE 328 00:14:53,679 --> 00:14:58,083 THAT WE ARE ALWAYS TRAINING NEW 329 00:14:58,083 --> 00:14:59,318 REVIEWERS AND THIS IS 330 00:14:59,318 --> 00:15:00,018 ACCOMPLISHED THROUGH OUR EARLY 331 00:15:00,018 --> 00:15:01,420 CAREER REVIEWER PROGRAM THIS IS 332 00:15:01,420 --> 00:15:03,155 A PROGRAM THAT'S REALLY 333 00:15:03,155 --> 00:15:05,023 WONDERFUL AND I WOULD HIGHLY 334 00:15:05,023 --> 00:15:07,326 RECOMMEND IF YOU YOURSELF ARE AN 335 00:15:07,326 --> 00:15:10,229 EARLY STAGE INVESTIGATOR OR IF 336 00:15:10,229 --> 00:15:11,964 YOU KNOW COLLEAGUES WHO ARE 337 00:15:11,964 --> 00:15:13,999 EARLY STAGE INVESTIGATORS AND 338 00:15:13,999 --> 00:15:16,034 HAVE NOT PARTICIPATED ON A STUDY 339 00:15:16,034 --> 00:15:19,071 SECTION YET IT'S A GREAT 340 00:15:19,071 --> 00:15:21,206 EXPERIENCE. THE APPLICATION TO 341 00:15:21,206 --> 00:15:22,441 THIS PROGRAM ESSENTIALLY JUST, 342 00:15:22,441 --> 00:15:23,675 YOU KNOW, ONLY THE ELIGIBILITY 343 00:15:23,675 --> 00:15:27,179 IS THAT THEY NEED TO BE ON ESI 344 00:15:27,179 --> 00:15:28,981 WHO HAS APPLIED FOR A GRANT 345 00:15:28,981 --> 00:15:30,382 APPLICATION, HAS RECEIVED THE 346 00:15:30,382 --> 00:15:32,317 SUMMARY STATEMENT BACK, DOES NOT 347 00:15:32,317 --> 00:15:35,320 HAVE AN RO 1 EQUIVALENT GRANT 348 00:15:35,320 --> 00:15:38,056 AND HAS NOT SERVED ON A STUDY 349 00:15:38,056 --> 00:15:39,324 SECTION YET THESE INDIVIDUALS 350 00:15:39,324 --> 00:15:41,426 COME IN AND BASICALLY GET 351 00:15:41,426 --> 00:15:42,661 TRAINED WHAT REVIEWERS ARE 352 00:15:42,661 --> 00:15:44,863 LOOKING FOR. ASSIGNMENTS ARE 353 00:15:44,863 --> 00:15:46,265 VERY LIGHT. THEY GET TWO 354 00:15:46,265 --> 00:15:48,000 APPLICATIONS TO REVIEW. BUT 355 00:15:48,000 --> 00:15:51,103 THEY -- BUT ASIDE FROM THAT THEY 356 00:15:51,103 --> 00:15:52,504 PARTICIPATE FULLY THEY 357 00:15:52,504 --> 00:15:53,939 PARTICIPATE IN THE ENTIRE TWO 358 00:15:53,939 --> 00:15:55,607 DAYS, ARE HIGHLY ENCOURAGED TO 359 00:15:55,607 --> 00:15:58,744 PARTICIPATE IN THE DISCUSSIONS, 360 00:15:58,744 --> 00:15:59,378 PROVIDE THEIR OPINIONS AND IN 361 00:15:59,378 --> 00:16:04,249 THE EVALUATION AND IT'S VERY 362 00:16:04,249 --> 00:16:07,119 LIGHT, VERY DESIRABLE. SO HOW 363 00:16:07,119 --> 00:16:10,022 IS YOUR APPLICATION EVALUATED? 364 00:16:10,022 --> 00:16:12,557 WELL, FOR THIS -- IS A TYPICAL 365 00:16:12,557 --> 00:16:18,797 REVIEW FOR AN RO 1 OR -- PROJECT 366 00:16:18,797 --> 00:16:22,100 RESEARCH PROJECT GRANT, RPG. SO 367 00:16:22,100 --> 00:16:24,670 THESE GRANTS HAVE FIVE REVIEW 368 00:16:24,670 --> 00:16:26,271 CRITERIA. SIGNIFICANCE, 369 00:16:26,271 --> 00:16:29,675 INVESTIGATORS, INNOVATION, 370 00:16:29,675 --> 00:16:31,510 APPROACH AND ENVIRONMENT. THE 371 00:16:31,510 --> 00:16:32,978 SUM OF THESE CRITERIA EQUALS THE 372 00:16:32,978 --> 00:16:35,147 OVERALL IMPACT OF THE 373 00:16:35,147 --> 00:16:37,582 EVALUATION. SO THE OVERALL 374 00:16:37,582 --> 00:16:38,617 IMPACT AND KIND OF THE MAIN 375 00:16:38,617 --> 00:16:40,919 THING THAT WE'RE LOOKING FOR IS, 376 00:16:40,919 --> 00:16:42,721 AND I'M JUST GOING TO READ IT 377 00:16:42,721 --> 00:16:44,256 HERE ASSESSMENT OF THE 378 00:16:44,256 --> 00:16:45,324 LIKELIHOOD OF THE PROJECT TO 379 00:16:45,324 --> 00:16:47,326 EXERT A SUSTAINED POWERFUL 380 00:16:47,326 --> 00:16:48,760 INFLUENCE ON THE FIELD. SO 381 00:16:48,760 --> 00:16:50,095 THAT'S REALLY THE SCIENTIFIC 382 00:16:50,095 --> 00:16:52,397 MERIT THAT WE'RE LOOKING FOR IN 383 00:16:52,397 --> 00:16:55,534 APPLICATIONS. NOW THESE REVIEW 384 00:16:55,534 --> 00:16:58,270 CRITERIA ARE, SIGNIFICANCE IS 385 00:16:58,270 --> 00:16:59,071 THE IMPORTANCE OF THE PROBLEM. 386 00:16:59,071 --> 00:17:01,073 WHAT PROBLEM IS BEING SOUGHT AT 387 00:17:01,073 --> 00:17:01,707 WITH THIS APPLICATION THAT IS 388 00:17:01,707 --> 00:17:04,309 GOING TO BE SOLVED. 389 00:17:04,309 --> 00:17:05,677 INVESTIGATORS SO DOES THE TEAM 390 00:17:05,677 --> 00:17:07,412 HAVE THE NECESSARY EXPERTISE TO 391 00:17:07,412 --> 00:17:10,082 REVIEW THE APPLICATIONS? 392 00:17:10,082 --> 00:17:11,817 INNOVATION, SO HOW, WHAT IS THE 393 00:17:11,817 --> 00:17:14,019 NOVELTY THAT IS BEING PROPOSED. 394 00:17:14,019 --> 00:17:15,721 ARE THERE NEW METHODS OR TOOLS 395 00:17:15,721 --> 00:17:17,556 THAT ARE BEING PROPOSED OR IS 396 00:17:17,556 --> 00:17:21,626 THERE GOING TO BE AN INCREMENTAL 397 00:17:21,626 --> 00:17:24,529 ADVANCE OR IS THERE GOING TO BE 398 00:17:24,529 --> 00:17:25,597 KIND OF AN INTEGRATION OF 399 00:17:25,597 --> 00:17:28,200 EXISTING METHODS OR TOOLS. 400 00:17:28,200 --> 00:17:32,437 APPROACH, THAT'S A KEY CRITERION 401 00:17:32,771 --> 00:17:34,706 IS THE RESEARCH PLAN WELL 402 00:17:34,706 --> 00:17:35,607 OUTLINED? WHAT IS THE RIGOROUS 403 00:17:35,607 --> 00:17:37,075 PRIOR RESEARCH THAT SUPPORTS 404 00:17:37,075 --> 00:17:39,511 WHAT IS BEING PROPOSED? IS 405 00:17:39,511 --> 00:17:43,148 THERE A RIGOROUS AND ROBUST 406 00:17:43,148 --> 00:17:45,484 SCIENTIFIC METHOD THAT ENSURES 407 00:17:45,484 --> 00:17:47,219 THAT THE RESEARCHERS HAVE 408 00:17:47,219 --> 00:17:47,753 PLANNED OUT ALL OF THE 409 00:17:47,753 --> 00:17:49,855 EXPERIMENTS AND ARE PLANNING TO 410 00:17:49,855 --> 00:17:52,290 USE ROBUST STATISTICAL ANALYSES 411 00:17:52,290 --> 00:17:54,960 FOR THE EVALUATION, FOR THE 412 00:17:54,960 --> 00:17:56,762 ANALYSIS. AND THEN FINALLY 413 00:17:56,762 --> 00:17:58,130 ENVIRONMENT. SO ARE THERE 414 00:17:58,130 --> 00:17:59,264 RESOURCES AND FACILITIES THAT 415 00:17:59,264 --> 00:18:01,800 ARE AVAILABLE TO THE TEAM? 416 00:18:01,800 --> 00:18:05,003 THESE ARE ALL SCORED ON A SCALE 417 00:18:05,003 --> 00:18:08,240 OF ONE THROUGH NINE. SCORE ONE 418 00:18:08,240 --> 00:18:10,675 IS THE HEIGHT IMPACT SCORE. 419 00:18:10,675 --> 00:18:13,345 SCORE NINE IS THE LOW IMPACT 420 00:18:13,345 --> 00:18:14,980 SCORE. WE GENERALLY ENCOURAGE 421 00:18:14,980 --> 00:18:16,982 REVIEWERS TO START AT FIVE. 422 00:18:16,982 --> 00:18:20,051 WHICH WE CALL A WELL-BALANCED 423 00:18:20,051 --> 00:18:21,219 APPLICATION WITH A BALANCE OF 424 00:18:21,219 --> 00:18:22,954 STRENGTHS AND WEAKNESSES. AND 425 00:18:22,954 --> 00:18:26,391 THEN AS THEY READ THEIR 426 00:18:26,391 --> 00:18:27,793 APPLICATIONS, THEN EITHER MOVE 427 00:18:27,793 --> 00:18:30,128 UP OR DOWN SO THEY CAN MAKE A 428 00:18:30,128 --> 00:18:32,464 DETERMINATION. NOW ALL OF THESE 429 00:18:32,464 --> 00:18:35,133 APPLICATIONS RECEIVE A SCORE. 430 00:18:35,133 --> 00:18:35,967 SO DISCUSSED APPLICATIONS 431 00:18:35,967 --> 00:18:38,370 RECEIVE AN AVERAGED OVERALL 432 00:18:38,370 --> 00:18:40,338 IMPACT SCORE. OF -- FROM NOT 433 00:18:40,338 --> 00:18:45,310 ONLY THOSE ASSIGNED APPLICATIONS 434 00:18:45,310 --> 00:18:46,878 BUT ALSO THE ENTIRE PANEL. SO 435 00:18:46,878 --> 00:18:48,680 THESE APPLICATIONS ARE GOING TO 436 00:18:48,680 --> 00:18:51,683 BE DISCUSSED AND THEN THE ENTIRE 437 00:18:51,683 --> 00:18:53,985 PANEL VOTES TO PROVIDE A SCORE 438 00:18:53,985 --> 00:18:55,020 FOR THOSE APPLICATIONS AND THEN 439 00:18:55,020 --> 00:18:58,290 THAT ULTIMATELY GETS PERCENTILED 440 00:18:58,290 --> 00:18:59,291 DEPENDING ON WHAT THE GRANT 441 00:18:59,291 --> 00:18:59,925 MECHANISM IS. 442 00:18:59,925 --> 00:19:03,361 AND THEN THAT'S WHAT YOU GET IN 443 00:19:03,361 --> 00:19:05,330 THE SUMMARY STATEMENT. IN 444 00:19:05,330 --> 00:19:07,299 ADDITION TO THE SCORE THOSE 445 00:19:07,299 --> 00:19:08,567 DISCUSSED APPLICATION ALSO GET A 446 00:19:08,567 --> 00:19:12,304 RESUME AND SUMMARY OF DISCUSSION 447 00:19:12,304 --> 00:19:13,905 ATCSR THOSE ARE ALL WRITTEN BY 448 00:19:13,905 --> 00:19:15,240 THE SRO. 449 00:19:15,240 --> 00:19:16,708 WE TRY TO SUMMARIZE WHAT THE 450 00:19:16,708 --> 00:19:17,676 DISCUSSION WAS AND TRY TO 451 00:19:17,676 --> 00:19:19,978 PROVIDE A LITTLE MORE GUIDANCE 452 00:19:19,978 --> 00:19:22,347 AND WHAT THE REVIEWERS HAD IN 453 00:19:22,347 --> 00:19:25,116 MIND, ESPECIALLY IF THE 454 00:19:25,116 --> 00:19:26,785 EVALUATIONS ALSO INVOLVED THE 455 00:19:26,785 --> 00:19:29,387 PANEL DISCUSSION WHICH IS VERY 456 00:19:29,387 --> 00:19:31,122 IMPORTANT TO US. AND THEN THE 457 00:19:31,122 --> 00:19:31,957 NON DISCUSSED APPLICATION 458 00:19:31,957 --> 00:19:34,025 RECEIVE ONLY THE CRITERION 459 00:19:34,025 --> 00:19:35,660 SCORES FROM THE THREE ASSIGNED 460 00:19:35,660 --> 00:19:36,695 REVIEWERS THE SUMMARY STATEMENT 461 00:19:36,695 --> 00:19:38,563 FOR NON DISCUSSED APPLICATIONS 462 00:19:38,563 --> 00:19:42,300 ARE ONLY GOING TO HAVE THE THREE 463 00:19:42,300 --> 00:19:43,301 CRITIQUES. 464 00:19:43,301 --> 00:19:45,904 SO THIS IS REALLY IMPORTANT. 465 00:19:45,904 --> 00:19:48,173 AND I HOPE THAT YOU NOT ONLY 466 00:19:48,173 --> 00:19:49,541 HEAR THIS NOW BUT ALSO PROMOTE 467 00:19:49,541 --> 00:19:53,812 THIS TO YOUR COLLEAGUES. THIS 468 00:19:53,812 --> 00:19:56,014 FRAMEWORK IS GOING TO BE 469 00:19:56,014 --> 00:19:59,317 CHANGED. STARTING FROM 470 00:19:59,317 --> 00:20:01,553 APPLICATIONS THAT ARE DUE DATES 471 00:20:01,553 --> 00:20:04,789 JANUARY 25, 2025, THE IMMEDIATE 472 00:20:04,789 --> 00:20:08,126 EFFECT WILL BE ON RPG SO RO 1S, 473 00:20:08,126 --> 00:20:10,195 R 23S, THERE IS A SIMILAR CHANGE 474 00:20:10,195 --> 00:20:14,199 THAT'S GOING TO BE OCCURRING FOR 475 00:20:14,199 --> 00:20:15,300 FELLOWSHIPS.WE DON'T REALLY HAVE 476 00:20:15,300 --> 00:20:18,069 INFORMATION ABOUT SBI RS JUST 477 00:20:18,069 --> 00:20:21,640 YET SO FOR NOW, LET'S FOCUS THIS 478 00:20:21,640 --> 00:20:23,575 ON RPGS. 479 00:20:23,575 --> 00:20:25,710 SO EVERYTHING I TOLD YOU IN THE 480 00:20:25,710 --> 00:20:27,779 LAST SLIDE, IN TERMS OF THE 481 00:20:27,779 --> 00:20:30,282 OVERALL IMPACT WILL REMAIN THE 482 00:20:30,282 --> 00:20:31,816 SAME. SO THE OVERALL IMPACT 483 00:20:31,816 --> 00:20:33,184 DOES NOT CHANGE, WE'RE STILL 484 00:20:33,184 --> 00:20:36,588 LOOK FOR APPLICATIONS THAT HAVE 485 00:20:36,588 --> 00:20:39,324 A HIGH AMOUNT OF SCIENTIFIC 486 00:20:39,324 --> 00:20:41,693 MERIT BUT THE FIVE CRITERIA WILL 487 00:20:41,693 --> 00:20:44,629 BE CONVERTED INTO THREE FACTORS. 488 00:20:44,629 --> 00:20:47,299 SO, BASICALLY COMBINING SOME OF 489 00:20:47,299 --> 00:20:49,601 THE CRITERIA AND ALSO AS APPEAR 490 00:20:49,601 --> 00:20:52,237 EFFORT TO REDUCE BIAS TO TAKE 491 00:20:52,237 --> 00:20:55,307 AWAY SOME OF THE ONGOING 492 00:20:55,307 --> 00:20:56,708 POTENTIAL IMPLICIT BIAS THAT 493 00:20:56,708 --> 00:21:01,413 COULD BE UNDULY -- UNDUE TO THE 494 00:21:01,413 --> 00:21:02,480 INVESTIGATORS AND ENVIRONMENT. 495 00:21:02,480 --> 00:21:03,448 SO RATHER THAN FIVE CRITERIA 496 00:21:03,448 --> 00:21:05,517 THERE'LL BE THREE FACTORS THE 497 00:21:05,517 --> 00:21:07,953 FIRST FACTOR IS THE IMPORTANCE 498 00:21:07,953 --> 00:21:13,124 OF THE RESEARCH. THIS SEFKT 499 00:21:13,124 --> 00:21:14,192 ESSENTIALLY COMBINES THE 500 00:21:14,192 --> 00:21:15,427 SIGNIFICANCE AND THE INNOVATION. 501 00:21:15,427 --> 00:21:17,062 SO HOW IMPORTANT IS THIS 502 00:21:17,062 --> 00:21:19,464 PROBLEM? WHAT KIND OF ADVANCE 503 00:21:19,464 --> 00:21:21,833 IS IT GOING TO MAKE AND IF YOU 504 00:21:21,833 --> 00:21:24,436 WILL, IT ASKS THE QUESTION, 505 00:21:24,436 --> 00:21:27,305 SHOULD THIS BE DONE? SO THIS IS 506 00:21:27,305 --> 00:21:29,374 THE SCORING WILL REMAIN THE SAME 507 00:21:29,374 --> 00:21:32,043 SO SCORE ONE THROUGH NINE. THE 508 00:21:32,043 --> 00:21:33,845 NEXT FACTOR IS RIGOR AND 509 00:21:33,845 --> 00:21:35,513 FEASIBILITY. SO THIS BASICALLY 510 00:21:35,513 --> 00:21:38,416 TAKES THE APPROACH INCLUDING THE 511 00:21:38,416 --> 00:21:39,751 SCIENTIFIC RIGOR AND REALLY ASKS 512 00:21:39,751 --> 00:21:43,321 THE QUESTION, CAN IT BE DONE? 513 00:21:43,321 --> 00:21:46,024 SO IT REALLY, IT ALSO INCLUDES 514 00:21:46,024 --> 00:21:49,060 HUMAN SUBJECTS, CLINICAL TRIALS, 515 00:21:49,060 --> 00:21:52,330 THINGS LIKE THAT. NOW THE THIRD 516 00:21:52,330 --> 00:21:55,300 FACTOR, TAKES THE INVESTIGATOR 517 00:21:55,300 --> 00:21:57,335 AND ENVIRONMENT, THIS IS NOT -- 518 00:21:57,335 --> 00:21:59,971 THIS WILL NOT BE SCORED. AND, 519 00:21:59,971 --> 00:22:02,807 AGAIN, IN AN EFFORT TO TRY TO 520 00:22:02,807 --> 00:22:05,977 REDUCE BIAS TO THE BEST OF OUR 521 00:22:05,977 --> 00:22:09,014 ABILITY, THIS FACTOR WILL 522 00:22:09,014 --> 00:22:10,348 EVALUATE WHETHER THERE IS 523 00:22:10,348 --> 00:22:11,983 RELEVANT EXPERTISE AND WHETHER 524 00:22:11,983 --> 00:22:16,154 THERE ARE RELEVANT RESOURCES. 525 00:22:16,154 --> 00:22:19,758 SO INSTEAD OF, YOU KNOW, GOING 526 00:22:19,758 --> 00:22:21,993 INTO GREAT DETAIL ABOUT CERTAIN 527 00:22:21,993 --> 00:22:24,629 INVESTIGATORS OR, YOU KNOW, HOW, 528 00:22:24,629 --> 00:22:29,701 YOU KNOW, HOW PRODUCTIVE THEY'VE 529 00:22:29,701 --> 00:22:31,369 BEEN OR HOW ACCOMPLISHED THEY'VE 530 00:22:31,369 --> 00:22:34,339 BEEN THIS WILL ONLY EVALUATE 531 00:22:34,339 --> 00:22:35,740 WHETHER THERE'S PROPER EXPERTISE 532 00:22:35,740 --> 00:22:37,475 AND IF NOT THE REVIEWERS WILL 533 00:22:37,475 --> 00:22:39,310 HAVE AN OPPORTUNITY TO PROVIDE 534 00:22:39,310 --> 00:22:41,246 WHAT EXPERTISE THEY BELIEVE WILL 535 00:22:41,246 --> 00:22:43,882 BE STILL NECESSARY AND MISSING. 536 00:22:43,882 --> 00:22:45,383 AND IT ALSO WILL EVALUATE THE 537 00:22:45,383 --> 00:22:47,719 ENVIRONMENT SO, AGAIN, TO TRY TO 538 00:22:47,719 --> 00:22:51,856 REDUCE BIAS AGAINST INSTITUTIONS 539 00:22:51,856 --> 00:22:54,959 THAT ARE MORE HEAVILY RESOURCED 540 00:22:54,959 --> 00:22:56,728 THAN OTHERS SO IT WILL ONLY 541 00:22:56,728 --> 00:22:57,495 EVALUATE WHETHER THERE'S 542 00:22:57,495 --> 00:22:59,297 ADEQUATE RESOURCES AND 543 00:22:59,297 --> 00:23:00,699 FACILITIES IN THAT ENVIRONMENT. 544 00:23:00,699 --> 00:23:03,334 AGAIN, THESE SLIDES, SO THIS HAS 545 00:23:03,334 --> 00:23:04,736 BEEN AN ONGOING PROCESS, THERE 546 00:23:04,736 --> 00:23:06,604 HAS BEEN A LOT OF COMMUNITY 547 00:23:06,604 --> 00:23:09,708 OUTREACH TO TRY TO PROMOTE THE 548 00:23:09,708 --> 00:23:11,242 UNDERSTANDING OF THIS REVISION. 549 00:23:11,242 --> 00:23:13,311 I HAVE A LOT OF LENGTH HERE IF 550 00:23:13,311 --> 00:23:15,747 YOU GET TO SEE THE SLIDES, I 551 00:23:15,747 --> 00:23:19,284 REALLY ENCOURAGE YOU TO LOOK 552 00:23:19,284 --> 00:23:20,752 INTO THEM. AND, ALSO TO PROMOTE 553 00:23:20,752 --> 00:23:26,291 THEM TO YOUR COLLEAGUES. OKAY. 554 00:23:26,291 --> 00:23:27,892 SO BACK TO STANDARD REVIEW FOR 555 00:23:27,892 --> 00:23:31,262 NOW. SO AT THE MEETING, THE 556 00:23:31,262 --> 00:23:33,331 APPLICATIONS AS I MENTIONED ARE 557 00:23:33,331 --> 00:23:35,300 SORTED FROM -- BASED ON THEIR 558 00:23:35,300 --> 00:23:36,367 SCORES PRIOR TO THE MEETING FROM 559 00:23:36,367 --> 00:23:37,969 BEST TO WORST. THIS 560 00:23:37,969 --> 00:23:39,304 DETERMINATION THE ORDER OF 561 00:23:39,304 --> 00:23:44,609 REVIEW SO, WE DISCUSSED TOP 50%. 562 00:23:44,609 --> 00:23:45,877 IMPORTANTLY, THE ENTIRE SLATE OF 563 00:23:45,877 --> 00:23:47,612 THE APPLICATIONS IS NOT 564 00:23:47,612 --> 00:23:50,348 CLUSTERED AS A WHOLE. IS NOT 565 00:23:50,348 --> 00:23:52,650 SORTED AS A WHOLE BUT IN FACT IS 566 00:23:52,650 --> 00:23:55,620 CLUSTERED BASED ON SPECIFIC 567 00:23:55,620 --> 00:23:59,190 REQUIREMENTS. ONE OF THESE 568 00:23:59,190 --> 00:24:01,326 REQUIREMENTS IS THE CAREER STAGE 569 00:24:01,326 --> 00:24:05,730 WE ALWAYS CLUSTER EARLY STAGE 570 00:24:05,730 --> 00:24:07,098 INVESTIGATORS HAVE ESTABLISHED 571 00:24:07,098 --> 00:24:11,302 INVESTIGATORS AND THESE 572 00:24:11,302 --> 00:24:11,836 INVESTIGATORS ARE EITHER 573 00:24:11,836 --> 00:24:12,470 INVESTIGATORS WHO HAVE, ARE 574 00:24:12,470 --> 00:24:16,508 STILL WITHIN THE TEN YEARS OF 575 00:24:16,508 --> 00:24:19,310 THEIR TERMINAL DEGREE PH.D. OR 576 00:24:19,310 --> 00:24:22,347 M.D. AND HAVE NOT SUCCESSFULLY 577 00:24:22,347 --> 00:24:24,649 COMPLETED FOR AN RO 1-LIKE GRANT 578 00:24:24,649 --> 00:24:28,319 OR NEW INVESTIGATORS SO A NEW 579 00:24:28,319 --> 00:24:30,855 INVESTIGATOR IS EVEN PAST THAT 580 00:24:30,855 --> 00:24:33,091 TEN YEAR LIMIT BUT STILL IS NOT 581 00:24:33,091 --> 00:24:36,761 SUCCESSFUL IN -- SUCCESSFULLY 582 00:24:36,761 --> 00:24:45,737 COMPUTED FOR NRPG SO THOSE ARE 583 00:24:45,737 --> 00:24:49,741 CLUSTERED SEPARATELY R 21S ARE 584 00:24:49,741 --> 00:24:52,277 ALSO CLUSTERED SUCCESSFULLY. 585 00:24:52,277 --> 00:24:55,113 THESE ARE SMALL, RO 1-LIKE 586 00:24:55,113 --> 00:24:57,682 GRANTS. THESE ARE THREES. 587 00:24:57,682 --> 00:24:59,551 THESE ARE ONE TO TWO YEAR PERIOD 588 00:24:59,551 --> 00:25:02,253 OF ABOUT 50,000 FOR THAT. WE 589 00:25:02,253 --> 00:25:05,723 SOMETIMES REVIEW U 01 SO THESE 590 00:25:05,723 --> 00:25:08,860 ARE BIOENGINEERING RESEARCH 591 00:25:08,860 --> 00:25:11,930 PROJECTS. PARTNERSHIPS. AND IF 592 00:25:11,930 --> 00:25:14,098 THERE'S ANY OTHER TYPE OF RFA 593 00:25:14,098 --> 00:25:15,500 THAT REQUIRES CLUSTERING. 594 00:25:15,500 --> 00:25:17,735 ANOTHER THING THAT WE CLUSTER IS 595 00:25:17,735 --> 00:25:21,539 THE SO-CALLED CATS R 01 SO THIS 596 00:25:21,539 --> 00:25:24,375 IS AN R 01 FOR EARLY STAGE 597 00:25:24,375 --> 00:25:25,276 INVESTIGATORS IT HAS VERY 598 00:25:25,276 --> 00:25:27,245 SPECIFIC REVIEW CRITERIA THAT I 599 00:25:27,245 --> 00:25:28,112 ENCOURAGE YOU TO LOOK INTO IF 600 00:25:28,112 --> 00:25:30,415 YOU KNOW ANYONE WHO IS A NEW 601 00:25:30,415 --> 00:25:31,182 INVESTIGATOR AND AS I MENTIONED 602 00:25:31,182 --> 00:25:33,852 SO THE NON DISCUSSED 603 00:25:33,852 --> 00:25:36,621 APPLICATIONS, THAT FALL ON THAT 604 00:25:36,621 --> 00:25:38,690 BOTTOM 50%, DOESN'T MEAN THAT 605 00:25:38,690 --> 00:25:40,158 THEY'RE BAD APPLICATIONS THEY 606 00:25:40,158 --> 00:25:43,294 JUST DIDN'T MEET THAT CUTOFF. 607 00:25:43,294 --> 00:25:45,930 WHATEVER THAT CUTOFF WAS AND THE 608 00:25:45,930 --> 00:25:47,298 CUTOFFS WILL BE DIFFERENT. NOW 609 00:25:47,298 --> 00:25:48,533 THOSE APPLICATIONS CAN STILL BE 610 00:25:48,533 --> 00:25:49,868 RECALLED BY ANYBODY AT THE 611 00:25:49,868 --> 00:25:53,071 MEETING. SO IF, FOR EXAMPLE, IF 612 00:25:53,071 --> 00:25:54,906 REVIEWERS HAD A VERY DISCREPANT 613 00:25:54,906 --> 00:25:56,574 SCORE THAT MADE THAT APPLICATION 614 00:25:56,574 --> 00:25:59,677 FALL TO THE BOTTOM OF THE 50%, 615 00:25:59,677 --> 00:26:01,079 THAT -- ANY REVIEWER CAN 616 00:26:01,079 --> 00:26:02,447 ACTUALLY RECALL THAT APPLICATION 617 00:26:02,447 --> 00:26:05,750 AND ASK FOR IT TO BE REVIEWED 618 00:26:05,750 --> 00:26:08,419 EVEN THOUGH IT WASN'T INITIALLY. 619 00:26:08,419 --> 00:26:11,322 OKAY WELL, SO AFTER THAT MEETING 620 00:26:11,322 --> 00:26:14,626 TAKES PLACE, THEN THE SCORES, 621 00:26:14,626 --> 00:26:16,027 THE PRIORITY SCORES AND THE 622 00:26:16,027 --> 00:26:17,729 FINAL -- THE FINAL SCORES AND 623 00:26:17,729 --> 00:26:19,330 THE PERCENTILES FOR THAT MEETING 624 00:26:19,330 --> 00:26:22,133 TYPICALLY GET RELEASED BETWEEN 625 00:26:22,133 --> 00:26:24,502 24-72 HOURS TO THE APPLICANT SO 626 00:26:24,502 --> 00:26:26,271 YOU CAN SEE RIGHT AWAY WHETHER 627 00:26:26,271 --> 00:26:28,473 YOUR APPLICATION WAS DISCUSSED. 628 00:26:28,473 --> 00:26:30,275 WHETHER IT WAS -- HOW WELL IT'S 629 00:26:30,275 --> 00:26:31,142 SCORED YOU CAN START THINKING 630 00:26:31,142 --> 00:26:33,878 ABOUT MAYBE NEXT STEPS. AND 631 00:26:33,878 --> 00:26:35,813 THEN THE SUMMARY STATEMENT GETS 632 00:26:35,813 --> 00:26:39,150 RELEASED WITHIN 30 DAYS. AS I 633 00:26:39,150 --> 00:26:41,085 MENTIONED, WE TAKE A LOT OF TIME 634 00:26:41,085 --> 00:26:42,987 INTO COMPRISING THE SUMMARY 635 00:26:42,987 --> 00:26:44,422 STATEMENTS. I WRITE THE RESUME 636 00:26:44,422 --> 00:26:47,025 AND SO THAT IS WHAT TAKES EXTRA 637 00:26:47,025 --> 00:26:49,327 TIME. NOW ONCE THAT SUMMARY 638 00:26:49,327 --> 00:26:51,296 STATEMENT IS RELEASED, THE SRO 639 00:26:51,296 --> 00:26:53,531 IS NO LONGER THE POINT OF 640 00:26:53,531 --> 00:26:55,867 CONTACT FOR DISCUSSING THAT 641 00:26:55,867 --> 00:26:56,834 SUMMARY STATEMENT. ONLY A 642 00:26:56,834 --> 00:27:00,405 PROGRAM IS. AND THE REASON FOR 643 00:27:00,405 --> 00:27:02,607 THAT IS BECAUSE FIRST OF ALL 644 00:27:02,607 --> 00:27:03,775 PROGRAM TYPICALLY LISTEN INTO 645 00:27:03,775 --> 00:27:05,710 THE DISCUSSION SO THEY ARE 646 00:27:05,710 --> 00:27:07,011 HIGHLY AWARE OF WHAT THINGS WERE 647 00:27:07,011 --> 00:27:10,415 SAID DURING THE DISCUSSION. 648 00:27:10,415 --> 00:27:11,082 ALTHOUGH TO A POINT BECAUSE 649 00:27:11,082 --> 00:27:13,184 AGAIN, YOU KNOW, REMEMBER THOSE 650 00:27:13,184 --> 00:27:14,285 DISCUSSIONS HAVE TO BE 651 00:27:14,285 --> 00:27:15,153 CONFIDENTIAL. SO THE PROGRAM 652 00:27:15,153 --> 00:27:16,354 CANNOT DISCLOSE TO YOU, FOR 653 00:27:16,354 --> 00:27:19,023 EXAMPLE, WHO THE REVIEWERS WERE. 654 00:27:19,023 --> 00:27:20,558 THEY CANNOT DISCLOSE TOO MANY 655 00:27:20,558 --> 00:27:23,094 SPECIFICS ABOUT WHAT WAS SAID. 656 00:27:23,094 --> 00:27:25,363 THAT'S STILL CONFIDENTIAL 657 00:27:25,363 --> 00:27:26,631 INFORMATION. BUT CERTAINLY THEY 658 00:27:26,631 --> 00:27:28,766 CAN HELP YOU MAKE THE 659 00:27:28,766 --> 00:27:30,735 DETERMINATION OF, YOU KNOW, WHAT 660 00:27:30,735 --> 00:27:31,536 GENERAL IDEA THERE WAS, YOU 661 00:27:31,536 --> 00:27:34,005 KNOW, AND MAKE RECOMMENDATIONS 662 00:27:34,005 --> 00:27:35,740 ABOUT WHAT TO DO WITH YOUR 663 00:27:35,740 --> 00:27:37,241 APPLICATION NEXT. IS THIS AN 664 00:27:37,241 --> 00:27:38,609 APPLICATION THAT'S GOING TO BE 665 00:27:38,609 --> 00:27:40,144 FUNDED? IS THIS AN APPLICATION 666 00:27:40,144 --> 00:27:43,381 THAT PERHAPS NEEDS TO BE 667 00:27:43,381 --> 00:27:46,250 RESUBMITTED? YOU CAN RESUBMIT 668 00:27:46,250 --> 00:27:48,653 APPLICATION AGAIN AND THAT CALLS 669 00:27:48,653 --> 00:27:53,758 IT AN A 1. A RESUBMISSION HAS 670 00:27:53,758 --> 00:27:54,859 AN ADDITIONAL REQUIREMENT FOR 671 00:27:54,859 --> 00:27:56,394 THAT. AFTER -- IF THAT 672 00:27:56,394 --> 00:27:58,563 APPLICATION IS UNSUCCESSFUL 673 00:27:58,563 --> 00:28:01,399 AGAIN, YOU CAN GO AHEAD AND 674 00:28:01,399 --> 00:28:03,001 RESUBMIT THAT APPLICATION A 675 00:28:03,001 --> 00:28:04,502 THIRD TIME ALTHOUGH AT THIS 676 00:28:04,502 --> 00:28:06,137 POINT IT WILL BE LIKE A NEW 677 00:28:06,137 --> 00:28:07,839 APPLICATION AGAIN. YOU CAN 678 00:28:07,839 --> 00:28:08,873 CONTINUE DOING THIS INDEFINITELY 679 00:28:08,873 --> 00:28:10,708 UNTIL, WELL, HOPEFULLY YOUR 680 00:28:10,708 --> 00:28:19,951 APPLICATION GETS FUNDED. OKAY 681 00:28:19,951 --> 00:28:21,085 OTHER THINGS THAT MIGHT BE ON 682 00:28:21,085 --> 00:28:21,853 THE STATEMENT. THERE'S 683 00:28:21,853 --> 00:28:23,254 REQUIREMENT TO INCLUDE THINGS 684 00:28:23,254 --> 00:28:25,656 LIKE THE RESOURCE SHARING PLAN. 685 00:28:25,656 --> 00:28:27,325 THE BIOSKETCH HAS TO BE IN THE 686 00:28:27,325 --> 00:28:29,727 CORRECT FORMAT. YOU HAVE TO BE 687 00:28:29,727 --> 00:28:30,695 REALLY CAREFUL ABOUT 688 00:28:30,695 --> 00:28:33,731 OVERSTUFFING SO THE RESEARCH 689 00:28:33,731 --> 00:28:39,303 PLAN HAS A CERTAIN TEXT LIMIT. 690 00:28:39,303 --> 00:28:42,073 YOU KNOW WLSHGS WHETHER IT'S 691 00:28:42,073 --> 00:28:43,708 SIX PAGES OR TWELVE PAGES. 692 00:28:43,708 --> 00:28:44,809 THERE'S RESPONSE REQUIREMENTS, 693 00:28:44,809 --> 00:28:46,844 LINE REQUIREMENTS, IF YOU PUT 694 00:28:46,844 --> 00:28:48,446 TOO MUCH THERE'S A CHANCE YOUR 695 00:28:48,446 --> 00:28:49,313 APPLICATION MIGHT GET WITHDRAWN 696 00:28:49,313 --> 00:28:50,681 DUE TO ELIGIBILITY SO PLEASE BE 697 00:28:50,681 --> 00:28:53,751 REALLY CAREFUL WHEN YOU ARE 698 00:28:53,751 --> 00:28:55,720 WRITING YOUR APPLICATIONS. 699 00:28:55,720 --> 00:28:57,755 OKAY, SO WHO CAN ANSWER YOUR 700 00:28:57,755 --> 00:29:01,259 QUESTIONS? SO BEFORE THE 701 00:29:01,259 --> 00:29:02,226 APPLICATION IS SUBMITTED, PLEASE 702 00:29:02,226 --> 00:29:06,898 REACH OUT TO YOUR PROGRAM 703 00:29:06,898 --> 00:29:07,932 OFFICER BECAUSE THEY CAN 704 00:29:07,932 --> 00:29:09,400 CERTAINLY HEAR OUT YOUR IDEA. 705 00:29:09,400 --> 00:29:11,636 AND LET YOU KNOW HOW WELL IT 706 00:29:11,636 --> 00:29:13,504 MIGHT FIT IN WITH THEIR 707 00:29:13,504 --> 00:29:15,106 PROGRAMMATIC GUIDELINES. IS 708 00:29:15,106 --> 00:29:17,642 THIS SOMETHING THAT THEY WOULD 709 00:29:17,642 --> 00:29:19,677 REALLY WANT TO BE FUNDED? YOU 710 00:29:19,677 --> 00:29:21,512 CAN CERTAINLY REACH OUT TO THE 711 00:29:21,512 --> 00:29:25,283 SRO BUT THE SRO AT CSR AT LEAST 712 00:29:25,283 --> 00:29:27,952 HAS LIMITATIONS ON WHAT I CAN 713 00:29:27,952 --> 00:29:30,354 TELL YOU. I CAN GIVE YOU SOME 714 00:29:30,354 --> 00:29:32,423 SUGGESTIONS ABOUT WHICH STUDY 715 00:29:32,423 --> 00:29:34,225 SECTIONS YOUR APPLICATION MIGHT 716 00:29:34,225 --> 00:29:36,594 FIT INTO ALTHOUGH EVEN IN THAT 717 00:29:36,594 --> 00:29:37,895 CASE I CAN'T EVER GIVE YOU A 718 00:29:37,895 --> 00:29:38,796 GUARANTEE AND THE REASON FOR 719 00:29:38,796 --> 00:29:40,798 THAT IS WE NEED THE APPLICATION 720 00:29:40,798 --> 00:29:41,799 TO BE COMPLETELY SUBMITTED 721 00:29:41,799 --> 00:29:45,837 BECAUSE, YOU KNOW, WHAT YOU SAY 722 00:29:45,837 --> 00:29:51,242 IN THE ABSTRACT OR SPECIFICS 723 00:29:51,242 --> 00:29:52,944 MIGHT NOT BE WHAT IS IN THE 724 00:29:52,944 --> 00:29:55,313 RESEARCH PLAN AND THIS HAS TO 725 00:29:55,313 --> 00:29:57,648 FIT IN WITH THE SCIENTIFIC GOALS 726 00:29:57,648 --> 00:29:58,850 YOU CAN CERTAINLY REACH OUT TO 727 00:29:58,850 --> 00:30:02,053 RECEIPT AND REFERRAL. WITH 728 00:30:02,053 --> 00:30:05,756 QUESTIONS. ABOUT MAKING 729 00:30:05,756 --> 00:30:07,125 SUGGESTIONS. THE CSR WEBSITE 730 00:30:07,125 --> 00:30:11,262 HAS A LOT OF INFORMATION ON IT. 731 00:30:11,262 --> 00:30:13,998 REGARDING THE -- MAKING 732 00:30:13,998 --> 00:30:16,400 DECISIONS ABOUT THE IC OR SOG. 733 00:30:16,400 --> 00:30:20,338 SO WHICH IC AND WHICH SCIENTIFIC 734 00:30:20,338 --> 00:30:22,573 REVIEW BRANCH. REVIEW MEETING 735 00:30:22,573 --> 00:30:24,609 TO, SEND YOUR APPLICATION TO. 736 00:30:24,609 --> 00:30:26,377 APPLICANTS CAN CERTAINLY MAKE A 737 00:30:26,377 --> 00:30:27,011 RECOMMENDATION. YOU CAN PUT IT 738 00:30:27,011 --> 00:30:29,447 IN THE COVER LETTER. THERE'S AN 739 00:30:29,447 --> 00:30:30,448 AN ASSIGNMENT REQUEST FORM. YOU 740 00:30:30,448 --> 00:30:33,351 CAN DO THAT BUT REALLY THE FINAL 741 00:30:33,351 --> 00:30:36,420 DETERMINATION IS MADE AT THE 742 00:30:36,420 --> 00:30:37,922 TIME OF RECEIPT. AFTER 743 00:30:37,922 --> 00:30:38,789 SUBMITTING, YOU CAN REACH OUT TO 744 00:30:38,789 --> 00:30:45,229 THE SRO IF, LET'S SAY, PERSON 745 00:30:45,229 --> 00:30:46,764 YOU DON'T KNOW WHERE ELSE TO 746 00:30:46,764 --> 00:30:49,267 TURN AND YOU NEED SOME GUIDANCE 747 00:30:49,267 --> 00:30:50,368 AND LET'S SAY YOU WANT YOUR 748 00:30:50,368 --> 00:30:51,302 APPLICATION TO GO TO A 749 00:30:51,302 --> 00:30:52,870 PARTICULAR IC AND YOU SEE IT 750 00:30:52,870 --> 00:30:54,705 WENT SOMEPLACE ELSE. YOU HAVE 751 00:30:54,705 --> 00:30:56,707 QUESTIONS ABOUT THAT, I CAN 752 00:30:56,707 --> 00:30:58,209 CERTAINLY NAVIGATE YOU TO THE 753 00:30:58,209 --> 00:30:59,544 RIGHT PEOPLE FOR THAT IF YOU 754 00:30:59,544 --> 00:31:01,279 HAVE, IF YOU DISAGREE WITH THE 755 00:31:01,279 --> 00:31:03,748 ASSIGNMENT OF THE STUDY SECTION, 756 00:31:03,748 --> 00:31:06,984 YOU CAN REACH OUT TO THE SRO AND 757 00:31:06,984 --> 00:31:07,985 WE CAN SEE WHAT WE CAN DO BUT 758 00:31:07,985 --> 00:31:10,354 AGAIN THE APPLICATION, YOU KNOW, 759 00:31:10,354 --> 00:31:13,758 GETS REVIEWED IN THE GROUP THAT 760 00:31:13,758 --> 00:31:15,860 BEST FITS THE SCIENCE OF THE 761 00:31:15,860 --> 00:31:16,494 APPLICATION. THAT IS REALLY 762 00:31:16,494 --> 00:31:18,563 KIND OF WHAT DETERMINES IT. A 763 00:31:18,563 --> 00:31:20,198 LOT OF TIMES APPLICANTS WILL 764 00:31:20,198 --> 00:31:22,633 REACH OUT TO US AND SAY THE 765 00:31:22,633 --> 00:31:25,603 APPLICATION WAS REVIEWED IN YOUR 766 00:31:25,603 --> 00:31:27,205 MEETING. IT DID REALLY POORLY. 767 00:31:27,205 --> 00:31:29,740 I WANTED TO GO TO A DIFFERENT 768 00:31:29,740 --> 00:31:32,977 MEETING. THAT'S NOT 769 00:31:32,977 --> 00:31:34,745 UNFORTUNATELY A CRITERION FOR US 770 00:31:34,745 --> 00:31:36,614 AND AFTER REVIEW AS I MENTIONED 771 00:31:36,614 --> 00:31:38,416 THE ASSIGNED PL THAT'S INDICATED 772 00:31:38,416 --> 00:31:42,320 ON THE UPPER LEFT CORNER OF THE 773 00:31:42,320 --> 00:31:44,889 STATEMENT. SO FINALLY, IF YOU 774 00:31:44,889 --> 00:31:46,190 HAVE ANY CONCERNS REGARDING THE 775 00:31:46,190 --> 00:31:49,327 OUTCOME OF YOUR REVIEW, WE HAVE 776 00:31:49,327 --> 00:31:50,595 CHANNELS THAT YOU CAN SUBMIT 777 00:31:50,595 --> 00:31:53,431 YOUR CONCERNS TO. IN 778 00:31:53,431 --> 00:31:54,865 PARTICULAR, YOU HAVE ANY 779 00:31:54,865 --> 00:31:57,335 CONCERNS ABOUT BIAS, OR ANYTHING 780 00:31:57,335 --> 00:32:00,705 ELSE THAT YOU FEEL BASICALLY 781 00:32:00,705 --> 00:32:02,173 COLORED THE FAIRNESS OF YOUR 782 00:32:02,173 --> 00:32:03,941 REVIEW THE PLACE TO REACH OUT 783 00:32:03,941 --> 00:32:04,875 FOR, OF COURSE YOU CAN ALWAYS 784 00:32:04,875 --> 00:32:07,178 REACH OUT TO THE SRO BUT WE DO 785 00:32:07,178 --> 00:32:10,181 HAVE CSR DOES HAVE CHANNELS THAT 786 00:32:10,181 --> 00:32:11,182 ARE SPECIFIC TO REPORTING BIAS. 787 00:32:11,182 --> 00:32:13,818 THERE'S THE E-MAIL THERE. AND 788 00:32:13,818 --> 00:32:16,921 IN THE EVENT THAT YOUR 789 00:32:16,921 --> 00:32:18,823 APPLICATION, OR YOUR SUMMARY 790 00:32:18,823 --> 00:32:20,625 STATEMENT DOES INDICATE SOME 791 00:32:20,625 --> 00:32:23,294 SORT OF BIAS, YOUR APPLICATION 792 00:32:23,294 --> 00:32:25,062 WILL BE RE-REVIEWED WITHIN THE 793 00:32:25,062 --> 00:32:29,433 SAME CYCLE. SO BEFORE THE IT 794 00:32:29,433 --> 00:32:30,568 COMES DOWN TO THAT AND IF YOU 795 00:32:30,568 --> 00:32:31,902 HAVE QUESTIONS AROUND THE REVIEW 796 00:32:31,902 --> 00:32:35,306 INTEGRITY THERE'S ALSO A 797 00:32:35,306 --> 00:32:39,610 SEPARATE CHANNEL FOR THAT. SO 798 00:32:39,610 --> 00:32:42,913 THAT'S EVERYTHING THAT I HAVE. 799 00:32:42,913 --> 00:32:47,318 AND I AM WELCOMING ANY OF YOUR 800 00:32:47,318 --> 00:32:52,023 QUESTIONS. 801 00:32:52,023 --> 00:32:57,795 >> DOES ANYONE HAVE QUESTIONS 802 00:32:57,795 --> 00:32:59,297 FOR DR. COHEN? CAN YOU COME UP 803 00:32:59,297 --> 00:33:07,305 TO THE MICROPHONE? 804 00:33:07,305 --> 00:33:11,309 >> AUDIENCE: I WANT TO SPEAK IF 805 00:33:11,309 --> 00:33:14,612 FOR YOUNG PEOPLE, NOT MANY YOUNG 806 00:33:14,612 --> 00:33:16,347 PEOPLE HERE BUT AT LEAST FOR 807 00:33:16,347 --> 00:33:19,950 HIM. SO I'M TOO SENIOR NOW. I 808 00:33:19,950 --> 00:33:22,553 KNOW, IN THE ENTIRE PROCESS, 809 00:33:22,553 --> 00:33:23,621 UNDERSTANDING THEN, THE ONE 810 00:33:23,621 --> 00:33:27,625 THING I AM GOING TO ASK IS, THIS 811 00:33:27,625 --> 00:33:29,293 IS MY FEELING SO IT MIGHT BE 812 00:33:29,293 --> 00:33:32,596 TRUE OR NOT BE TRUE BUT I ALSO 813 00:33:32,596 --> 00:33:33,731 TALK TO MY COLLEAGUE ABOUT THE 814 00:33:33,731 --> 00:33:37,768 REVIEW PROCESS. THERE USED TO 815 00:33:37,768 --> 00:33:42,940 BE MULTIPLE THING, SIGNIFICANCE 816 00:33:42,940 --> 00:33:44,275 APPROACH, ET CETERA, UP UNTIL 817 00:33:44,275 --> 00:33:53,751 NOW WHAT I FELT WAS CALLING 818 00:33:53,751 --> 00:33:57,421 BECAUSE OF THE SCORE. THE 819 00:33:57,421 --> 00:33:58,422 IMPACT SCORE WAS DETERMINED BY 820 00:33:58,422 --> 00:33:59,757 THE APPROACH AND I WANT TO KNOW 821 00:33:59,757 --> 00:34:02,193 IF THAT'S TRUE OR NOT. THE 822 00:34:02,193 --> 00:34:06,097 SECOND QUESTION IS OVER BIAS. I 823 00:34:06,097 --> 00:34:08,799 WELCOME THE NEW CHANGE. 824 00:34:08,799 --> 00:34:09,967 POTENTIALLY HAVE ALREADY AT THE 825 00:34:09,967 --> 00:34:15,740 END OF THE DAY, I'M A JUNIOR AND 826 00:34:15,740 --> 00:34:17,041 I'M SUCCESSFUL FOR OTHER FUNDING 827 00:34:17,041 --> 00:34:21,112 BUT NIH WHEN I WAS VERY JUNIOR I 828 00:34:21,112 --> 00:34:23,314 NOT VERY MUCH HAVE SUCCESS AND 829 00:34:23,314 --> 00:34:24,749 AFTER THAT I LIMIT MY SUBMISSION 830 00:34:24,749 --> 00:34:27,084 BECAUSE I FEEL LIKE THIS IS NOT 831 00:34:27,084 --> 00:34:29,754 MY COMMUNITY, THIS IS MORE THE 832 00:34:29,754 --> 00:34:30,955 SCIENCE COMMUNITY OR THE 833 00:34:30,955 --> 00:34:35,292 ADAPTERS COMMUNITY. SO THE 834 00:34:35,292 --> 00:34:38,929 SECOND QUESTION IS I HOPE THIS 835 00:34:38,929 --> 00:34:40,097 WILL CHANGE THE, WHATEVER BIAS 836 00:34:40,097 --> 00:34:42,700 KIND OF PROBLEM IN THE STUDY 837 00:34:42,700 --> 00:34:45,936 SECTION. BUT IS IT REALLY? 838 00:34:45,936 --> 00:34:49,206 KIND OF TREMENDOUSLY KIND OF 839 00:34:49,206 --> 00:34:52,877 CHANGED THE CULTURE OR YOU 840 00:34:52,877 --> 00:34:53,744 EXPECTING SLOW STEP BY STEP 841 00:34:53,744 --> 00:34:56,213 CHANGE IN THE FUTURE? I WANT TO 842 00:34:56,213 --> 00:34:57,815 SPEAK FOR HIM BECAUSE HE 843 00:34:57,815 --> 00:34:59,417 PROBABLY CANNOT ASK THAT KIND OF 844 00:34:59,417 --> 00:35:02,920 QUESTION BECAUSE HE'S TOO JU 845 00:35:02,920 --> 00:35:03,154 JUNIOR. 846 00:35:03,154 --> 00:35:04,221 >> I'M GLAD YOU ASKED THAT 847 00:35:04,221 --> 00:35:05,289 QUESTION. BOTH OF THOSE ARE 848 00:35:05,289 --> 00:35:06,991 REALLY GOOD QUESTIONS. LET ME 849 00:35:06,991 --> 00:35:08,292 TAKE THE FIRST ONE FIRST. SO 850 00:35:08,292 --> 00:35:10,161 THE PURPOSE OF THE REVIEW IS TO 851 00:35:10,161 --> 00:35:12,463 EVALUATE FOR SCIENTIFIC MERITS 852 00:35:12,463 --> 00:35:15,299 WHICH IS THE SIGNIFICANCE. AND 853 00:35:15,299 --> 00:35:17,902 THE OVERALL IMPACT. THIS IS 854 00:35:17,902 --> 00:35:20,037 WHAT WE TRAIN OUR REVIEWERS TO 855 00:35:20,037 --> 00:35:23,274 DO. NOW HOW WELL THE REVIEWERS 856 00:35:23,274 --> 00:35:25,409 MIGHT COMPLY WITH THAT, IT COULD 857 00:35:25,409 --> 00:35:27,077 VARY. WE HOPE THAT WE ARE DOING 858 00:35:27,077 --> 00:35:28,379 BETTER. WE HOPE THAT WE ARE 859 00:35:28,379 --> 00:35:30,915 CONTINUING TO DO BETTER. BUT 860 00:35:30,915 --> 00:35:34,552 THE APPROACH IS IMPORTANT. YES, 861 00:35:34,552 --> 00:35:37,087 BUT WE REALLY STRIVE TO 862 00:35:37,087 --> 00:35:38,722 ENCOURAGE THE REVIEWERS TO THINK 863 00:35:38,722 --> 00:35:41,759 ABOUT THE IMPORTANCE OF THE 864 00:35:41,759 --> 00:35:43,294 PROBLEM. SOMETIMES THE APPROACH 865 00:35:43,294 --> 00:35:44,728 CAN BE FIXED CERTAINLY IN 866 00:35:44,728 --> 00:35:46,363 RESUBMISSIONS, YOU KNOW, IF 867 00:35:46,363 --> 00:35:48,098 THERE ARE SOME WEAKNESSES IN THE 868 00:35:48,098 --> 00:35:49,767 APPROACH THAT'S ALL DOABLE WHAT 869 00:35:49,767 --> 00:35:51,302 CAN'T BE FIXED IS THE 870 00:35:51,302 --> 00:35:53,671 SIGNIFICANCE SO IF THE PROBLEM 871 00:35:53,671 --> 00:35:56,974 IS SIMPLY NOT LARGE ENOUGH TO 872 00:35:56,974 --> 00:35:59,310 MAKE AN ADVANCE, NOT IMPORTANT 873 00:35:59,310 --> 00:36:00,911 ENOUGH TO MAKE AN IMPORTANT 874 00:36:00,911 --> 00:36:02,379 ADVANCE ON THE FIELD, THERE'S 875 00:36:02,379 --> 00:36:03,981 NOT A WHOLE LOT THAT CAN BE DONE 876 00:36:03,981 --> 00:36:05,749 WITH THAT PROJECT. SO THAT'S 877 00:36:05,749 --> 00:36:07,284 WHAT WE -- THAT'S HOW WE TRAIN 878 00:36:07,284 --> 00:36:10,154 OUR REVIEWERS, THAT'S WHAT WE 879 00:36:10,154 --> 00:36:12,256 EXPECT TO DO THEM AND, BUT 880 00:36:12,256 --> 00:36:14,959 REVIEWERS AS HUMANS MIGHT PICK 881 00:36:14,959 --> 00:36:16,494 THINGS UP AT DIFFERENT LEVELS 882 00:36:16,494 --> 00:36:19,230 BUT THAT'S CERTAINLY HOW I TRAIN 883 00:36:19,230 --> 00:36:21,298 MY REVIEWERS AND I EXPECT THEM 884 00:36:21,298 --> 00:36:24,568 TO UPHOLD THAT TYPE OF STANDARD 885 00:36:24,568 --> 00:36:27,271 SO FOR THE SECOND QUESTION, SRF, 886 00:36:27,271 --> 00:36:28,739 YEAH, WE ARE -- WE HAVE HIGH 887 00:36:28,739 --> 00:36:30,808 HOPES THAT THIS IS GOING TO 888 00:36:30,808 --> 00:36:33,777 REALLY CHANGE THE CULTURE OF 889 00:36:33,777 --> 00:36:37,014 REVIEW. WE ARE AWARE THAT NIH 890 00:36:37,014 --> 00:36:38,649 HAS BEEN STRUGGLING WITH BIAS 891 00:36:38,649 --> 00:36:41,752 FOR MANY YEARS. WE STARTED OFF 892 00:36:41,752 --> 00:36:43,854 TO ADDRESS THIS BIAS THROUGH THE 893 00:36:43,854 --> 00:36:45,689 TRAININGS THAT WE DEVELOPED. 894 00:36:45,689 --> 00:36:47,658 AND WE DIDN'T THINK THAT IT WENT 895 00:36:47,658 --> 00:36:50,160 FAR ENOUGH AND SO WE WENT TO THE 896 00:36:50,160 --> 00:36:51,495 COMMUNITY TO ASK WHAT THE 897 00:36:51,495 --> 00:36:53,197 COMMUNITY WOULD LIKE TO DO. AND 898 00:36:53,197 --> 00:36:55,432 SO THE COMMUNITY REALLY CAME UP 899 00:36:55,432 --> 00:36:56,867 WITH THESE -- WITH THIS 900 00:36:56,867 --> 00:37:01,505 SIMPLIFIED REVIEW FRAMEWORK THAT 901 00:37:01,505 --> 00:37:04,508 REALLY SEGREGATES BIAS INTO A 902 00:37:04,508 --> 00:37:07,611 NON SCORED CATEGORY. NOW, 903 00:37:07,611 --> 00:37:09,146 REGARDING JUNIOR, I DON'T THINK 904 00:37:09,146 --> 00:37:13,951 THE WORD JUNIOR, EARLY STAGE 905 00:37:13,951 --> 00:37:15,319 INVESTIGATORS, YOU KNOW, AS I 906 00:37:15,319 --> 00:37:16,387 MENTIONED, THOSE APPLICATIONS DO 907 00:37:16,387 --> 00:37:19,323 GET CLUSTERED. THEY DO HAVE A 908 00:37:19,323 --> 00:37:20,491 DIFFERENT PERCENTILING SYSTEM I 909 00:37:20,491 --> 00:37:23,294 KNOW INSTITUTES DO THE TWO 910 00:37:23,294 --> 00:37:23,894 THINGS DIFFERENTLY. 911 00:37:23,894 --> 00:37:26,997 WHATEVER THE PERCENTILE IS, SO, 912 00:37:26,997 --> 00:37:28,465 SOME OF THIS IS OUTSIDE THE, YOU 913 00:37:28,465 --> 00:37:32,369 KNOW, WHAT I CAN EXPLAIN AS AN 914 00:37:32,369 --> 00:37:34,505 SRO BECAUSE MY ROLE IS TRAINING 915 00:37:34,505 --> 00:37:36,941 REVIEWERS MY ROLE IS NOT RELATED 916 00:37:36,941 --> 00:37:38,409 TO FUNDING ON ANY LEVEL SO WE 917 00:37:38,409 --> 00:37:40,077 REALLY KEEP THOSE VERY SEPARATE 918 00:37:40,077 --> 00:37:41,245 BUT AS FAR AS TRAINING THE 919 00:37:41,245 --> 00:37:44,181 REVIEWERS AND ENSURING THAT THEY 920 00:37:44,181 --> 00:37:46,617 TAKE INTO ACCOUNT THAT AN EARLY 921 00:37:46,617 --> 00:37:48,519 STAGE INVESTIGATOR IS, YOU KNOW, 922 00:37:48,519 --> 00:37:50,454 NOT GOING TO HAVE, YOU KNOW, THE 923 00:37:50,454 --> 00:37:51,388 SAME RECORD OF ACCOMPLISHMENT, 924 00:37:51,388 --> 00:37:53,324 IS NOT GOING TO HAVE THE SAME 925 00:37:53,324 --> 00:37:55,225 STATURE IN THE FIELD IS VERY 926 00:37:55,225 --> 00:37:57,328 IMPORTANT AND THIS IS, AGAIN, 927 00:37:57,328 --> 00:37:59,730 WHAT FEEDS INTO THE REASON WHY 928 00:37:59,730 --> 00:38:05,736 FACTOR THREE WAS CREATED. SO 929 00:38:05,736 --> 00:38:09,773 THAT INSTEAD OF IN THE PAST 930 00:38:09,773 --> 00:38:12,142 THERE WAS THE STATURE OF THE 931 00:38:12,142 --> 00:38:13,677 INVESTIGATOR. THE REVIEWERS 932 00:38:13,677 --> 00:38:14,678 WOULD SAY I KNOW THIS PERSON AND 933 00:38:14,678 --> 00:38:16,580 I KNOW THAT THEY ARE, YOU KNOW, 934 00:38:16,580 --> 00:38:19,850 VERY IMPORTANT IN THE FIELD VERY 935 00:38:19,850 --> 00:38:21,819 RENOWNED. SO REGARDLESS OF WHAT 936 00:38:21,819 --> 00:38:25,155 THE APPLICATION IS, THEY KNOW 937 00:38:25,155 --> 00:38:29,760 WHAT THEY'RE DOING. SO STARTED 938 00:38:29,760 --> 00:38:31,295 ADDRESSING THIS THREE YEARS AGO 939 00:38:31,295 --> 00:38:32,796 WITH THE BASE TRAINING. WE 940 00:38:32,796 --> 00:38:35,299 THINK WE ARE DOING BETTER. WE 941 00:38:35,299 --> 00:38:36,767 DO GET RESOLUTION OF CASES. 942 00:38:36,767 --> 00:38:37,835 WHERE PEOPLE, YOU KNOW, COME 943 00:38:37,835 --> 00:38:40,270 BACK TO US WITH QUESTIONS WELL, 944 00:38:40,270 --> 00:38:42,773 YOU KNOW I THINK THE REVIEW WAS 945 00:38:42,773 --> 00:38:44,375 BIASED AND WELL WHEN WAS THE 946 00:38:44,375 --> 00:38:45,409 REVIEW DONE? IT WAS DONE THREE 947 00:38:45,409 --> 00:38:47,745 YEARS AGO. OKAY, SO WE'RE 948 00:38:47,745 --> 00:38:49,380 TAKING DIFFERENT STEPS TO 949 00:38:49,380 --> 00:38:51,015 ADDRESS THIS. AND THE HOPE IS 950 00:38:51,015 --> 00:38:55,052 THAT SRF WILL ALLOW US TO 951 00:38:55,052 --> 00:38:57,321 CONTINUE TO DOWNPLAY THESE KIND 952 00:38:57,321 --> 00:38:59,256 OF BIASES EVEN FURTHER. 953 00:38:59,256 --> 00:39:02,760 >> AUDIENCE: I SEE, DO -- SO I 954 00:39:02,760 --> 00:39:09,166 CAN -- GIVE TWO COMMENTS? I 955 00:39:09,166 --> 00:39:10,434 ASKED THE QUESTION BASED ON MY 956 00:39:10,434 --> 00:39:13,137 VERY LIMITED NUMBER OF 957 00:39:13,137 --> 00:39:14,171 SUBMISSION. THE -- I KIND OF 958 00:39:14,171 --> 00:39:16,440 LOOK AT THE SCORE AND THE FINAL 959 00:39:16,440 --> 00:39:17,741 IMPACT SCORE AND SOMEHOW AN 960 00:39:17,741 --> 00:39:19,143 APPROACH CAN CORRELATE WITH THAT 961 00:39:19,143 --> 00:39:20,644 ONE AND THEN I GOT THE OTHER 962 00:39:20,644 --> 00:39:23,747 ONE, THE OTHER ONE IS VERY 963 00:39:23,747 --> 00:39:26,483 HEAVILY APPROACHED IN DEEP CARE 964 00:39:26,483 --> 00:39:28,585 AND SOMEHOW THE RECENT ONE NOT 965 00:39:28,585 --> 00:39:30,988 DISCUSSED WE DIDN'T DO THAT MUCH 966 00:39:30,988 --> 00:39:31,889 DETAIL, NO APPROACH DESCRIPTION 967 00:39:31,889 --> 00:39:34,992 AND THEN WE ARE NOT DISCUSSED 968 00:39:34,992 --> 00:39:36,160 EVEN THOUGH I THOUGHT I FELT 969 00:39:36,160 --> 00:39:38,195 THAT PROPOSES THE BEST IDEA I 970 00:39:38,195 --> 00:39:39,797 EVER, YOU KNOW, IMAGINED. SO 971 00:39:39,797 --> 00:39:41,999 THAT IS BECAUSE OF THAT, AND I 972 00:39:41,999 --> 00:39:43,133 KIND OF HAVE THAT COMMENT OR THE 973 00:39:43,133 --> 00:39:46,403 QUESTION. THE SECOND ONE IS 974 00:39:46,403 --> 00:39:49,540 ABOUT THE EARLY CAREER, YOU 975 00:39:49,540 --> 00:39:53,544 KNOW, DEBUT PANEL VULNERABILITY. 976 00:39:53,544 --> 00:39:56,747 I ACTUALLY WAS SELECTED AND I 977 00:39:56,747 --> 00:39:58,282 HOPE THAT IS CHANGING IN THE 978 00:39:58,282 --> 00:39:59,750 FUTURE. IF YOU NEED SOME NAMES 979 00:39:59,750 --> 00:40:05,756 I CAN GIVE 200 NAMES FOR YOU. 980 00:40:05,756 --> 00:40:08,592 AND I'M HAPPY TO PROVIDE THEM. 981 00:40:08,592 --> 00:40:10,794 >> THANK YOU FOR THAT THE ECR 982 00:40:10,794 --> 00:40:12,396 PROGRAM WAS ACTUALLY REVISED 983 00:40:12,396 --> 00:40:14,531 SEVERAL YEARS AGO SO WE USED TO 984 00:40:14,531 --> 00:40:16,100 HAVE THE REQUIREMENT WAS TO 985 00:40:16,100 --> 00:40:20,838 INCLUDE AN ECR ON ONE ECR ON 986 00:40:20,838 --> 00:40:22,706 EVERY STANDING PANEL. THE -- 987 00:40:22,706 --> 00:40:24,508 AND THEY WOULD REVIEW ACTUALLY 988 00:40:24,508 --> 00:40:26,710 FOUR APPLICATIONS. NOW THE 989 00:40:26,710 --> 00:40:28,879 REQUIREMENT IS TWO ECRS SO WE 990 00:40:28,879 --> 00:40:30,981 CAN ACTUALLY GET MORE PEOPLE 991 00:40:30,981 --> 00:40:32,182 TRAINED TO UNDERSTAND WHAT IS 992 00:40:32,182 --> 00:40:34,184 INVOLVED IN THE REVIEW. AND AS 993 00:40:34,184 --> 00:40:36,487 I MENTIONED, IT'S REALLY A GREAT 994 00:40:36,487 --> 00:40:38,122 PROGRAM SO PLEASE APPLY ONLINE, 995 00:40:38,122 --> 00:40:39,823 THE APPLICATION PROCESS IS VERY 996 00:40:39,823 --> 00:40:41,759 QUICK. YOU CAN, YOU KNOW, IF 997 00:40:41,759 --> 00:40:42,960 YOU ARE ELIGIBLE YOU CAN GET 998 00:40:42,960 --> 00:40:47,297 TURNED AROUND IN 24 HOURS. AND 999 00:40:47,297 --> 00:40:52,336 THEN IT'S A -- SOME ECRS ARE 1000 00:40:52,336 --> 00:40:54,371 SELECTED DIRECTLY BY SROS AND 1001 00:40:54,371 --> 00:40:56,540 THIS IS A GENERAL COMMENT TO 1002 00:40:56,540 --> 00:40:57,741 COMMUNITY. WHATEVER QUESTIONS 1003 00:40:57,741 --> 00:40:59,743 YOU MAY HAVE ABOUT KIND OF THE 1004 00:40:59,743 --> 00:41:01,211 MYSTERY, RIGHT, LIKE THE BLACK 1005 00:41:01,211 --> 00:41:05,749 BOX OF NIH I HIGHLY ENCOURAGE 1006 00:41:05,749 --> 00:41:14,191 YOU TO SERVE AS A PANEL MEMBER. 1007 00:41:14,191 --> 00:41:16,727 IF YOU'RE INVITED AND ELECTED TO 1008 00:41:16,727 --> 00:41:18,862 COME AS A STANDING MEMBER THE 1009 00:41:18,862 --> 00:41:20,397 MYSTERY GETS RESOLVED. YOU SEE 1010 00:41:20,397 --> 00:41:23,066 THE APPLICATIONS THAT ARE 1011 00:41:23,066 --> 00:41:24,001 REVIEWED. SOMETIMES, YOU KNOW 1012 00:41:24,001 --> 00:41:25,903 THE APPLICANT MIGHT THINK IT'S 1013 00:41:25,903 --> 00:41:28,839 THE BEST IDEA THEY'VE HAD BUT LO 1014 00:41:28,839 --> 00:41:32,576 AND BEHOLD THERE ARE FIVE OTHER 1015 00:41:32,576 --> 00:41:33,811 APPLICATIONS THAT POSE A SIMILAR 1016 00:41:33,811 --> 00:41:37,514 IDEA IN THE SAME STUDY SECTION 1017 00:41:37,514 --> 00:41:38,382 AND SO ANOTHER THING TO POINT 1018 00:41:38,382 --> 00:41:41,251 OUT IS, YOU KNOW, YOU MIGHT END 1019 00:41:41,251 --> 00:41:44,555 UP IN A SITUATION WHERE YOU 1020 00:41:44,555 --> 00:41:46,623 APPLY YOUR FIRST INITIAL 1021 00:41:46,623 --> 00:41:47,257 SUBMISSION GETS A PARTICULAR 1022 00:41:47,257 --> 00:41:50,527 SCORE IS DISCUSSED, YOU RESUBMIT 1023 00:41:50,527 --> 00:41:52,296 AND THAT APPLICATION IS NO 1024 00:41:52,296 --> 00:41:53,697 LONGER DISCUSSED. THAT CAN 1025 00:41:53,697 --> 00:41:55,032 HAPPEN. AND THE REASON FOR 1026 00:41:55,032 --> 00:41:59,269 THAT, WELL, TWO, IS THE FIRST 1027 00:41:59,269 --> 00:42:07,144 REASON IS DEPENDING ON HOW THE 1028 00:42:07,144 --> 00:42:09,046 APPLICATION SCORING TOOK PLACE. 1029 00:42:09,046 --> 00:42:10,080 WHAT TYPE OF SCORING THEY 1030 00:42:10,080 --> 00:42:12,316 RECEIVED THAT DETERMINES THE 50% 1031 00:42:12,316 --> 00:42:14,651 CUTOFF. IN ONE ROUND LET'S SAY 1032 00:42:14,651 --> 00:42:17,754 AN R 01 ESTABLISHED 1033 00:42:17,754 --> 00:42:19,289 INVESTIGATORS MIGHT HAVE A 1034 00:42:19,289 --> 00:42:21,425 CUTOFF OF 4.0. IN ANOTHER ROUND 1035 00:42:21,425 --> 00:42:22,826 THAT MIGHT BE 3.7 IT DOESN'T 1036 00:42:22,826 --> 00:42:24,394 MEAN THE APPLICATION IS WORSE OR 1037 00:42:24,394 --> 00:42:26,396 YOU KNOW WHY WASN'T IT 1038 00:42:26,396 --> 00:42:27,764 DISCUSSED? IT DOESN'T MEAN IT'S 1039 00:42:27,764 --> 00:42:29,233 BAD IT'S JUST THAT IT DIDN'T 1040 00:42:29,233 --> 00:42:30,367 MAKE IT UNFORTUNATELY TO THAT 1041 00:42:30,367 --> 00:42:33,871 TOP 50%. AND SO BY SERVING AS A 1042 00:42:33,871 --> 00:42:35,272 REVIEWER YOU REALLY KIND OF, YOU 1043 00:42:35,272 --> 00:42:39,576 KNOW, DELVE INTO THE MYSTERY OF 1044 00:42:39,576 --> 00:42:41,111 THESE. S 1045 00:42:41,111 --> 00:42:43,046 >> AUDIENCE: I'M AN OFFICER ON 1046 00:42:43,046 --> 00:42:45,949 THE OTHER SIDE OF REVIEW. SO WE 1047 00:42:45,949 --> 00:42:49,453 OFTEN ENCOUNTER A SITUATION 1048 00:42:49,453 --> 00:42:55,225 WHERE PI'S ARE JUST MAD IN THE 1049 00:42:55,225 --> 00:42:56,994 SUMMARY STATEMENT. SO, YOU 1050 00:42:56,994 --> 00:42:59,630 KNOW, BELIEVE IT OR NOT I ALWAYS 1051 00:42:59,630 --> 00:43:03,066 TELL PEOPLE DON'T CALL ME IF YOU 1052 00:43:03,066 --> 00:43:05,002 ARE NOT DISGUST ENOUGH TO KNOW 1053 00:43:05,002 --> 00:43:06,536 AFTER READING THE SUMMARY AT THE 1054 00:43:06,536 --> 00:43:09,239 SAME TIME BUT SOMETIMES THEY'RE 1055 00:43:09,239 --> 00:43:13,176 RIGHT. FOR EXAMPLE, IF PI 1056 00:43:13,176 --> 00:43:14,478 PROPOSE TO DO SOME LINE OF 1057 00:43:14,478 --> 00:43:15,746 RESEARCH, AND THEN REVIEWER ONE 1058 00:43:15,746 --> 00:43:18,382 WHICH IS SUPPOSED TO BE THE MOST 1059 00:43:18,382 --> 00:43:20,550 FITTING REVIEWER SAID THAT HAS 1060 00:43:20,550 --> 00:43:22,419 BEEN DONE ALREADY, IN REALITY 1061 00:43:22,419 --> 00:43:23,854 IT'S NOT, IN OTHER WORDS, 1062 00:43:23,854 --> 00:43:28,692 PROGRAM OFFICER AGREES WITH THE 1063 00:43:28,692 --> 00:43:30,527 PI. SO IN THAT CASE, I MEAN, 1064 00:43:30,527 --> 00:43:32,496 WHAT I NORMALLY DO IS I REACH 1065 00:43:32,496 --> 00:43:36,533 OUT TO SRO AND HAVE A 1066 00:43:36,533 --> 00:43:43,974 CONVERSATION. AND MY QUESTION 1067 00:43:43,974 --> 00:43:45,676 IS SHOULD PI WORK AFTER THIS 1068 00:43:45,676 --> 00:43:47,311 CASE? I UNDERSTAND THEY'RE NOT 1069 00:43:47,311 --> 00:43:50,047 SUPPOSED TO TALK TO YOU GUYS. 1070 00:43:50,047 --> 00:43:51,715 >> I AM GLAD YOU ASKED THAT. 1071 00:43:51,715 --> 00:43:53,083 UNFORTUNATELY, NO, WE REALLY TRY 1072 00:43:53,083 --> 00:43:56,720 TO SEPARATE AND I THINK THE 1073 00:43:56,720 --> 00:43:58,255 SOURCE OF THE CONFUSION MIGHT BE 1074 00:43:58,255 --> 00:44:01,224 BECAUSE ICS THAT ALSO DO REVIEW, 1075 00:44:01,224 --> 00:44:03,160 YOU KNOW, THE ROLE OF THE SRO 1076 00:44:03,160 --> 00:44:05,696 AND THE PO IS DIFFERENT AND SO, 1077 00:44:05,696 --> 00:44:13,403 YOU KNOW, AT NCI AND N ISNIB BS 1078 00:44:13,403 --> 00:44:16,173 TOO THE SRO IS MORE INVOLVED AT 1079 00:44:16,173 --> 00:44:18,475 CSR THE SRO IS NOT INVOLVE IN 1080 00:44:18,475 --> 00:44:20,744 THE POST REVIEW DISCUSSIONS. 1081 00:44:20,744 --> 00:44:22,079 OUR JOB IS TO MAKE SURE 1082 00:44:22,079 --> 00:44:23,747 EVERYTHING IN THE SUMMARY 1083 00:44:23,747 --> 00:44:25,515 STATEMENT IS CLEAR ENOUGH SO 1084 00:44:25,515 --> 00:44:27,751 THAT, YOU KNOW, WE CAN PREVENT 1085 00:44:27,751 --> 00:44:30,954 THIS KIND OF THING. NOW I'M 1086 00:44:30,954 --> 00:44:32,622 CERTAINLY WE CAN'T PREVENT THE 1087 00:44:32,622 --> 00:44:34,491 PIS FROM BEING DISAPPOINTED, 1088 00:44:34,491 --> 00:44:36,293 EVEN UPSET AT THE OUTCOME, YOU 1089 00:44:36,293 --> 00:44:39,663 KNOW, THAT'S UNFORTUNATELY THE 1090 00:44:39,663 --> 00:44:43,066 GAME. AND, YOU KNOW, WE, YOU 1091 00:44:43,066 --> 00:44:49,306 KNOW, NEED TO MAKE SURE TO THAT 1092 00:44:49,306 --> 00:44:52,209 THE SUMMARY STATEMENT CONVEYS 1093 00:44:52,209 --> 00:44:55,178 WHAT IS THE GENERAL ASSESSMENT 1094 00:44:55,178 --> 00:44:56,480 AND SO FOR THE PROGRAM IT IS 1095 00:44:56,480 --> 00:44:59,082 IMPORTANT TO KIND OF BE ABLE TO 1096 00:44:59,082 --> 00:45:01,752 CONVEY AND TRANSLATE WHAT THE 1097 00:45:01,752 --> 00:45:03,353 SUMMARY STATEMENT MEAN TO THE 1098 00:45:03,353 --> 00:45:05,188 APPLICANT AND WHAT THEY CAN DO 1099 00:45:05,188 --> 00:45:06,390 ABOUT IT. THE ONLY THING THAT 1100 00:45:06,390 --> 00:45:08,291 THE SRO COULD BE CONTACTED ABOUT 1101 00:45:08,291 --> 00:45:10,994 IS IF THERE'S ANY -- IF THERE'S 1102 00:45:10,994 --> 00:45:12,329 ANY ALLEGATION OF BIAS. WHICH 1103 00:45:12,329 --> 00:45:15,232 AS I SAID, IF THAT IS 1104 00:45:15,232 --> 00:45:16,600 DETERMINED, SO BIAS WOULD NOT 1105 00:45:16,600 --> 00:45:18,702 BE, YOU KNOW, THEY DIDN'T LIKE 1106 00:45:18,702 --> 00:45:19,903 MY APPLICATION, THEY THOUGHT IT 1107 00:45:19,903 --> 00:45:21,838 WASN'T INNOVATIVE ENOUGH. BIAS 1108 00:45:21,838 --> 00:45:23,807 WOULD BE, YOU KNOW, I AM GETTING 1109 00:45:23,807 --> 00:45:25,075 THE SENSE THAT THERE WAS 1110 00:45:25,075 --> 00:45:27,110 SOMETHING AGAINST ME AS AN 1111 00:45:27,110 --> 00:45:29,913 INVESTIGATOR. THAT SEEMS TO 1112 00:45:29,913 --> 00:45:33,250 HAVE MATRICULATED INTO THIS 1113 00:45:33,250 --> 00:45:37,020 APPLICATI 1114 00:45:37,020 --> 00:45:37,320 APPLICATION. 1115 00:45:37,320 --> 00:45:38,221 >> IF IT'S QUICK YOU CAN ASK. 1116 00:45:38,221 --> 00:45:39,222 >> AUDIENCE: YOU MENTIONED IN 1117 00:45:39,222 --> 00:45:40,524 THE THREE FACTOR REVIEW APPROACH 1118 00:45:40,524 --> 00:45:42,793 THAT THAT THIRD FACTOR ISN'T 1119 00:45:42,793 --> 00:45:45,262 SCORED. DID I GET THAT RIGHT? 1120 00:45:45,262 --> 00:45:47,731 >> A LITTLE LOUDER. 1121 00:45:47,731 --> 00:45:49,366 >> AUDIENCE: YOU MENTIONED THE 1122 00:45:49,366 --> 00:45:51,401 THIRD FACTOR IS NOT SCORED? SO 1123 00:45:51,401 --> 00:45:52,402 HOW, I DIDN'T QUITE UNDERSTAND 1124 00:45:52,402 --> 00:45:54,037 THEN HOW IS IT TAKEN INTO 1125 00:45:54,037 --> 00:45:56,406 ACCOUNT? HOW IS IT IMPACTFUL? 1126 00:45:56,406 --> 00:45:59,743 >> YEAH, I MEAN, YEAH, SO THE 1127 00:45:59,743 --> 00:46:02,712 GOAL BASICALLY IS, YOU KNOW, 1128 00:46:02,712 --> 00:46:05,749 THAT FINAL SCORE THE OVERALL 1129 00:46:05,749 --> 00:46:08,552 IMPACT SCORE, RIGHT? THE FIRST 1130 00:46:08,552 --> 00:46:10,387 TWO FACTORS WILL BE SCORED THE 1131 00:46:10,387 --> 00:46:11,755 THIRD FACTOR WILL NOT BE SCORED 1132 00:46:11,755 --> 00:46:14,858 SO THAT MEANS THAT YOU MIGHT GET 1133 00:46:14,858 --> 00:46:16,760 SOMETHING LIKE, ONE OR TWO AND 1134 00:46:16,760 --> 00:46:22,966 OVERALL IMPACT IS FIVE. COMING 1135 00:46:22,966 --> 00:46:27,003 FROM THAT LACK OF EXPERTISE OR 1136 00:46:27,003 --> 00:46:29,372 LACK OF RESOURCES IN THE THIRD 1137 00:46:29,372 --> 00:46:32,409 FACTOR THIS IS A VERY COMMON 1138 00:46:32,409 --> 00:46:34,377 QUESTION. NOT ONLY FROM THE 1139 00:46:34,377 --> 00:46:35,445 SCIENTIFIC COMMUNITY OR 1140 00:46:35,445 --> 00:46:37,547 SOMETHING THAT NIH IS TRYING TO 1141 00:46:37,547 --> 00:46:39,549 FIGURE OUT THE BEST WAY TO TRAIN 1142 00:46:39,549 --> 00:46:41,184 REVIEWERS ON THAT. SO IT WILL 1143 00:46:41,184 --> 00:46:45,589 BE DEPICTED IN THE THIRD FACTOR 1144 00:46:45,589 --> 00:46:47,257 IN OTHER WORDS IT WILL SAY 1145 00:46:47,257 --> 00:46:48,825 UNACCEPTABLE EXPERTISE OR 1146 00:46:48,825 --> 00:46:50,060 RESOURCES. THERE'LL BE A SPACE 1147 00:46:50,060 --> 00:46:52,429 FOR THE REVIEWER TO PROVIDE 1148 00:46:52,429 --> 00:46:53,363 ADDITIONAL INFORMATION, WHY THEY 1149 00:46:53,363 --> 00:46:55,432 FEEL THAT. AND THEN THE OVERALL 1150 00:46:55,432 --> 00:47:00,203 IMPACT WILL HAVE TO EXPLAIN WHAT 1151 00:47:00,203 --> 00:47:02,906 IT WAS THAT THEY SCORED SO LOW 1152 00:47:02,906 --> 00:47:03,573 WE DON'T ANTICIPATE THAT IT WILL 1153 00:47:03,573 --> 00:47:06,710 BE A ONE-ON-ONE, AND AN 80 BUT 1154 00:47:06,710 --> 00:47:10,046 WE DO WANT TO MAKE SURE THE 1155 00:47:10,046 --> 00:47:12,315 REVIEWERS ARE PREPARED TO -- IF 1156 00:47:12,315 --> 00:47:14,885 THEY FEEL THE EXPERTISE IS 1157 00:47:14,885 --> 00:47:17,821 MISSING AND THE RESEARCH PLAN 1158 00:47:17,821 --> 00:47:20,423 STILL NEEDS TO -- WE'RE NOT 1159 00:47:20,423 --> 00:47:23,193 GOING BASED ON THE BIO SCHEDULE 1160 00:47:23,193 --> 00:47:25,328 BUT HOW WELL THE RESEARCH PLAN 1161 00:47:25,328 --> 00:47:27,297 IS OUTLINED. THIS IS ESPECIALLY 1162 00:47:27,297 --> 00:47:29,132 IMPORTANT FOR NEW INVESTIGATORS 1163 00:47:29,132 --> 00:47:30,734 THEY MIGHT NOT HAVE THAT MY 1164 00:47:30,734 --> 00:47:32,536 PUBLICATION TO SPEAK OF BUT THE 1165 00:47:32,536 --> 00:47:34,237 RESEARCH PLAN NEEDS TO BE 1166 00:47:34,237 --> 00:47:35,472 CLEARLY THOUGHT OUT. ANOTHER 1167 00:47:35,472 --> 00:47:38,375 THING THAT'S -- THAT THIS IS 1168 00:47:38,375 --> 00:47:41,811 RELEVANT TO IS APPLICATIONS THAT 1169 00:47:41,811 --> 00:47:43,380 DON'T -- ARE A PHASE THAT DON'T 1170 00:47:43,380 --> 00:47:45,815 REQUIRE PRELIMINARY DATA. 1171 00:47:45,815 --> 00:47:49,419 THINGS LIKE THE CATS R 01. NO 1172 00:47:49,419 --> 00:47:52,622 PRELIMINARY DATA REQUIRED. SO 1173 00:47:52,622 --> 00:47:53,757 THE RESEARCH PLAN REALLY NEEDS 1174 00:47:53,757 --> 00:47:55,625 TO BE CLEARLY LAID OUT, CLEARLY 1175 00:47:55,625 --> 00:47:56,493 THOUGHT OUT AND WE UNDERSTAND 1176 00:47:56,493 --> 00:48:01,264 THAT THERE IS A LIMIT ON SPACE 1177 00:48:01,264 --> 00:48:02,899 BUT IT HAS TO BE ABLE TO INSTILL 1178 00:48:02,899 --> 00:48:04,100 CONFIDENCE IN THE REVIEWERS THAT 1179 00:48:04,100 --> 00:48:05,335 YES, THEY THOUGHT THIS THROUGH 1180 00:48:05,335 --> 00:48:08,471 AND THEY KNOW WHAT THEY'RE DOING 1181 00:48:08,471 --> 00:48:09,506 AND REGARDLESS OF WHETHER THEY 1182 00:48:09,506 --> 00:48:11,308 HAVE BEEN IN THE FIELD FOR 20 1183 00:48:11,308 --> 00:48:15,212 YEARS OR 2 YEARS, THEY HAVE 1184 00:48:15,212 --> 00:48:17,447 THOUGHT IT OUT ENOUGH TO PROVIDE 1185 00:48:17,447 --> 00:48:20,183 FEASIBILITY OR TO EXECUTE 1186 00:48:20,183 --> 00:48:22,285 ANOTHER ONE. 1187 00:48:22,285 --> 00:48:23,286 >> AUDIENCE: THANK YOU. 1188 00:48:23,286 --> 00:48:24,487 >> THANK YOU, DOCTOR COHEN. 1189 00:48:24,487 --> 00:48:34,664 >> OKAY. 1190 00:48:37,634 --> 00:48:42,105 >> OUR NEXT SPEAKER WILL BE A 1191 00:48:42,105 --> 00:48:43,240 PROGRAM MANAGER DISCUSSING THE 1192 00:48:43,240 --> 00:48:52,882 WORKSHOP. THANK YOU. 1193 00:48:52,882 --> 00:48:53,717 >> GOOD MORNING, EVERYONE, TODAY 1194 00:48:53,717 --> 00:48:56,353 I'M GOING TO SHARE A BRIEF 1195 00:48:56,353 --> 00:48:58,588 OVERVIEW OF OUR WORKSHOP ON 1196 00:48:58,588 --> 00:49:01,258 SYNTHETIC BIOLOGY FOR MOLECULAR 1197 00:49:01,258 --> 00:49:03,360 IMAGING IN CANCER WHICH WAS 1198 00:49:03,360 --> 00:49:05,395 ORGANIZED BY THE CANCER IMAGING 1199 00:49:05,395 --> 00:49:16,072 PROGRAM AT NCI AMEDICAL IMAGING 1200 00:49:16,473 --> 00:49:19,075 TECHNOLOGY ARE CENTRAL IN CARE. 1201 00:49:19,075 --> 00:49:21,678 IT PLAYS ESSENTIAL ROLES IN 1202 00:49:21,678 --> 00:49:23,680 CANCER DETECTION, DIAGNOSIS, 1203 00:49:23,680 --> 00:49:26,049 TREATMENT, AND MONITOR. SO 1204 00:49:26,049 --> 00:49:27,183 ACCORDINGLY, IMPROVING THE 1205 00:49:27,183 --> 00:49:30,687 QUALITY OF THE IMAGING AGENT, 1206 00:49:30,687 --> 00:49:33,890 IMAGING METHOD, DIRECTLY 1207 00:49:33,890 --> 00:49:42,299 BENEFITTING THE CANCER PATIENT. 1208 00:49:42,299 --> 00:49:47,304 SO, SO ONE OF THE CHALLENGE IN 1209 00:49:47,304 --> 00:49:50,640 ACHIEVING THE CANCER IMAGING 1210 00:49:50,640 --> 00:49:54,377 LIES IN THE DEVELOPMENT OF SUCH 1211 00:49:54,377 --> 00:49:59,215 SPECIFIC IMAGING PROBES. THE 1212 00:49:59,215 --> 00:50:01,551 IDEAL IMAGING PROBES EVEN IF 1213 00:50:01,551 --> 00:50:02,752 THEY HAVE CRUCIAL PROPERTIES AS 1214 00:50:02,752 --> 00:50:04,688 LISTED IN THIS PAM ON THE RIGHT 1215 00:50:04,688 --> 00:50:07,257 SIDE. IT HAS TO BE SENSITIVE 1216 00:50:07,257 --> 00:50:08,658 ENOUGH TO DETECT EARLY LESIONS 1217 00:50:08,658 --> 00:50:10,460 OR SMALL TUMORS. 1218 00:50:10,460 --> 00:50:13,596 IT HAS TO HAVE THE SPECIFICITIES 1219 00:50:13,596 --> 00:50:17,367 TO GIVE ACCURATE DIAGNOSIS. THE 1220 00:50:17,367 --> 00:50:19,302 ADDITION TO THAT, THESE 1221 00:50:19,302 --> 00:50:19,936 CONTROLLED FUNCTIONALITIES AND 1222 00:50:19,936 --> 00:50:22,472 THE LONG-TERM REPORTINGS ARE 1223 00:50:22,472 --> 00:50:27,310 CRITICAL PROPERTIES FOR GOOD 1224 00:50:27,310 --> 00:50:29,479 IMAGING AGENT THAT'S WHERE YOUR 1225 00:50:29,479 --> 00:50:31,614 EXPERTISE IN BIOLOGY COMES IN. 1226 00:50:31,614 --> 00:50:36,152 IN SYNTHETIC BIOLOGY, OVER THE 1227 00:50:36,152 --> 00:50:39,122 POTENTIAL STATE IS THE DESIGNER 1228 00:50:39,122 --> 00:50:41,725 OF IMAGING AGENT TO ADDRESS 1229 00:50:41,725 --> 00:50:44,394 THESE CHALLENGES SO LET ME 1230 00:50:44,394 --> 00:50:45,562 BRIEFLY SHOW YOU EXAMPLES SHARED 1231 00:50:45,562 --> 00:50:49,933 BY THE SPEAKERS IN THIS 1232 00:50:49,933 --> 00:50:52,168 WORKSHOP. THE PANEL STUDY DONE 1233 00:50:52,168 --> 00:50:56,306 BY THE GROUP FROM THE CALTECH, 1234 00:50:56,306 --> 00:51:03,313 FOCUSING ON THE PROCESSING ON 1235 00:51:03,313 --> 00:51:05,749 NATURALLY EXISTING PROCESSES. 1236 00:51:05,749 --> 00:51:08,151 SO THERE ARE TWO PARTS IN HIS 1237 00:51:08,151 --> 00:51:11,020 STUDIES THE TOP ONE FOCUS ON THE 1238 00:51:11,020 --> 00:51:13,256 MAGNETIC CRYSTALS WHICH EXIST IN 1239 00:51:13,256 --> 00:51:17,193 THE MAGNETIC BACTERIA GUIDE 1240 00:51:17,193 --> 00:51:21,131 ALONG THE MAGNETIC FIELD. THE 1241 00:51:21,131 --> 00:51:24,634 BOTTOM PANEL IN THE LEFT SIDE IS 1242 00:51:24,634 --> 00:51:27,303 THE AIR BUBBLES WHICH EXIST IN 1243 00:51:27,303 --> 00:51:32,075 THE AQUATIC BACTERIA. IN 1244 00:51:32,075 --> 00:51:33,576 INNOVATIVE ENGINEERING, IN 1245 00:51:33,576 --> 00:51:40,283 PROPERTIES SUCH AS GUY DANCE -- 1246 00:51:40,283 --> 00:51:43,019 GUIDANCE IN THESE PARTICLES. 1247 00:51:43,019 --> 00:51:46,423 THIS IS AIR BUBBLES AS THE AGENT 1248 00:51:46,423 --> 00:51:49,459 FOR ULTRASOUND IN THESE STUDIES. 1249 00:51:49,459 --> 00:51:51,294 THE MIDDLE PANEL IS USING THE 1250 00:51:51,294 --> 00:51:53,763 SYNTHETIC RECEPTORS. 1251 00:51:53,763 --> 00:51:55,498 SPECIFICALLY USING THE SYNTHETIC 1252 00:51:55,498 --> 00:51:59,302 MATCH RECEPTORS I AM SURE YOU 1253 00:51:59,302 --> 00:52:03,306 HAVE HEARD THE TALK BY LYNN FROM 1254 00:52:03,306 --> 00:52:05,675 UC S KRS 1255 00:52:05,675 --> 00:52:08,244 UCSF SO IN THE MIDDLE THERE ARE 1256 00:52:08,244 --> 00:52:10,680 TWO STUDIES FROM TWO GROUPS ONE 1257 00:52:10,680 --> 00:52:14,250 IS FROM THE GROUP FROM CANADA. 1258 00:52:14,250 --> 00:52:19,189 THE SECOND ONE IS FROM THE 1259 00:52:19,189 --> 00:52:21,524 WILSON GROUP. THEY UTILIZE 1260 00:52:21,524 --> 00:52:23,059 THESE RECEPTORS AND REPLACE THE 1261 00:52:23,059 --> 00:52:26,529 EEXTRACELLULAR DOMAIN WITH A 1262 00:52:26,529 --> 00:52:28,331 PEPTIDE THAT RECOGNIZE THE 1263 00:52:28,331 --> 00:52:28,598 ENERGIES. 1264 00:52:28,598 --> 00:52:31,234 THEREFORE YOU HAVE A NOBLE INPUT 1265 00:52:31,234 --> 00:52:35,138 IN THE TUMOR SPECIFIC SIGNALS. 1266 00:52:35,138 --> 00:52:38,608 THEN REPLACE THE INTRACELLULAR 1267 00:52:38,608 --> 00:52:40,977 DOMAIN. THESE ARE FOR 1268 00:52:40,977 --> 00:52:41,945 REPORTING. THAT'S -- THEY HAVE 1269 00:52:41,945 --> 00:52:44,747 THE WILSON'S STUDY FROM UCSF AND 1270 00:52:44,747 --> 00:52:47,283 THE OMI REPORTERS. THEREFORE 1271 00:52:47,283 --> 00:52:51,855 THEY CAN CREATE THIS IMAGING 1272 00:52:51,855 --> 00:53:02,398 AGENT FOR MRI IMAGING. DESPITE 1273 00:53:08,338 --> 00:53:09,706 THESE POTENTIALS THIS FIELD IS 1274 00:53:09,706 --> 00:53:11,741 IN AN EARLY STAGE. THIS GAP IS 1275 00:53:11,741 --> 00:53:15,144 REALLY THE DRIVING FORCE FOR US 1276 00:53:15,144 --> 00:53:16,613 TO ORGANIZE THIS WORKSHOP. THE 1277 00:53:16,613 --> 00:53:19,115 GOAL OF THE WORKSHOP IS TO BRING 1278 00:53:19,115 --> 00:53:21,584 THE EXPERT LIKE YOU IN SYNTHETIC 1279 00:53:21,584 --> 00:53:23,019 BIOLOGY TO WORK WITH THE MEDICAL 1280 00:53:23,019 --> 00:53:25,154 IMAGERS TO CREATE A ROBUST, 1281 00:53:25,154 --> 00:53:27,290 SENSITIVE AND PRECISION IMAGING 1282 00:53:27,290 --> 00:53:31,494 AGENT. SO THIS WILL ULTIMATELY 1283 00:53:31,494 --> 00:53:34,898 BENEFIT THE PATIENT OF CANCER SO 1284 00:53:34,898 --> 00:53:36,900 THE WORKSHOP WAS ORGANIZED BY 1285 00:53:36,900 --> 00:53:41,738 THE CANCER IMAGING PROGRAM IN 1286 00:53:41,738 --> 00:53:44,207 COLLABORATION WITH CALTECH AND 1287 00:53:44,207 --> 00:53:46,910 THE WORKSHOP WAS MANAGED AND 1288 00:53:46,910 --> 00:53:49,012 ASSISTED BY THE VARIOUS FOLKS 1289 00:53:49,012 --> 00:53:56,486 FROM NCI AS WELL AS FROM NIBIB. 1290 00:53:56,486 --> 00:54:02,225 SO THE MEETING IS VIRTUAL, A TWO 1291 00:54:02,225 --> 00:54:03,359 DAY EVENT AND WE RECEIVED 1292 00:54:03,359 --> 00:54:05,395 POSITIVE TURNOUTS. WE HAD MORE 1293 00:54:05,395 --> 00:54:09,465 THAN 200 PEOPLE ATTEND THIS 1294 00:54:09,465 --> 00:54:11,200 WORKSHOP. THEY ARE FOUR 1295 00:54:11,200 --> 00:54:12,735 SESSIONS IN THE WORKSHOP OVER 1296 00:54:12,735 --> 00:54:15,838 TWO DAYS. SO EACH SESSION -- 1297 00:54:15,838 --> 00:54:18,775 EACH DAY AS TWO SESSIONS. EACH 1298 00:54:18,775 --> 00:54:19,976 SESSION HAS FIVE SPEAKERS SO WE 1299 00:54:19,976 --> 00:54:21,578 TOTAL HAVE 20 PRESENTATIONS. WE 1300 00:54:21,578 --> 00:54:29,352 HAVE A PANEL DISCUSSION. AT 1301 00:54:29,352 --> 00:54:30,920 EACH SESSION. LET ME GIVE YOU 1302 00:54:30,920 --> 00:54:32,488 AN OVERVIEW OF THE SCIENTIFIC 1303 00:54:32,488 --> 00:54:35,758 SESSIONS. THE FIRST IS ON 1304 00:54:35,758 --> 00:54:38,828 APPLICATIONS OF BIOLOGY. IT IS 1305 00:54:38,828 --> 00:54:40,964 RARELY SERVED AS PRODUCTION. 1306 00:54:40,964 --> 00:54:44,767 THIS SESSION WAS CHAIRED BY JOSH 1307 00:54:44,767 --> 00:54:47,737 LEONARD FROM NORTHWESTERN SO HE 1308 00:54:47,737 --> 00:54:51,207 STUDIED THE PREDECISION ON 1309 00:54:51,207 --> 00:54:54,277 ENGINEERING AND THE INFORMATION 1310 00:54:54,277 --> 00:54:54,577 PROCESS. 1311 00:54:54,577 --> 00:55:01,451 THEREFORE ANOTHER FROM UCF 1312 00:55:01,451 --> 00:55:02,752 DEVELOPED THE -- DEVELOPED A THE 1313 00:55:02,752 --> 00:55:08,257 SYNTHETIC RECEPTORS TO IMPROVE 1314 00:55:08,257 --> 00:55:11,661 THE SENSITIVITY IN CELLS. THEN 1315 00:55:11,661 --> 00:55:17,333 FOLLOWED BY THE HAM MY DIDEPAR 1316 00:55:17,333 --> 00:55:19,535 HE'S FROM UNIVERSITY OF PENN. 1317 00:55:19,535 --> 00:55:21,437 AND THEN WILSON WONG FROM BOSTON 1318 00:55:21,437 --> 00:55:24,374 UNIVERSITY TALKED ABOUT 1319 00:55:24,374 --> 00:55:26,576 IMPROVING THE CELLS AS WELL AS 1320 00:55:26,576 --> 00:55:30,146 THE CELL AMPLIFIER RNA FOR 1321 00:55:30,146 --> 00:55:34,517 VACCINE DEVELOPMENT. AND THE -- 1322 00:55:34,517 --> 00:55:37,553 THIS SESSION WAS END WITH THE 1323 00:55:37,553 --> 00:55:45,561 KEVIN MCHOW -- MCHUGH FROM RICE 1324 00:55:45,561 --> 00:55:46,129 UNIVERSITY. 1325 00:55:46,129 --> 00:55:50,099 THE SESSION TWO AND THREE AND 1326 00:55:50,099 --> 00:55:59,308 FOUR, DIRECTED INTO IMAGING 1327 00:55:59,308 --> 00:56:02,345 INNOVATION. AND THUZ WAS 1328 00:56:02,345 --> 00:56:05,181 CHAIRED BY MICK HAIL FROM 1329 00:56:05,181 --> 00:56:06,482 CALTECH. 1330 00:56:06,482 --> 00:56:08,785 AND WAS WORKED WITH IMAGING AND 1331 00:56:08,785 --> 00:56:11,754 ULTRASOUND AND THEN FOLLOWED BY 1332 00:56:11,754 --> 00:56:14,590 JERSEY TALKED ABOUT THE 1333 00:56:14,590 --> 00:56:18,461 NONINVASIVE MANAGING OF BRAIN 1334 00:56:18,461 --> 00:56:20,897 ACTIVITIES AND AR NAB FROM UC 1335 00:56:20,897 --> 00:56:23,733 SANTA BARBARA TALKED ABOUT THE 1336 00:56:23,733 --> 00:56:27,036 ENGINEERING REPORTER GENES FOR 1337 00:56:27,036 --> 00:56:31,708 MR IMAGING AND CHRISTOPHER CAVE 1338 00:56:31,708 --> 00:56:34,110 A TALK OBJECT SYNTHETIC 1339 00:56:34,110 --> 00:56:36,679 ORGANELLE FOR INVIVO IMAGING AND 1340 00:56:36,679 --> 00:56:37,747 THIS SESSION ENDED WITH A TALK 1341 00:56:37,747 --> 00:56:40,817 FROM NICHOLAS WHO IS FROM THE 1342 00:56:40,817 --> 00:56:48,191 NST GROUP FROM STANFORD AND 1343 00:56:48,191 --> 00:56:53,429 TALKED ABOUT THE SYNTHETIC GPR. 1344 00:56:53,429 --> 00:56:55,298 AND SESSION THREE CONTINUED ON 1345 00:56:55,298 --> 00:56:59,001 THE IMAGING FRAME AND THIS WAS 1346 00:56:59,001 --> 00:57:01,270 SHARED FROM ONE FROM UKRAINE AND 1347 00:57:01,270 --> 00:57:02,905 THIS STUDY GAVE A TALK ON THE 1348 00:57:02,905 --> 00:57:07,310 PROTEIN TECH FOR IMAGING THE 1349 00:57:07,310 --> 00:57:11,748 IMMUNE CELLS. AND THIS USES 1350 00:57:11,748 --> 00:57:15,284 SYNTHETIC ANALYSIS RECEPTORS 1351 00:57:15,284 --> 00:57:22,725 INTO REPORTERS. THEN GABE 1352 00:57:22,725 --> 00:57:25,828 WORKED WITH EARLY CANCER 1353 00:57:25,828 --> 00:57:28,765 DETECTION AND THEN TET SUE HERO 1354 00:57:28,765 --> 00:57:31,300 WHAT ARE REE KNOW TO WITH HIS 1355 00:57:31,300 --> 00:57:35,304 GROUP AT COLUMBIA, THEY TALK 1356 00:57:35,304 --> 00:57:39,308 ABOUT ENGINEERED BACTERIA FOR 1357 00:57:39,308 --> 00:57:43,279 DRUG DELIVERY. AND THE SESSION 1358 00:57:43,279 --> 00:57:47,750 WAS ENDED WITH TIM TALKING ABOUT 1359 00:57:47,750 --> 00:57:48,951 SYNTHETIC BIOLOGY FOR NEXT 1360 00:57:48,951 --> 00:57:53,756 GENERATION THERAPEUTICS. THE 1361 00:57:53,756 --> 00:57:55,792 LAST SINCE WAS ON CLINICAL NEEDS 1362 00:57:55,792 --> 00:57:59,262 AND THIS SESSION WAS CHAIRED BY 1363 00:57:59,262 --> 00:58:02,632 ANNA WU AND SHE STUDIED THE 1364 00:58:02,632 --> 00:58:08,137 FIRST TALK WITH THE HUMANIZED 1365 00:58:08,137 --> 00:58:12,008 ANTIBODIES FOR IMMUNOLOGINOLOGY 1366 00:58:12,008 --> 00:58:14,510 INPATIENT CARE. AND THEN WE HAD 1367 00:58:14,510 --> 00:58:19,282 DAVID WILSON WHO I MENTIONED HAD 1368 00:58:19,282 --> 00:58:22,485 REPORTS FOR CANCER IMAGE AND 1369 00:58:22,485 --> 00:58:25,688 THEN VLADIMIR FROM MSK HE TALKED 1370 00:58:25,688 --> 00:58:29,759 ABOUT USING THE REPORTER TOOLS 1371 00:58:29,759 --> 00:58:33,763 IN THE MODELS AND IN THE PATIENT 1372 00:58:33,763 --> 00:58:36,165 CLINICAL TRIALS. OUR FOURTH WAS 1373 00:58:36,165 --> 00:58:42,205 LAURA FROM THE UCSF, SHE 1374 00:58:42,205 --> 00:58:44,807 SUPPORTED THE CLINICAL TRIALS SO 1375 00:58:44,807 --> 00:58:47,276 SHE BASICALLY WAS SOME INSIGHT 1376 00:58:47,276 --> 00:58:50,746 HOW TO AUGMENT IMAGING FEATURES 1377 00:58:50,746 --> 00:58:54,550 FROM A TUMOR. AND THE FINAL 1378 00:58:54,550 --> 00:58:59,188 TALK WAS SUPPORTED BY NCI FROM 1379 00:58:59,188 --> 00:59:00,456 THE PINNACLE WORKS GROUP. SO 1380 00:59:00,456 --> 00:59:04,527 THEY CREATE AN IMAGING AGENT TO 1381 00:59:04,527 --> 00:59:05,728 IMAG 1382 00:59:05,728 --> 00:59:09,665 IMAGING LABELS SO THEY ARE 1383 00:59:09,665 --> 00:59:11,634 MOVING THIS FROM THE PRECLINICAL 1384 00:59:11,634 --> 00:59:12,869 MODELS TOWARD THE CLINICAL 1385 00:59:12,869 --> 00:59:16,873 STUDIES. SO WE HAD A LIST OF 1386 00:59:16,873 --> 00:59:21,310 SPEAKERS AND VERY EXCITING 1387 00:59:21,310 --> 00:59:25,514 RESEARCH. IF YOU WANT TO KNOW 1388 00:59:25,514 --> 00:59:27,550 MORE I HAVE A LIST OF LINKS 1389 00:59:27,550 --> 00:59:30,586 HERE. THE FIRST LINK WILL TAKE 1390 00:59:30,586 --> 00:59:32,555 YOU TO THE MEETING PAGE. YOU 1391 00:59:32,555 --> 00:59:39,295 HAVE THE BIO. AND THE NEXT IS 1392 00:59:39,295 --> 00:59:41,430 THE WORKSHOP. WITH THAT, I 1393 00:59:41,430 --> 00:59:42,598 THANK YOU FOR YOUR ATTENTION. 1394 00:59:42,598 --> 00:59:51,307 IF YOU HAVE ANY QUESTIONS. 1395 00:59:51,307 --> 00:59:53,910 >> DOES ANYONE HAVE ANY 1396 00:59:53,910 --> 00:59:54,577 QUESTIONS? ALL RIGHT. THANK YOU 1397 00:59:54,577 --> 00:59:55,311 DOCTOR. 1398 00:59:55,311 --> 01:00:02,184 >> THANK YOU. 1399 01:00:02,184 --> 01:00:12,662 >> NEXT UP IS DR. FEI WANG. 1400 01:00:17,366 --> 01:00:18,501 >> GOOD MORNING I WOULD LIKE TO 1401 01:00:18,501 --> 01:00:23,306 THANK THE ORGANIZER FOR INVITING 1402 01:00:23,306 --> 01:00:25,708 US. TUBA DO YOU WANT TO JUST 1403 01:00:25,708 --> 01:00:29,478 COME UP? YEAH SO TUBA AND I 1404 01:00:29,478 --> 01:00:33,049 WILL GIVE YOU A REPORT OF A 1405 01:00:33,049 --> 01:00:34,650 WORKSHOP TOOK PLACE LAST YEAR 1406 01:00:34,650 --> 01:00:39,755 AND IT WAS ORGANIZED BY NIA AND 1407 01:00:39,755 --> 01:00:42,458 NIBIB BY PREVIOUS SUPERVISOR 1408 01:00:42,458 --> 01:00:45,661 DR. RON WAS WORKING WITH TUBA 1409 01:00:45,661 --> 01:00:48,864 VERY CLOSELY AND MADE THIS 1410 01:00:48,864 --> 01:00:49,732 HAPPEN. SO BEFORE WE EVEN GO 1411 01:00:49,732 --> 01:00:52,902 INTO THE WORKSHOP, I THOUGHT I 1412 01:00:52,902 --> 01:00:54,937 WOULD GIVE YOU A BRIEF 1413 01:00:54,937 --> 01:00:57,273 INTRODUCTION OF -- FOR DIVISION 1414 01:00:57,273 --> 01:00:59,141 OF AGING BIOLOGY IN THE NATIONAL 1415 01:00:59,141 --> 01:01:03,312 INSTITUTES ON AGING. BECAUSE 1416 01:01:03,312 --> 01:01:04,347 USUALLY WE ARE THE -- WE ARE NOT 1417 01:01:04,347 --> 01:01:06,082 THE NORMAL PLAYER HERE. 1418 01:01:06,082 --> 01:01:07,683 I THOUGHT JUST GIVE YOU A LITTLE 1419 01:01:07,683 --> 01:01:14,857 BIT OF WHAT WE DO. SO BASICALLY 1420 01:01:14,857 --> 01:01:17,760 WE ARE SUPPORTING RESEARCH AND 1421 01:01:17,760 --> 01:01:20,329 TRAINING AND TO THE MOLECULAR 1422 01:01:20,329 --> 01:01:22,965 LEVEL. ANYTHING BASIC, AGEING 1423 01:01:22,965 --> 01:01:24,767 RELATED, DISEASE AND SO ON SO 1424 01:01:24,767 --> 01:01:27,003 FORTH. SO WE ARE SORT OF, I 1425 01:01:27,003 --> 01:01:29,472 CALL IT THE BASIC EVERYTHING. 1426 01:01:29,472 --> 01:01:35,745 OKAY. AND THEN WE HAVE THREE 1427 01:01:35,745 --> 01:01:37,813 BRANCHES IN ADDITION. ONE IS 1428 01:01:37,813 --> 01:01:41,751 AGING PHYSIOLOGY BRANCH. YOU 1429 01:01:41,751 --> 01:01:44,286 SEE MANY PROGRAMS IN HERE. SO 1430 01:01:44,286 --> 01:01:45,821 LET'S SEE WHETHER I CAN MAKE 1431 01:01:45,821 --> 01:01:47,590 THIS -- YOU SEE ALL THESE 1432 01:01:47,590 --> 01:01:50,760 PROGRAMS IN HERE. AND THEN WE 1433 01:01:50,760 --> 01:01:53,362 ALSO HAVE CELL BIOLOGY BRANCH. 1434 01:01:53,362 --> 01:01:57,299 I LEAD AS A TRANSLATIONAL 1435 01:01:57,299 --> 01:01:59,301 RESEARCH BRANCH, I LITERALLY 1436 01:01:59,301 --> 01:02:03,739 MANAGE THE SYNTHETIC AGING 1437 01:02:03,739 --> 01:02:06,208 BIOLOGY PORTFOLIO AND THE OTHER 1438 01:02:06,208 --> 01:02:08,077 RELEVANT ONE YOU MAY WANT TO PAY 1439 01:02:08,077 --> 01:02:11,280 ATTENTION IS WE HAVE EMERGENT 1440 01:02:11,280 --> 01:02:12,915 TECHNOLOGY PROGRAM SO IN 1441 01:02:12,915 --> 01:02:16,685 ADDITION TO DO AGING BASIC 1442 01:02:16,685 --> 01:02:23,292 BIOLOGY RESEARCH, WE ALSO 1443 01:02:23,292 --> 01:02:24,427 SUPPORT TECHNOLOGY. THERE ARE 1444 01:02:24,427 --> 01:02:25,661 MANY ISSUES IN AGING RESEARCH 1445 01:02:25,661 --> 01:02:28,697 AND SOME OF THE CHALLENGES COULD 1446 01:02:28,697 --> 01:02:31,300 BE MATCHED BY OUR INVESTIGATOR, 1447 01:02:31,300 --> 01:02:32,501 WORKING WITH YOU GUYS, WHICH WAS 1448 01:02:32,501 --> 01:02:37,740 THE REASON FOR THE WORKSHOP. 1449 01:02:37,740 --> 01:02:40,643 >> YEAH SO AS FEI MENTIONED THIS 1450 01:02:40,643 --> 01:02:42,878 WORKSHOP GREW OUT AFTER A MUTUAL 1451 01:02:42,878 --> 01:02:47,750 INTEREST AND THE APPLICATION OF 1452 01:02:47,750 --> 01:02:48,984 BIOLOGY IN HOW WE CAN USE 1453 01:02:48,984 --> 01:02:51,220 SYNTHETIC BIOLOGY APPROACHES AND 1454 01:02:51,220 --> 01:02:53,589 HOW TO IMPROVE OUR UNDERSTANDING 1455 01:02:53,589 --> 01:02:56,158 OF AGING BIOLOGY AND IN TURN 1456 01:02:56,158 --> 01:02:58,160 MAYBE TAKE ATE STEP FURTHER IN 1457 01:02:58,160 --> 01:03:00,396 USING THESE TOLLS TO IMPACT WHAT 1458 01:03:00,396 --> 01:03:02,665 WE LEARNED FROM WHAT WE 1459 01:03:02,665 --> 01:03:03,365 UNDERSTAND ABOUT AGING BIOLOGY. 1460 01:03:03,365 --> 01:03:05,534 AND TURN THAT INTO A STRATEGIES 1461 01:03:05,534 --> 01:03:08,471 TO IMPACT AGING PROCESSES AND 1462 01:03:08,471 --> 01:03:11,207 OUTCOMES, AGAIN USING SYNTHETIC 1463 01:03:11,207 --> 01:03:12,775 BIOLOGY TOOLS SO THE WORKSHOP 1464 01:03:12,775 --> 01:03:13,576 GOAL WAS TO REALLY BRING 1465 01:03:13,576 --> 01:03:17,780 TOGETHER THE TWO COMMUNITIES OF 1466 01:03:17,780 --> 01:03:18,414 SYNTHETIC BIOLOGY TOOL MAKERS 1467 01:03:18,414 --> 01:03:20,716 AND AGING BIOLOGY RESEARCHERS TO 1468 01:03:20,716 --> 01:03:22,685 PROMOTE AWARENESS OF SYNTHETIC 1469 01:03:22,685 --> 01:03:24,420 BIOLOGY IN THE AGING RESEARCH 1470 01:03:24,420 --> 01:03:26,655 FIELD AND ALSO TO FOSTER NEW 1471 01:03:26,655 --> 01:03:27,923 COLLABORATIONS AMONG THESE 1472 01:03:27,923 --> 01:03:29,225 PARTICIPANTS TO GENERATE 1473 01:03:29,225 --> 01:03:31,827 SPECIFIC ACTION PLANS IN TERMS 1474 01:03:31,827 --> 01:03:33,429 OF MAYBE JOINT GRANT 1475 01:03:33,429 --> 01:03:36,765 APPLICATIONS WE HAD A WONDERFUL 1476 01:03:36,765 --> 01:03:38,300 PLANNING TEAM AND PUT TOGETHER 1477 01:03:38,300 --> 01:03:43,272 THIS WORKSHOP. TO, AGAIN, 1478 01:03:43,272 --> 01:03:44,707 EXPLORE BROADLY IDEAS ABOUT HOW 1479 01:03:44,707 --> 01:03:48,177 WE CAN USE SYNTHETIC BIOLOGY TO 1480 01:03:48,177 --> 01:03:51,280 TAKE AGING OR SON NECESSARY 1481 01:03:51,280 --> 01:03:53,749 SENSE CELLS AND MAYBE TURN BACK 1482 01:03:53,749 --> 01:03:55,284 THE CLOCK ON THEM TOWARDS A 1483 01:03:55,284 --> 01:03:58,320 NORMAL PHENOTYPE. 1484 01:03:58,320 --> 01:04:00,256 AND THE LOGISTICS AND THE FORMAT 1485 01:04:00,256 --> 01:04:02,191 OF THIS WORKSHOP BECAUSE OUR 1486 01:04:02,191 --> 01:04:02,725 GOALS WERE A LITTLE BIT 1487 01:04:02,725 --> 01:04:04,960 DIFFERENT IN TERMS OF, YOU KNOW, 1488 01:04:04,960 --> 01:04:06,595 INTRODUCING THESE TWO 1489 01:04:06,595 --> 01:04:08,297 COMMUNITIES TO EACH OTHER AND 1490 01:04:08,297 --> 01:04:08,964 FOSTERING COLLABORATIONS THIS UZ 1491 01:04:08,964 --> 01:04:11,600 WITH UNLIKE A TRADITIONAL NIH 1492 01:04:11,600 --> 01:04:15,304 WORKSHOP THAT YOU MAY BE 1493 01:04:15,304 --> 01:04:16,205 FAMILIAR WITH WITH FORMAL TALKS. 1494 01:04:16,205 --> 01:04:19,742 WE STRUCTURED IT SUCH THAT WE 1495 01:04:19,742 --> 01:04:22,511 INVITED FIVE PIS AND FIVE 1496 01:04:22,511 --> 01:04:24,980 TRAINEES FROM THEIR LABS FROM 1497 01:04:24,980 --> 01:04:27,283 THE AGING RESEARCH FIELD. AND 1498 01:04:27,283 --> 01:04:28,817 FROM THE SYNTHETIC RESEARCH 1499 01:04:28,817 --> 01:04:30,686 FIELD AND PUT THEM TOGETHER IN A 1500 01:04:30,686 --> 01:04:34,590 ROOM AND SO JUST CHAT AWAY 1501 01:04:34,590 --> 01:04:36,959 ESSENTIALLY. WE PROVIDED ZOOM 1502 01:04:36,959 --> 01:04:37,726 PARTICIPATION FOR OTHERS SO THEY 1503 01:04:37,726 --> 01:04:39,061 COULD WATCH THESE DISCUSSIONS 1504 01:04:39,061 --> 01:04:39,762 AND THEN PARTICIPATE, ASK 1505 01:04:39,762 --> 01:04:41,830 QUESTIONS IN THE CHATBOXES. AND 1506 01:04:41,830 --> 01:04:44,166 WE HELD THIS WORKSHOP OVER TWO 1507 01:04:44,166 --> 01:04:46,569 DAYS IN 2023 IN SEPTEMBER. 1508 01:04:46,569 --> 01:04:49,238 AGAIN, THE EMPHASIS WAS THAT NO 1509 01:04:49,238 --> 01:04:52,074 FORMAL SCIENTIFIC TALKS WHILE WE 1510 01:04:52,074 --> 01:04:55,978 ASKED THE PARTICIPANTS TO 1511 01:04:55,978 --> 01:04:57,112 DISCUSS WAS BROADLY THEIR 1512 01:04:57,112 --> 01:04:58,113 EXPERTISE AND THE SCIENTIFIC 1513 01:04:58,113 --> 01:04:59,915 QUESTIONS THAT THEY ARE TACKLING 1514 01:04:59,915 --> 01:05:01,283 AND WHETHER THERE WERE ANY 1515 01:05:01,283 --> 01:05:01,917 INTERSECTIONS WITH THE OTHER 1516 01:05:01,917 --> 01:05:04,787 FIELD, RESEARCH FROM THE OTHER 1517 01:05:04,787 --> 01:05:07,323 FEEL. SO WE EMPHASIZE MORE 1518 01:05:07,323 --> 01:05:08,357 INTERACTIVE DISCUSSION BASED 1519 01:05:08,357 --> 01:05:11,327 BREAKOUT SESSIONS AFTER VERY 1520 01:05:11,327 --> 01:05:13,996 SHORT INTRODUCTORY TALKS BY EACH 1521 01:05:13,996 --> 01:05:15,531 OF THE ATTENDEES AND THE FOCUS 1522 01:05:15,531 --> 01:05:18,601 WAS ON, YOU KNOW, WHAT ARE THE 1523 01:05:18,601 --> 01:05:19,468 BIGGEST CHALLENGES, 1524 01:05:19,468 --> 01:05:21,036 OPPORTUNITIES, OR OUTSTANDING 1525 01:05:21,036 --> 01:05:23,339 QUESTIONS IN THE AGING AND 1526 01:05:23,339 --> 01:05:25,908 SYNTHETIC BIOLOGY FIELDS 1527 01:05:25,908 --> 01:05:31,880 RESPECTIVELY AND WHAT CAN EACH 1528 01:05:31,880 --> 01:05:34,083 PERSON OFFER FOR POTENTIAL 1529 01:05:34,083 --> 01:05:35,317 COLLABORATIONS TO ADDRESS THESE 1530 01:05:35,317 --> 01:05:37,820 QUESTIONS? SO THAT WAS THE 1531 01:05:37,820 --> 01:05:39,421 GENERAL GOAL ON THE FORMAT OF 1532 01:05:39,421 --> 01:05:41,790 THE WORKSHOP SO THEY ONE, FOR 1533 01:05:41,790 --> 01:05:42,891 THAT REASON CONSISTED OF TWO 1534 01:05:42,891 --> 01:05:45,761 SETS OF TALKS, VERY SHORT TALKS. 1535 01:05:45,761 --> 01:05:48,897 ONE SET WAS FLASH TALKS BY PIS, 1536 01:05:48,897 --> 01:05:50,799 ONLY THREE SLIDES, FIVE MINUTES, 1537 01:05:50,799 --> 01:05:52,167 THAT'S IT, JUST INTRODUCE WHO 1538 01:05:52,167 --> 01:05:54,270 YOU ARE, WHAT YOU WORK ON, WHAT 1539 01:05:54,270 --> 01:05:57,906 YOUR EXPERTISE IS AND WHAT 1540 01:05:57,906 --> 01:06:00,209 YOU'RE BRINGING TO THE TABLE. 1541 01:06:00,209 --> 01:06:01,877 AN ELEVATOR PITCH TO THE OTHERS 1542 01:06:01,877 --> 01:06:04,813 IN THE OTHER FIELD AND THEN 1543 01:06:04,813 --> 01:06:05,547 FOLLOWED BY LIGHTENING TALKS 1544 01:06:05,547 --> 01:06:07,783 AGAIN BY THE TRAINEES TO, JUST, 1545 01:06:07,783 --> 01:06:08,684 YOU KNOW, INTRODUCE THEMSELVES 1546 01:06:08,684 --> 01:06:09,818 AND, YOU KNOW, TALK ABOUT THEIR 1547 01:06:09,818 --> 01:06:16,825 RESEARCH AND EXPERTISE. THEN WE 1548 01:06:16,825 --> 01:06:19,361 HAD THREE BREAKOUT SESSIONS AND 1549 01:06:19,361 --> 01:06:21,196 STRUCTURED THEM FIRST IN THESE 1550 01:06:21,196 --> 01:06:23,332 BREAKOUT SESSIONS WAS WE SORT OF 1551 01:06:23,332 --> 01:06:26,568 RANDOMLY PAIRED THESE FOLKS FROM 1552 01:06:26,568 --> 01:06:29,204 DIFFERENT FIELDS AND JUST 1553 01:06:29,204 --> 01:06:30,906 ENCOURAGED THEM TO DO A MORE 1554 01:06:30,906 --> 01:06:33,142 LANDSCAPE ANALYSIS AND BLUE SKY 1555 01:06:33,142 --> 01:06:34,543 IDEATION SO WHAT ARE, AGAIN, 1556 01:06:34,543 --> 01:06:35,878 SOME OF THESE BIG QUESTIONS? 1557 01:06:35,878 --> 01:06:37,780 THAT THEY'RE TRYING TO TACKLE? 1558 01:06:37,780 --> 01:06:39,515 AND ASK QUESTIONS LIKE, WOULDN'T 1559 01:06:39,515 --> 01:06:42,384 IT BE ARE GREAT IF WE WOULD DO 1560 01:06:42,384 --> 01:06:43,986 THIS? WOULDN'T BE IT GREAT IF 1561 01:06:43,986 --> 01:06:46,755 WE HAD THIS TOOL TO ANSWER THIS 1562 01:06:46,755 --> 01:06:48,123 OUTSTANDING QUESTION IN AGING 1563 01:06:48,123 --> 01:06:49,825 BIOLOGY AND THEN VICE VERSA. 1564 01:06:49,825 --> 01:06:51,327 WOULDN'T IT BE GREAT IF I TOOK 1565 01:06:51,327 --> 01:06:53,329 MY TOOL AS A SYNTHETIC BIOLOGIST 1566 01:06:53,329 --> 01:06:55,197 AND APPLY IT IN THIS FIELD OF 1567 01:06:55,197 --> 01:06:58,967 AGING BIOLOGY? SO IT'S VERY BIG 1568 01:06:58,967 --> 01:07:00,903 PICTURE THINKING. AND THEN WE 1569 01:07:00,903 --> 01:07:02,004 DIVIDED THEM UP AGAIN INTO 1570 01:07:02,004 --> 01:07:03,539 DIFFERENT BREAKOUT SESSIONS TO, 1571 01:07:03,539 --> 01:07:05,808 YOU KNOW, WITH THESE QUESTIONS 1572 01:07:05,808 --> 01:07:09,712 IN THEIR MIND, TO TALK ABOUT 1573 01:07:09,712 --> 01:07:10,713 POTENTIAL CONNECTIONS AND ANY 1574 01:07:10,713 --> 01:07:13,415 MUTUAL INTEREST AND 1575 01:07:13,415 --> 01:07:14,550 OPPORTUNITIES THAT MAY BE 1576 01:07:14,550 --> 01:07:15,417 OBVIOUS TO THEM AFTER THINKING 1577 01:07:15,417 --> 01:07:16,585 ABOUT THESE TYPES OF QUESTIONS. 1578 01:07:16,585 --> 01:07:18,554 AND THEN THE THIRD ONE WAS MORE 1579 01:07:18,554 --> 01:07:21,890 OF AN OPEN DISCUSSION FORMAT 1580 01:07:21,890 --> 01:07:26,762 WHERE, YOU KNOW, THEY EXPANDED 1581 01:07:26,762 --> 01:07:27,763 ON THOSE DISCUSSIONS AND 1582 01:07:27,763 --> 01:07:29,798 IDENTIFIED SOME, MAYBE, HIGHLY 1583 01:07:29,798 --> 01:07:33,836 IMPACTFUL OPPORTUNITIES RELEVANT 1584 01:07:33,836 --> 01:07:36,538 OPPORTUNITIES. WE ALSO HAD A 1585 01:07:36,538 --> 01:07:37,840 TRAINING SESSION BY TRAINING 1586 01:07:37,840 --> 01:07:41,276 OFFICERS FROM NIH AND NIBAB AND 1587 01:07:41,276 --> 01:07:46,348 WE WRAPPED UP THAT DAY AND ASKED 1588 01:07:46,348 --> 01:07:47,516 EVERYONE TO THINK ABOUT WHAT 1589 01:07:47,516 --> 01:07:49,985 THEY DISCUSSED DURING THE DAY 1590 01:07:49,985 --> 01:07:51,920 FOR THE NEXT DAY REPORT OUT 1591 01:07:51,920 --> 01:07:53,455 SESSION AND THE REPORT OUT 1592 01:07:53,455 --> 01:07:57,693 SESSION TO LAY OUT ALL THE 1593 01:07:57,693 --> 01:07:59,328 DISCUSSION. THERE WAS A LOT OF 1594 01:07:59,328 --> 01:08:01,897 DISCUSSIONS GOING ON AND THE 1595 01:08:01,897 --> 01:08:05,801 REPORT OUT FOCUSED ON WHAT THE 1596 01:08:05,801 --> 01:08:07,336 NEXT STEPS ARE AND 1597 01:08:07,336 --> 01:08:08,303 IDENTIFICATION OF LIKE SOME 1598 01:08:08,303 --> 01:08:09,772 SOLID OPPORTUNITIES. SOME 1599 01:08:09,772 --> 01:08:15,310 ACTION PLANS. AND WE ALSO -- WE 1600 01:08:15,310 --> 01:08:17,813 ALSO DID A PRIORITIZATION OF 1601 01:08:17,813 --> 01:08:21,183 THESE IDENTIFIED AREAS. GAP 1602 01:08:21,183 --> 01:08:23,585 AREAS AND OPPORTUNITIES WITHIN 1603 01:08:23,585 --> 01:08:27,322 THOSE AREAS. SO AGAIN VERY 1604 01:08:27,322 --> 01:08:29,792 SPECIFICALLY FOCUSED ON 1605 01:08:29,792 --> 01:08:31,226 COLLABORATIONS BETWEEN THE TWO 1606 01:08:31,226 --> 01:08:32,961 SCIENTIFIC FIELDS AND THEN WE 1607 01:08:32,961 --> 01:08:34,997 WRAPPED IT UP AND IF -- I FORGOT 1608 01:08:34,997 --> 01:08:36,865 TO PUT IT IN MY SLIDES BUT IF 1609 01:08:36,865 --> 01:08:38,333 ANY OF YOU WANT TO WATCH ANY OF 1610 01:08:38,333 --> 01:08:40,135 THE BREAKOUT SESSIONS OR THE 1611 01:08:40,135 --> 01:08:40,869 MAIN PLENARY SESSIONS THEY'RE 1612 01:08:40,869 --> 01:08:43,338 ALL AVAILABLE ON THE SYNTHETIC 1613 01:08:43,338 --> 01:08:47,109 BIOLOGY CONSORTIUM WEBSITE ON 1614 01:08:47,109 --> 01:08:48,710 NIBAB AND YOU CAN WATCH THEM AND 1615 01:08:48,710 --> 01:08:50,946 THERE'S A WORKSHOP REPORT THAT 1616 01:08:50,946 --> 01:08:52,648 IS ON THE WEBSITE YOU CAN READ. 1617 01:08:52,648 --> 01:08:53,582 AND THERE WERE GREAT 1618 01:08:53,582 --> 01:08:54,983 RECOMMENDATIONS THAT CAME OUT OF 1619 01:08:54,983 --> 01:08:57,019 THIS WORKSHOP WHICH FEI WILL NOW 1620 01:08:57,019 --> 01:08:57,519 GO OVER. 1621 01:08:57,519 --> 01:09:02,124 >> COSO SO T -- SO CLEARLY IT 1622 01:09:02,124 --> 01:09:06,528 WAS A VERY SUCCESSFUL WORKSHOP. 1623 01:09:06,528 --> 01:09:07,329 AND MANY RECOMMENDATION CAME OUT 1624 01:09:07,329 --> 01:09:09,932 OF IT. IN THIS SLIDE I LIST 1625 01:09:09,932 --> 01:09:12,534 SOME IN DISCOVERY RESEARCH SOME 1626 01:09:12,534 --> 01:09:13,902 THERAPEUTICS, DEVELOPMENT, I 1627 01:09:13,902 --> 01:09:16,004 DON'T EXPECT YOU TO READ IT NOW. 1628 01:09:16,004 --> 01:09:17,539 AND IF YOU ARE INTERESTED, THERE 1629 01:09:17,539 --> 01:09:22,211 IS A WEBSITE ALL YOU NEED TO DO 1630 01:09:22,211 --> 01:09:25,113 IS GOOGLE NIBIB WORKSHOP AND 1631 01:09:25,113 --> 01:09:27,216 REPORTS, YOU WILL GET THERE. IT 1632 01:09:27,216 --> 01:09:30,118 HAS THE EXACT SUMMARIES AND ALSO 1633 01:09:30,118 --> 01:09:34,890 SOME DETAILS, RECOMMENDATION. 1634 01:09:34,890 --> 01:09:41,230 WHAT CAME OUT REALLY LOUD AND 1635 01:09:41,230 --> 01:09:43,031 CLEAR IS -- SOMEHOW THIS IS NOT 1636 01:09:43,031 --> 01:09:44,833 WORKING RIGHT. OKAY, SO, SO 1637 01:09:44,833 --> 01:09:47,002 BASICALLY YOU GOT TWO SPACE, 1638 01:09:47,002 --> 01:09:49,204 RIGHT? YOU HAVE THE BIOLOGY OF 1639 01:09:49,204 --> 01:09:50,706 AGING RESEARCH. YOU HAVE THE 1640 01:09:50,706 --> 01:09:55,177 SYNTHETIC BIOLOGY INVESTIGATORS. 1641 01:09:55,177 --> 01:09:59,815 AND IT IS THE INTERSECTION WE'RE 1642 01:09:59,815 --> 01:10:04,019 HOPING THAT YOU GUYS EITHER ARE 1643 01:10:04,019 --> 01:10:05,854 THE TWO DEVELOPER OR GOT SOME 1644 01:10:05,854 --> 01:10:09,157 IDEAS IN AGING RESEARCH. THAT 1645 01:10:09,157 --> 01:10:11,426 WILL HELP US IN THE APPLICATION 1646 01:10:11,426 --> 01:10:14,930 AREA. AND I WAS HAVING A 1647 01:10:14,930 --> 01:10:17,866 CONVERSATION WITH A TEAM 1648 01:10:17,866 --> 01:10:19,902 YESTERDAY ABOUT SIMPLE THINGS 1649 01:10:19,902 --> 01:10:21,837 LIKE WE WERE TALKING ABOUT THE 1650 01:10:21,837 --> 01:10:23,939 STEM CELL RESEARCH ALL THE TIME, 1651 01:10:23,939 --> 01:10:27,376 RIGHT? REGENERATIVE MEDICINE, 1652 01:10:27,376 --> 01:10:30,412 HAVE WE THOUGHT ABOUT AGING? 1653 01:10:30,412 --> 01:10:32,681 AND WHEN YOU DO IPS CELL YOU 1654 01:10:32,681 --> 01:10:35,250 BRING IT BACK TO THE STATE. IN 1655 01:10:35,250 --> 01:10:36,418 MY PREVIOUS LIFE I DIDN'T REALLY 1656 01:10:36,418 --> 01:10:39,321 CARE ABOUT AGING NOW I'M IN THE 1657 01:10:39,321 --> 01:10:40,789 NATURAL INSTITUTE ON AGING, I 1658 01:10:40,789 --> 01:10:42,424 THINK ABOUT THESE THINGS. AND 1659 01:10:42,424 --> 01:10:44,126 THE AGING POSSESS. 1660 01:10:44,126 --> 01:10:46,094 IT'S NOT SIMPLY WE DEAL WITH 1661 01:10:46,094 --> 01:10:48,363 ELDERLY. THE PROCESS LEADS TO 1662 01:10:48,363 --> 01:10:50,365 AGING. A 50 YEARS OLD IS 1663 01:10:50,365 --> 01:10:52,467 DIFFERENT FROM 15 YEARS OLD. 1664 01:10:52,467 --> 01:10:55,003 RIGHT? ONE IS RUNNING MARATHON, 1665 01:10:55,003 --> 01:10:58,974 ANOTHER ONE HAS ALL THESE KNEE 1666 01:10:58,974 --> 01:11:01,476 OSTEOARTHRITIS PROBLEMS SO IN 1667 01:11:01,476 --> 01:11:04,112 OTHER WORDS ONE OF THE BIG 1668 01:11:04,112 --> 01:11:05,814 CHALLENGE IN OUR FIELD IS WHAT 1669 01:11:05,814 --> 01:11:11,787 IS A MARKER FOR AGING? CAN YOU 1670 01:11:11,787 --> 01:11:16,959 GUYS BE RELEVANT OF A MARKER FOR 1671 01:11:16,959 --> 01:11:17,559 US? JUST SIMPLE THINGS LIKE 1672 01:11:17,559 --> 01:11:18,427 THIS I SEE A LOT OF 1673 01:11:18,427 --> 01:11:20,095 OPPORTUNITIES FOR US TO WORK 1674 01:11:20,095 --> 01:11:22,097 TOGETHER. AND I THINK THE 1675 01:11:22,097 --> 01:11:25,300 IMPORTANT THING IS FOR THE TWO 1676 01:11:25,300 --> 01:11:27,269 DEVELOPERS ENGAGE WITH THE 1677 01:11:27,269 --> 01:11:29,738 INVESTIGATORS WORKING IN THE 1678 01:11:29,738 --> 01:11:31,340 AGING BIOLOGY AREA SO YOU CAN 1679 01:11:31,340 --> 01:11:32,507 UNDERSTAND EACH OTHER'S 1680 01:11:32,507 --> 01:11:34,476 CHALLENGE. OF THE RESULT, YOU 1681 01:11:34,476 --> 01:11:36,745 CAN WORK TOGETHER, MAKE THINGS 1682 01:11:36,745 --> 01:11:38,647 HAPPEN. SO WITH THAT, I WANT TO 1683 01:11:38,647 --> 01:11:41,016 THANK YOU. AND MY CONTACT 1684 01:11:41,016 --> 01:11:43,218 INFORMATION TUBA'S CONTACT 1685 01:11:43,218 --> 01:11:43,919 INFORMATION IS UP THERE I 1686 01:11:43,919 --> 01:11:46,455 WELCOME YOU TO REACH OUT TO US 1687 01:11:46,455 --> 01:11:50,258 AND FOR ANY POTENTIAL QUESTIONS 1688 01:11:50,258 --> 01:11:56,098 YOU MAY HAVE. THANK YOU. 1689 01:11:56,098 --> 01:11:59,034 >> LOOKS LIKE WE HAVE MAYBE ONE 1690 01:11:59,034 --> 01:11:59,868 QUESTION MAYBE? ALL RIGHT. 1691 01:11:59,868 --> 01:12:00,802 >> AUDIENCE: THANK YOU SO MUCH I 1692 01:12:00,802 --> 01:12:03,338 AM SO GLAD I DIDN'T KNOW ABOUT 1693 01:12:03,338 --> 01:12:05,707 THIS WORKSHOP UNTIL TODAY. I 1694 01:12:05,707 --> 01:12:10,045 ENTER AGING RESEARCH THIS FIELD 1695 01:12:10,045 --> 01:12:11,980 THIS YEAR. AFTER APPROACHED BY 1696 01:12:11,980 --> 01:12:15,317 THE PLENARY SO I AM GOING TO 1697 01:12:15,317 --> 01:12:17,786 TAKE WHATEVER MONEY OR WHATEVER. 1698 01:12:17,786 --> 01:12:20,722 ONE THING, THEY ACTUALLY ACCEPT 1699 01:12:20,722 --> 01:12:23,725 THE SAID THING THEY NOT THAT 1700 01:12:23,725 --> 01:12:25,661 HAPPY WITH THE RESEARCH THE LAST 1701 01:12:25,661 --> 01:12:28,330 DECADE OF THE AGING RESEARCH 1702 01:12:28,330 --> 01:12:29,798 BECAUSE VERY TRADITIONAL 1703 01:12:29,798 --> 01:12:31,199 APPROACH. AND THEN THEY INVITE 1704 01:12:31,199 --> 01:12:33,902 ME TO GIVE A TALK IN ONE OF THE 1705 01:12:33,902 --> 01:12:36,672 BIGGEST AGING RESEARCH 1706 01:12:36,672 --> 01:12:38,407 CONFERENCE IN DENMARK THAT IS 1707 01:12:38,407 --> 01:12:40,008 THE MOST BORING CONFERENCE I 1708 01:12:40,008 --> 01:12:42,844 EVER ATTENDED. BECAUSE THEY 1709 01:12:42,844 --> 01:12:44,112 ONLY TALKING ABOUT VERY 1710 01:12:44,112 --> 01:12:45,514 TRADITIONAL APPROACH TO 1711 01:12:45,514 --> 01:12:48,717 UNDERSTAND THE AGING. SO THE 1712 01:12:48,717 --> 01:12:54,022 QUESTION I HAVE IS, YOU DON'T -- 1713 01:12:54,022 --> 01:12:55,957 ABOUT THE WORKSHOP LAST YEAR AND 1714 01:12:55,957 --> 01:12:58,360 SINCE THAT, DO YOU SEE SOME 1715 01:12:58,360 --> 01:13:02,030 CHANGE IN THE PREVIOUS STUDY 1716 01:13:02,030 --> 01:13:03,699 SECTION ABOUT AGING RESEARCH? 1717 01:13:03,699 --> 01:13:05,667 OR NEW SUBMISSION THAT 1718 01:13:05,667 --> 01:13:09,638 INCORPORATE SYNTHETIC BIOLOGY? 1719 01:13:09,638 --> 01:13:13,008 >> SO, THE SIMPLE ANSWER IS DO 1720 01:13:13,008 --> 01:13:14,576 WE HAVE MORE INVESTIGATOR 1721 01:13:14,576 --> 01:13:17,979 WORKING IN THIS SPACE, RIGHT? I 1722 01:13:17,979 --> 01:13:21,249 MEAN, WE HAVE OUR ISOS FROM CR 1723 01:13:21,249 --> 01:13:23,351 HERE, RIGHT? SO LET ME USE A 1724 01:13:23,351 --> 01:13:26,688 DIFFERENT EXAMPLE. YOU KNOW NIH 1725 01:13:26,688 --> 01:13:28,423 ALWAYS HAVE THIS COMMON FOUND 1726 01:13:28,423 --> 01:13:31,126 ACTIVITY, RIGHT? AND THEN IN MY 1727 01:13:31,126 --> 01:13:33,829 PREVIOUS LIFE I ALWAYS TELL 1728 01:13:33,829 --> 01:13:36,598 INVESTIGATOR IF YOU ARE THE ONLY 1729 01:13:36,598 --> 01:13:38,333 APPLICATION IN THAT 200 1730 01:13:38,333 --> 01:13:39,768 APPLICATION STUDIES SECTION DO 1731 01:13:39,768 --> 01:13:41,470 YOU THINK YOU WILL HAVE A 1732 01:13:41,470 --> 01:13:43,238 REVIEWER THAT APPRECIATES YOUR 1733 01:13:43,238 --> 01:13:43,438 WORK? 1734 01:13:43,438 --> 01:13:44,206 >> AUDIENCE: I DON'T THINK SO. 1735 01:13:44,206 --> 01:13:45,707 THAT'S WHY I HESITATE. 1736 01:13:45,707 --> 01:13:47,976 >> IT'S NOT SIMPLY THE STUDY 1737 01:13:47,976 --> 01:13:51,780 SECTION. IT IS DO WE HAVE A 1738 01:13:51,780 --> 01:13:58,086 COMMUNITY, RIGHT? SO IF WE HAVE 1739 01:13:58,086 --> 01:14:01,289 A COMMUNITY THEN THE REVIEWERS 1740 01:14:01,289 --> 01:14:02,357 WILL BE MORE. YOU WOULDN'T 1741 01:14:02,357 --> 01:14:04,893 INVITE A SPECIFIC REVIEWER WHEN 1742 01:14:04,893 --> 01:14:06,161 YOU HAVE ONE APPLICATION IN YOUR 1743 01:14:06,161 --> 01:14:09,264 STUDY SECTION YOU ONLY INVITE 25 1744 01:14:09,264 --> 01:14:09,998 REVIEWERS. IT'S AS SIMPLE AS 1745 01:14:09,998 --> 01:14:12,334 THAT SO THAT'S WHY I AM HERE TO 1746 01:14:12,334 --> 01:14:19,941 TELL YOU GUYS, NOT ONLY NIBIB IS 1747 01:14:19,941 --> 01:14:21,643 INTERESTED. NOT ONLY CI. AGING 1748 01:14:21,643 --> 01:14:22,911 IS ALSO INTERESTED. 1749 01:14:22,911 --> 01:14:25,313 >> AUDIENCE: OKAY, I AM HAPPY TO 1750 01:14:25,313 --> 01:14:26,882 CREATE A COMMUNITY WITH SOME 1751 01:14:26,882 --> 01:14:27,482 YOUNG PEOPLE WITH YOU. THANK 1752 01:14:27,482 --> 01:14:29,818 YOU. 1753 01:14:29,818 --> 01:14:30,986 >> ANY OTHER QUESTIONS? GREAT. 1754 01:14:30,986 --> 01:14:32,454 THANK YOU, BOTH. 1755 01:14:32,454 --> 01:14:40,095 >> THANK YOU. 1756 01:14:40,095 --> 01:14:43,532 >> I WILL STAY ON FOR MY 1757 01:14:43,532 --> 01:14:43,865 PRESENTATION. 1758 01:14:43,865 --> 01:14:50,038 >> NEXT IS TALKING ABOUT AN 1759 01:14:50,038 --> 01:14:54,643 EXCITING NEW MECHANISM THAT SHE 1760 01:14:54,643 --> 01:14:54,910 DEVELOPED. 1761 01:14:54,910 --> 01:14:57,279 >> OKAY, SO THIS ONE IS A NEW 1762 01:14:57,279 --> 01:15:00,282 PROGRAM THAT WE LAUNCHED AT 1763 01:15:00,282 --> 01:15:02,217 NIBIB IN COLLABORATION WITH THE 1764 01:15:02,217 --> 01:15:04,753 NSF AND IT'S CALLED BIOMEDICAL 1765 01:15:04,753 --> 01:15:05,854 RESEARCH INITIATIVE FOR NEXT 1766 01:15:05,854 --> 01:15:08,690 GENERATION BIOTECHNOLOGIES. SIN 1767 01:15:08,690 --> 01:15:11,326 BIO CONTROL EDITION. THIS IS A 1768 01:15:11,326 --> 01:15:13,328 SOLICITATION THAT HIT THE 1769 01:15:13,328 --> 01:15:16,298 STREETS SOMETIMES IN SEPTEMBER. 1770 01:15:16,298 --> 01:15:18,700 AND THE DEADLINE IS DECEMBER 1771 01:15:18,700 --> 01:15:20,969 4TH. YOU HAVE ABOUT TWO WEEKS. 1772 01:15:20,969 --> 01:15:22,771 IF YOU ARE RUSHING BUT HOPEFULLY 1773 01:15:22,771 --> 01:15:25,574 YOU'VE HEARD ABOUT IT A WHILE 1774 01:15:25,574 --> 01:15:27,742 AGO BECAUSE WE SENT OUT A LOT OF 1775 01:15:27,742 --> 01:15:29,578 E-MAILS AND PUT IT ON OUR 1776 01:15:29,578 --> 01:15:32,781 WEBSITE. SO WE DID A LOT OF 1777 01:15:32,781 --> 01:15:34,749 RESEARCH TO THE SYNTHETIC 1778 01:15:34,749 --> 01:15:36,084 BIOLOGY COMMUNITY AND I WANT TO 1779 01:15:36,084 --> 01:15:37,619 USE THIS OPPORTUNITY TO GO OVER 1780 01:15:37,619 --> 01:15:39,554 WHAT THE PROGRAM'S ABOUT AND THE 1781 01:15:39,554 --> 01:15:41,656 GOALS OF IT. AND AGAIN, I DON'T 1782 01:15:41,656 --> 01:15:43,592 EXPECT ANYONE TO PUT TOGETHER A 1783 01:15:43,592 --> 01:15:45,360 BRAND NEW APPLICATION BY 1784 01:15:45,360 --> 01:15:48,029 DECEMBER 4TH BUT YOU CAN BE 1785 01:15:48,029 --> 01:15:50,298 AWARE OF THE APPROACH WE TOOK IN 1786 01:15:50,298 --> 01:15:53,034 THIS NEW TYPE OF COLLABORATION 1787 01:15:53,034 --> 01:15:55,604 WITH THE NSF. IF YOU WOULD LIKE 1788 01:15:55,604 --> 01:15:58,106 TO READ ABOUT THIS, THIS IS THE 1789 01:15:58,106 --> 01:16:01,042 WEBSITE HERE AND THERE IS ALSO A 1790 01:16:01,042 --> 01:16:03,345 WEBINAR WE HELD FOR POTENTIAL 1791 01:16:03,345 --> 01:16:04,880 APPLICANTS THAT GO OVER THE 1792 01:16:04,880 --> 01:16:05,914 SOLICITATION AND THE 1793 01:16:05,914 --> 01:16:11,319 REQUIREMENTS THAT YOU COULD ALSO 1794 01:16:11,319 --> 01:16:15,223 WATCH. NOW, BRING SIN BIO WE 1795 01:16:15,223 --> 01:16:17,859 DEVELOPED THIS PROGRAM AS A 1796 01:16:17,859 --> 01:16:18,927 COLLABORATION TOOL BETWEEN TWO 1797 01:16:18,927 --> 01:16:21,296 AGENCIES THAT ARE INTERESTED IN 1798 01:16:21,296 --> 01:16:22,364 FUNDING SYNTHETIC BIOLOGY 1799 01:16:22,364 --> 01:16:22,631 RESEARCH. 1800 01:16:22,631 --> 01:16:24,299 OR INTERESTED IN COLLABORATING 1801 01:16:24,299 --> 01:16:26,601 IN GENERAL. SO WE HAVE HAD 1802 01:16:26,601 --> 01:16:27,903 LONG-STANDING COLLABORATIONS 1803 01:16:27,903 --> 01:16:32,173 WITH THE NDF AND OTHER PROGRAMS 1804 01:16:32,173 --> 01:16:34,943 BUT AS WE ALL KNOW RESEARCH IS A 1805 01:16:34,943 --> 01:16:37,212 SPECTRUM AND INTERESTS FALL AT 1806 01:16:37,212 --> 01:16:38,713 THE DIFFERENT ENDS OF THE 1807 01:16:38,713 --> 01:16:41,116 SPECTRUM AND FOR OUR PURPOSES 1808 01:16:41,116 --> 01:16:42,851 WITHIN THIS COLLABORATIVE SPACE 1809 01:16:42,851 --> 01:16:46,321 NSF FALLS ON THE MORE 1810 01:16:46,321 --> 01:16:48,189 FOUNDATIONAL ASPECT OF QUESTIONS 1811 01:16:48,189 --> 01:16:50,025 ASKED WHEREAS NIH IS INTERESTED 1812 01:16:50,025 --> 01:16:53,862 IN MORE BIOMEDICAL AND HEALTH 1813 01:16:53,862 --> 01:16:55,297 RELEVANT RESEARCH SO WE SORT OF 1814 01:16:55,297 --> 01:16:57,599 FALL ON THE OPPOSITE ENDS OF THE 1815 01:16:57,599 --> 01:16:59,701 SPECTRUM. AND BECAUSE OF THAT, 1816 01:16:59,701 --> 01:17:01,703 THE NATURE OF THE EXISTING 1817 01:17:01,703 --> 01:17:03,471 COLLABORATIONS WITH THE NSF HAS 1818 01:17:03,471 --> 01:17:05,974 MOSTLY FALLEN IN A SPACE THAT IS 1819 01:17:05,974 --> 01:17:07,976 IN BETWEEN WHERE, FOR EXAMPLE, 1820 01:17:07,976 --> 01:17:09,344 AN APPLICATION OR A RESEARCH 1821 01:17:09,344 --> 01:17:11,846 PROJECT COULD EITHER GO TO THE 1822 01:17:11,846 --> 01:17:15,884 NSF OR NIH IN GENERAL. SO WHAT 1823 01:17:15,884 --> 01:17:19,254 WE WANTED TO DO WAS TO REALLY 1824 01:17:19,254 --> 01:17:22,324 CAPTURE MORE OF THE DISCOVERIES 1825 01:17:22,324 --> 01:17:23,858 THAT HAS COME OUT OF 1826 01:17:23,858 --> 01:17:27,629 FOUNDATIONAL, MORE FOUNDATIONAL 1827 01:17:27,629 --> 01:17:30,098 RESEARCH, SO TOWARDS THE LEFT 1828 01:17:30,098 --> 01:17:32,033 END OF THE SPECTRUM, LET ME SEE 1829 01:17:32,033 --> 01:17:36,571 IF I CAN GET A LASER POINTER WE 1830 01:17:36,571 --> 01:17:38,840 FELT THE KNOWLEDGE AND THE 1831 01:17:38,840 --> 01:17:39,507 INNOVATION AND DISCOVERIES THAT 1832 01:17:39,507 --> 01:17:42,644 COME OUT OF FROM THE NSF SPACE 1833 01:17:42,644 --> 01:17:44,779 TOWARDS A MORE FOUNDATIONAL 1834 01:17:44,779 --> 01:17:48,383 RESEARCH AREAS, SO THE STATE 1835 01:17:48,383 --> 01:17:49,317 SILOED AND DID NOT MAKE THEIR 1836 01:17:49,317 --> 01:17:50,919 WAY INTO THE NIH DOMAIN BECAUSE 1837 01:17:50,919 --> 01:17:53,388 OF THE HIGH ACTIVATION THRESHOLD 1838 01:17:53,388 --> 01:17:55,690 OF PUSHING THESE DISCOVERIES 1839 01:17:55,690 --> 01:18:01,496 INTO THE NIH DOMAIN APPLICATION 1840 01:18:01,496 --> 01:18:03,999 INTO THE HUMAN RELEVANCE AREAS. 1841 01:18:03,999 --> 01:18:08,570 SO WHO WE WANTED TO DO WAS TO 1842 01:18:08,570 --> 01:18:09,504 REALLY CAPTURE THE KNOWLEDGE 1843 01:18:09,504 --> 01:18:15,310 THAT COMES OUT OF NSF AND PUT IN 1844 01:18:15,310 --> 01:18:17,312 INTENTIONAL DIRECTIONALITY OF 1845 01:18:17,312 --> 01:18:18,747 TAKING THIS KNOWLEDGE AND 1846 01:18:18,747 --> 01:18:20,548 TURNING INTO BIOMEDICALLY 1847 01:18:20,548 --> 01:18:21,850 RELEVANT RESEARCH PROJECTS AT 1848 01:18:21,850 --> 01:18:25,620 THE NIH SO OUR GOAL WAS TO, 1849 01:18:25,620 --> 01:18:29,391 AGAIN, BRIDGE MORE OF THE 1850 01:18:29,391 --> 01:18:30,492 FOUNDATIONAL RESEARCH 1851 01:18:30,492 --> 01:18:31,026 DISCOVERIES AND THEIR 1852 01:18:31,026 --> 01:18:32,527 APPLICATIONS IN THE BIOMEDICAL 1853 01:18:32,527 --> 01:18:35,630 SPACE BY PUTTING IN THIS ARROW 1854 01:18:35,630 --> 01:18:38,700 HERE. SO WE THOUGHT LONG AND 1855 01:18:38,700 --> 01:18:40,535 HARD ABOUT IT. AND HAD TO JUMP 1856 01:18:40,535 --> 01:18:41,870 THROUGH A LOT OF BUREAUCRATIC 1857 01:18:41,870 --> 01:18:43,738 HOOPS AND LOOPS BUT WE MADE IT 1858 01:18:43,738 --> 01:18:47,642 HAPPEN IN A UNIQUE WAY. AND 1859 01:18:47,642 --> 01:18:54,616 WHAT WE DECIDED TO DO WAS AGAIN, 1860 01:18:54,616 --> 01:18:57,519 TAKE A RESEARCH PROJECT BUT 1861 01:18:57,519 --> 01:19:01,523 SPLIT IT INTO TWO PHASES. SUCH 1862 01:19:01,523 --> 01:19:03,024 THAT THERE WOULD BE AN ACTUAL 1863 01:19:03,024 --> 01:19:05,860 CONNECTION BETWEEN THE TWO 1864 01:19:05,860 --> 01:19:08,396 PHASES. THAT PUTS IN THAT, YOU 1865 01:19:08,396 --> 01:19:09,898 KNOW, DIRECTIONALITY OF THIS 1866 01:19:09,898 --> 01:19:12,834 ARROW. SO WE CALL IT A BIPHASIC 1867 01:19:12,834 --> 01:19:14,436 APPROACH BECAUSE THERE ARE TWO 1868 01:19:14,436 --> 01:19:16,538 PHASE TO THE RESEARCH PROJECT. 1869 01:19:16,538 --> 01:19:18,506 AND THE RESEARCH IS A SINGLE 1870 01:19:18,506 --> 01:19:19,307 APPLICATION. 1871 01:19:19,307 --> 01:19:22,944 A SINGLE PROPOSAL. WITH AN 1872 01:19:22,944 --> 01:19:25,447 INTEGRATED PROJECT THAT ALLOWS 1873 01:19:25,447 --> 01:19:26,681 THE RAPID AND SEAMLESS 1874 01:19:26,681 --> 01:19:27,916 TRANSITION OF FUNDAMENTAL 1875 01:19:27,916 --> 01:19:29,951 DISCOVERIES. WITHIN THE NSF 1876 01:19:29,951 --> 01:19:33,855 DOMAIN. WE CALL THIS PHASE ONE. 1877 01:19:33,855 --> 01:19:38,560 AND SHEPHERD THEM THROUGH TO 1878 01:19:38,560 --> 01:19:39,561 BIOMEDICALLY RELEVANT 1879 01:19:39,561 --> 01:19:42,030 TECHNOLOGIES THAT ARE WITHIN NIH 1880 01:19:42,030 --> 01:19:46,734 MISSION. IN PHASE TWO. SO WE 1881 01:19:46,734 --> 01:19:47,869 INTENTIONALLY LINKED THE TWO 1882 01:19:47,869 --> 01:19:49,637 PHASES SUCH THAT WHATEVER COMES 1883 01:19:49,637 --> 01:19:55,610 OUT OF PHASE ONE WOULD NATURALLY 1884 01:19:55,610 --> 01:19:57,212 NOW INTO PHASE TWO NOW THE 1885 01:19:57,212 --> 01:19:58,446 ADVANTAGES OF THE BIPHASIC 1886 01:19:58,446 --> 01:20:00,181 CONCEPT IS NOT ONLY IS THIS A 1887 01:20:00,181 --> 01:20:02,183 UNIQUE FUNDING TOOL FOR 1888 01:20:02,183 --> 01:20:04,619 INTERAGENCY COLLABORATION AGAIN 1889 01:20:04,619 --> 01:20:06,588 TAKING NSF DISCOVERIES THAT MAY 1890 01:20:06,588 --> 01:20:08,857 MAKE THEMSELVES SILOED AND NOT 1891 01:20:08,857 --> 01:20:14,195 MAKE THEIR WAY INTO NSF OR 1892 01:20:14,195 --> 01:20:15,897 DISCOVERIES. AND I THINK OF 1893 01:20:15,897 --> 01:20:17,599 COMPUTER SCIENCE, BUT TAKE THOSE 1894 01:20:17,599 --> 01:20:21,936 AND TURN THEM INTO HUMAN HEALTH. 1895 01:20:21,936 --> 01:20:25,707 AND THERE IS ALSO AN INTENTIONAL 1896 01:20:25,707 --> 01:20:27,308 PUSHING AND PULLING OF THESE 1897 01:20:27,308 --> 01:20:28,576 FUNDAMENTAL DISCOVERIES, AGAIN, 1898 01:20:28,576 --> 01:20:30,912 THE ARROW THAT I DISCUSSED 1899 01:20:30,912 --> 01:20:33,348 EARLIER. WHERE NSF 1900 01:20:33,348 --> 01:20:35,617 INTENTIONALLY PUSHES DISCOVERIES 1901 01:20:35,617 --> 01:20:38,186 OUT OF PHASE ONE. AND WE PULL 1902 01:20:38,186 --> 01:20:40,755 IT INTO PHASE TWO. AT THE NIH 1903 01:20:40,755 --> 01:20:42,490 SO THEY AGAIN BRING IN THAT 1904 01:20:42,490 --> 01:20:43,825 DIRECTIONALITY SO THIS PROVIDES 1905 01:20:43,825 --> 01:20:46,427 A RAPID PATHWAY FOR CONTINUED 1906 01:20:46,427 --> 01:20:47,896 ACTIVITIES AT THE NIH WITHOUT A 1907 01:20:47,896 --> 01:20:49,864 BREAK IN FUNDING IN PHASE ONE 1908 01:20:49,864 --> 01:20:51,332 BECAUSE OTHERWISE, PEOPLE WOULD 1909 01:20:51,332 --> 01:20:53,368 DO THEIR RESEARCH AT NSF AND 1910 01:20:53,368 --> 01:20:57,138 MAYBE NOT BOTHER TAKING A STEP 1911 01:20:57,138 --> 01:20:59,307 FURTHER IN APPLYING FOR AN NIH 1912 01:20:59,307 --> 01:21:00,842 GRANT TO TURN IT INTO 1913 01:21:00,842 --> 01:21:02,343 DISCOVERIES RELEVANT TO OUR 1914 01:21:02,343 --> 01:21:04,479 MISSION SO WE WANTED TO SORT OF 1915 01:21:04,479 --> 01:21:05,747 DECREASE THAT ACTIVATION ENERGY 1916 01:21:05,747 --> 01:21:08,149 AND SORT OF PROVIDE THIS 1917 01:21:08,149 --> 01:21:10,251 PATHWAY, RAPID PATHWAY FOR 1918 01:21:10,251 --> 01:21:10,885 CONTINUED ACTIVITIES AND ALSO 1919 01:21:10,885 --> 01:21:13,488 WHAT THIS BRING TO THE TABLE IS 1920 01:21:13,488 --> 01:21:17,625 THAT PHASE ONE IS AN INDEPENDENT 1921 01:21:17,625 --> 01:21:19,394 NSF AWARD. SO WE ROLLED TWO 1922 01:21:19,394 --> 01:21:22,830 AWARDS INTO ONE. IT'S LIKE BUY 1923 01:21:22,830 --> 01:21:25,099 ONE GET ONE FREE ALTHOUGH PHASE 1924 01:21:25,099 --> 01:21:27,335 TWO IS NOT GUARANTEED THIS 1925 01:21:27,335 --> 01:21:29,037 PROVIDES THE P SISHGS THEY GET 1926 01:21:29,037 --> 01:21:33,975 TWO INDEPEN -- AWARDS AS WELL. 1927 01:21:33,975 --> 01:21:37,412 WE SEE IT AS A WIN-WIN AGAIN WE 1928 01:21:37,412 --> 01:21:40,815 STRUCTURED THIS PROGRAM IN TWO 1929 01:21:40,815 --> 01:21:46,221 PHASES. AND PHASE ONE SHOULD 1930 01:21:46,221 --> 01:21:49,357 FIT INTO THE NSF AND INTERESTS. 1931 01:21:49,357 --> 01:21:53,895 AND PHASE TWO SHOULD FIT INTO 1932 01:21:53,895 --> 01:21:55,330 NIBIB MISSION AND INTERESTS SO 1933 01:21:55,330 --> 01:21:57,865 PHASE ONE IS MOSTLY PROOF OF 1934 01:21:57,865 --> 01:21:59,334 PRINCIPLE, FOUNDATIONAL, SIN 1935 01:21:59,334 --> 01:22:04,405 THREAT -- SYNTHETIC. 1936 01:22:04,405 --> 01:22:07,308 AND THEN, PHASE TWO, WOULD 1937 01:22:07,308 --> 01:22:09,911 EXPAND ON THIS KNOWLEDGE 1938 01:22:09,911 --> 01:22:12,647 GENERATED DURING PHASE ONE. 1939 01:22:12,647 --> 01:22:14,315 TOWARDS EXPANDED BIOMEDICAL 1940 01:22:14,315 --> 01:22:16,251 TECHNOLOGY DEVELOPMENT WHICH IS 1941 01:22:16,251 --> 01:22:18,586 SUPPORTED BY NIBIB. BUT THESE 1942 01:22:18,586 --> 01:22:21,022 TWO PHASES CANNOT BE 1943 01:22:21,022 --> 01:22:22,590 INDEPENDENT. THEY'RE A NATURAL 1944 01:22:22,590 --> 01:22:23,258 CONTINUATION OF EACH OTHER SO TO 1945 01:22:23,258 --> 01:22:29,731 DO THAT YOU NEED TO 1946 01:22:29,731 --> 01:22:30,231 INTENTIONALLY LINK THEM 1947 01:22:30,231 --> 01:22:30,898 SCIENTIFICALLY AND YOU DO THAT 1948 01:22:30,898 --> 01:22:33,668 BY MILESTONES. THESE ARE 1949 01:22:33,668 --> 01:22:36,037 QUANTITATIVE BENCHMARKS FOR 1950 01:22:36,037 --> 01:22:37,639 JUSTIFYING CONTINUATION INTO 1951 01:22:37,639 --> 01:22:39,274 PHASE TWO. OF PHASE ONE 1952 01:22:39,274 --> 01:22:41,142 RESEARCH SO PHASE ONE AT THE END 1953 01:22:41,142 --> 01:22:45,346 OF PHASE ONE, WE INCLUDED A 1954 01:22:45,346 --> 01:22:48,716 REQUIREMENT FOR MILESTONES SUCH 1955 01:22:48,716 --> 01:22:51,085 THAT THE PI WOULD KNOW THAT THEY 1956 01:22:51,085 --> 01:22:52,453 HAVE SUCCEEDED. THEY HAD THEIR 1957 01:22:52,453 --> 01:22:53,354 BENCHMARKS AT THE BEGINNING SO 1958 01:22:53,354 --> 01:22:54,789 THIS IS INCLUDED IN THE 1959 01:22:54,789 --> 01:22:55,990 APPLICATION PACKAGE. THEY KNOW 1960 01:22:55,990 --> 01:22:58,459 WHAT SUCCESS LOOKS LIKE. AT THE 1961 01:22:58,459 --> 01:23:01,629 END OF PHASE ONE AND THEN IF 1962 01:23:01,629 --> 01:23:04,899 THEY ACHIEVE THEIR MILESTONES 1963 01:23:04,899 --> 01:23:05,733 THEY HAVE THE RIGHT TO CONTINUE 1964 01:23:05,733 --> 01:23:07,935 INTO PHASE TWO. SO IF THEY 1965 01:23:07,935 --> 01:23:09,304 HAVE, IF THINGS DIDN'T WORK OUT. 1966 01:23:09,304 --> 01:23:11,306 IF THEY DIDN'T REACH THEIR 1967 01:23:11,306 --> 01:23:12,874 MILESTONES IT'S AN INDICATION 1968 01:23:12,874 --> 01:23:14,275 THAT MAYBE IT'S TIME TO PULL THE 1969 01:23:14,275 --> 01:23:17,178 PLUG ON THE PROJECT. AND WE DO 1970 01:23:17,178 --> 01:23:20,448 NOT SUPPORT CLINICAL TRIALS FOR 1971 01:23:20,448 --> 01:23:24,819 THIS VERSION OF THE BRING SIN 1972 01:23:24,819 --> 01:23:25,586 BIO PROGRAM. 1973 01:23:25,586 --> 01:23:28,323 SO, AGAIN, JUST TO GIVE YOU THE 1974 01:23:28,323 --> 01:23:29,757 OVERVIEW, THE PHASE -- WHAT'S 1975 01:23:29,757 --> 01:23:30,658 UNIQUE ABOUT THE PROGRAM IS NOT 1976 01:23:30,658 --> 01:23:35,430 ONLY THE PHASE ONE AND THE PHASE 1977 01:23:35,430 --> 01:23:36,931 TWO AND THE SEPARATION OF 1978 01:23:36,931 --> 01:23:37,932 ACTIVITIES BUT ALSO THE 1979 01:23:37,932 --> 01:23:41,102 INCLUSION OF MILESTONES AS A 1980 01:23:41,102 --> 01:23:42,670 BRIDGE AND A GO-NO-GO 1981 01:23:42,670 --> 01:23:45,506 TRANSITION. GO-NO-GO DECISION 1982 01:23:45,506 --> 01:23:46,240 POINT FOR TRANSITIONING OF THESE 1983 01:23:46,240 --> 01:23:47,909 PHASE ONE ACTIVITIES INTO PHASE 1984 01:23:47,909 --> 01:23:49,977 TWO. THERE THESE TO BE A GOOD 1985 01:23:49,977 --> 01:23:51,045 JUSTIFICATION FOR CONTINUED 1986 01:23:51,045 --> 01:23:53,081 FUNDING FOR THE PROJECT. SO THE 1987 01:23:53,081 --> 01:23:55,016 GO-NO-GO DECISION IS BASED ON 1988 01:23:55,016 --> 01:23:56,984 SUCCESSFUL COMPLETION OF PHASE 1989 01:23:56,984 --> 01:23:59,320 ONE MILESTONES AND THIS WILL BE 1990 01:23:59,320 --> 01:24:01,989 ADMINISTRATIVELY EVALUATED BY 1991 01:24:01,989 --> 01:24:04,425 NIBIB TO DETERMINE ELIGIBILITY 1992 01:24:04,425 --> 01:24:07,295 AND THE TRANSITION TO PHASE TWO 1993 01:24:07,295 --> 01:24:07,995 IS NEITHER AUTOMATIC OR 1994 01:24:07,995 --> 01:24:10,732 GUARANTEED. YOU HAVE TO SHOW US 1995 01:24:10,732 --> 01:24:12,367 THAT YOU HAVE BEEN SUCCESSFUL 1996 01:24:12,367 --> 01:24:13,134 AND WE'RE STILL INTERESTED IN 1997 01:24:13,134 --> 01:24:15,303 THE PROJECT AS THE TIME OF 1998 01:24:15,303 --> 01:24:16,738 TRANSITION. JUST TO GIVE YOU AN 1999 01:24:16,738 --> 01:24:19,807 IDEA OF AWARD SIZE AND 2000 01:24:19,807 --> 01:24:21,109 TRANSITION. SO TO BRING AN 2001 01:24:21,109 --> 01:24:23,311 UMBRELLA FOR COLLABORATION IS A 2002 01:24:23,311 --> 01:24:26,180 BIG UMBRELLA. THE BRING SIMPLE 2003 01:24:26,180 --> 01:24:28,783 BIO WAS A TEST CASE FOR TRYING 2004 01:24:28,783 --> 01:24:29,217 THIS COLLABORATION. 2005 01:24:29,217 --> 01:24:30,985 SO WE WANTED A PILOT'S CASE 2006 01:24:30,985 --> 01:24:32,754 ESSENTIALLY. SO IT'S THE -- THE 2007 01:24:32,754 --> 01:24:34,422 AWARD AMOUNTS ARE NOT VERY BIG 2008 01:24:34,422 --> 01:24:37,258 BUT IT'S FOR TWO YEARS: 2009 01:24:37,258 --> 01:24:39,694 AND EACH AGENCY. AND NSF 2010 01:24:39,694 --> 01:24:42,363 PROVIDES AN ESTIMATED OF, YOU 2011 01:24:42,363 --> 01:24:44,799 KNOW, 300,000 DOLLARS TOTAL 2012 01:24:44,799 --> 01:24:46,868 COSTS OVER TWO YEARS. AND 2013 01:24:46,868 --> 01:24:48,870 ESTIMATES TO MAKE 6-8 AWARDS. 2014 01:24:48,870 --> 01:24:51,305 THE DEADLINE IS NOT, YOU KNOW, 2015 01:24:51,305 --> 01:24:53,207 PAST YET SO WE'RE STILL, WE 2016 01:24:53,207 --> 01:24:54,842 DON'T KNOW HOW MANY -- WE WILL 2017 01:24:54,842 --> 01:24:57,011 RECEIVE BUT WE PLAN TO MAKE SIX 2018 01:24:57,011 --> 01:24:59,814 TO EIGHT AWARDS AT THE NSF AND 2019 01:24:59,814 --> 01:25:01,382 THEN NIH WILL PROVIDE SOMETHING 2020 01:25:01,382 --> 01:25:05,520 ALONG THE LINES OF AN OUGHT 21. 2021 01:25:05,520 --> 01:25:14,362 SO A TWO YEAR PROJECT, 275,000 2022 01:25:14,362 --> 01:25:16,130 DOLLARS COST IN TWO YEARS. AND 2023 01:25:16,130 --> 01:25:18,232 NOT EVERYBODY WILL TRANSITION. 2024 01:25:18,232 --> 01:25:20,701 SO THERE NEEDS TO BE A GOOD 2025 01:25:20,701 --> 01:25:21,869 JUSTIFICATION FOR HITTING THE 2026 01:25:21,869 --> 01:25:26,407 MILESTONES AND OTHER CRITERIA. 2027 01:25:26,407 --> 01:25:27,642 SO WHAT'S DIFFERENT THEN -- 2028 01:25:27,642 --> 01:25:29,076 DIFFERENT IN THIS PROGRAM THAN 2029 01:25:29,076 --> 01:25:30,611 OTHERS IS THE APPLICATIONS NEED 2030 01:25:30,611 --> 01:25:32,680 TO INCLUDE SEPARATE, YOU KNOW, 2031 01:25:32,680 --> 01:25:34,682 RESEARCH PLANS FOR PHASE ONE AND 2032 01:25:34,682 --> 01:25:39,086 PHASE TWO. AND FOR SUBJECT 2033 01:25:39,086 --> 01:25:41,155 BUDGETS FOR EACH PHASE ONE AND 2034 01:25:41,155 --> 01:25:42,590 PHASE TWO. THERE'S SOME 2035 01:25:42,590 --> 01:25:43,591 BUREAUCRACY THERE. THAT WE HAVE 2036 01:25:43,591 --> 01:25:46,260 TO FIGURE OUT AND TO REITERATE 2037 01:25:46,260 --> 01:25:50,598 NOT ALL AWARDS WILL TRANSITION. 2038 01:25:50,598 --> 01:25:54,936 NOW, HOW ARE THESE PROPOSALS 2039 01:25:54,936 --> 01:25:56,637 REVIEWED AND FUNDED? AGAIN 2040 01:25:56,637 --> 01:25:57,839 BECAUSE THIS IS A TRUE 2041 01:25:57,839 --> 01:25:59,307 COLLABORATION BETWEEN THE TWO 2042 01:25:59,307 --> 01:26:00,408 AGENCIES WE DECIDED THAT THE 2043 01:26:00,408 --> 01:26:03,845 APPLICATIONS WILL GO TO NSF 2044 01:26:03,845 --> 01:26:05,646 BECAUSE WILL IMPLEMENT PHASE ONE 2045 01:26:05,646 --> 01:26:08,883 AND THAT WILL BE AN NSF PROJECT 2046 01:26:08,883 --> 01:26:09,851 ESSENTIALLY AND SO THE 2047 01:26:09,851 --> 01:26:11,385 APPLICATION CONTAINS BOTH NSF 2048 01:26:11,385 --> 01:26:14,021 AND NIH PORTIONS OF THE RESEARCH 2049 01:26:14,021 --> 01:26:17,258 BUT GOES TO NSF FOR REVIEW. THE 2050 01:26:17,258 --> 01:26:19,760 REVIEW IN -- THE REVIEW PANEL 2051 01:26:19,760 --> 01:26:20,828 INCLUDES REVIEWERS IDENTIFIED BY 2052 01:26:20,828 --> 01:26:26,234 THE NSF AND ALSO AN NIH REVIEW 2053 01:26:26,234 --> 01:26:27,335 OFFICER WITH OTHER 2054 01:26:27,335 --> 01:26:29,103 REPRESENTATIVES SUCH AS ME AND 2055 01:26:29,103 --> 01:26:30,671 PROGRAM STAFF AS OBSERVERS AND 2056 01:26:30,671 --> 01:26:33,007 AFTER THE REVIEW FUNDING 2057 01:26:33,007 --> 01:26:34,041 DECISION ARE MADE JOINT BY BY 2058 01:26:34,041 --> 01:26:36,244 THE PROGRAM STAFF BECAUSE AGAIN, 2059 01:26:36,244 --> 01:26:39,347 WE BOTH NEED TO FEEL COMFORTABLE 2060 01:26:39,347 --> 01:26:41,949 THAT PHASE ONES FITS WHAT THEY 2061 01:26:41,949 --> 01:26:44,118 ARE LOOKING FOR AND THERE'S A 2062 01:26:44,118 --> 01:26:44,919 NATURAL CONTINUATION OF EACH 2063 01:26:44,919 --> 01:26:46,888 OTHER. AND NSF WANTS PHASE ONE 2064 01:26:46,888 --> 01:26:50,324 AND TWO YEARS LATER NIH FUNDS 2065 01:26:50,324 --> 01:26:53,961 PHASE TWO. AGAIN, AFTER THE 2066 01:26:53,961 --> 01:26:59,300 ADMINISTRATIVE REVIEW OF THE 2067 01:26:59,300 --> 01:27:01,469 TRANSITION CHECKPOINT. TO 2068 01:27:01,469 --> 01:27:02,870 ENSURE THE SUCCESS OF THIS 2069 01:27:02,870 --> 01:27:05,072 CONCEPT, IT'S BRAND NEW, WE PUT 2070 01:27:05,072 --> 01:27:07,308 IN TWO CHECKPOINTS IN THERE IN 2071 01:27:07,308 --> 01:27:09,310 TERMS OF PROGRAMMATIC OVERSIGHT 2072 01:27:09,310 --> 01:27:11,245 AND THE FIRST IS THE 2073 01:27:11,245 --> 01:27:11,946 QUANTITATIVE MILESTONE SO IT'S 2074 01:27:11,946 --> 01:27:13,514 UP TO THE PI TO COME UP WITH 2075 01:27:13,514 --> 01:27:14,982 WHAT SUCCESS LOOKS LIKE AT THE 2076 01:27:14,982 --> 01:27:17,418 END OF PHASE ONE BUT WE CAN LOOK 2077 01:27:17,418 --> 01:27:18,686 AT THESE BENCHMARKS AND 2078 01:27:18,686 --> 01:27:19,720 NEGOTIATE WITH THE PI BEFORE WE 2079 01:27:19,720 --> 01:27:22,623 MAKE AN AWARD THAT, YOU KNOW, 2080 01:27:22,623 --> 01:27:24,191 YOUR SUCCESS BENCHMARKS ARE A 2081 01:27:24,191 --> 01:27:25,526 LITTLE VAGUE, LET'S NEGOTIATE 2082 01:27:25,526 --> 01:27:28,563 THEM TO MAKE IT A LITTLE MORE 2083 01:27:28,563 --> 01:27:29,830 CONCRETE, FOR EXAMPLE. AND SO 2084 01:27:29,830 --> 01:27:32,033 THE INCLUSION OF THOSE 2085 01:27:32,033 --> 01:27:33,234 MILESTONES, HOLDING THEM UP TO A 2086 01:27:33,234 --> 01:27:36,370 CERTAIN STANDARD OF SUCCESS IS 2087 01:27:36,370 --> 01:27:38,906 MEANT TO ENSURE SUCCESS OF THE 2088 01:27:38,906 --> 01:27:41,142 PROJECT. THE SECOND ONE IS THE 2089 01:27:41,142 --> 01:27:43,311 ADMINISTRATIVE MIDPOINT 2090 01:27:43,311 --> 01:27:45,613 PROGRAMMATIC REVIEW. AGAIN, 2091 01:27:45,613 --> 01:27:50,217 THERE ARE THREE CRITERIA FOR 2092 01:27:50,217 --> 01:27:50,885 JUSTIFYING TRANSITIONING A 2093 01:27:50,885 --> 01:27:56,023 PROJECT INTO PHASE TWO AND ITS 2094 01:27:56,023 --> 01:27:57,458 SUCCESSFUL COMPLETION OF 2095 01:27:57,458 --> 01:27:59,226 MILESTONES AND THAT'S NOT BY 2096 01:27:59,226 --> 01:28:03,331 ITSELF SUFFICIENT. THE SECOND 2097 01:28:03,331 --> 01:28:05,766 CRITERIA IS NIBIB PROGRAM 2098 01:28:05,766 --> 01:28:08,135 PRIORITIES IF YOU SUBMIT THE 2099 01:28:08,135 --> 01:28:09,537 APPLICATION DECEMBER 4TH IT'LL 2100 01:28:09,537 --> 01:28:11,973 BE TWO YEARS. WE DON'T KNOW 2101 01:28:11,973 --> 01:28:12,940 WHAT OUR PRIORITIES WILL BE AT 2102 01:28:12,940 --> 01:28:15,009 THAT POINT IN TIME SO WE RESERVE 2103 01:28:15,009 --> 01:28:19,313 THE RIGHT TO SAY THIS IS NO 2104 01:28:19,313 --> 01:28:20,514 LONGER AN INTEREST OF OURS OR WE 2105 01:28:20,514 --> 01:28:22,416 DON'T HAVE THE FUNDS FOR IT. SO 2106 01:28:22,416 --> 01:28:23,951 THESE CRITERIA NEED TO BE MET 2107 01:28:23,951 --> 01:28:27,154 AND THE TRANSITION IS NEITHER 2108 01:28:27,154 --> 01:28:29,323 AUTOMATIC OR GUARANTEED BUT 2109 01:28:29,323 --> 01:28:32,960 ANYONE WHO IS IN PHASE ONE CAN 2110 01:28:32,960 --> 01:28:34,061 SUBMIT A PACKAGE TO CONTINUE 2111 01:28:34,061 --> 01:28:35,930 INTO PHASE TWO BUT WE WILL 2112 01:28:35,930 --> 01:28:38,432 REVIEW THAT THERE WILL NOT BE 2113 01:28:38,432 --> 01:28:41,369 ANY SCIENTIFIC PEER REVIEW. 2114 01:28:41,369 --> 01:28:43,237 ASSOCIATED WITH IT. NOW, THE 2115 01:28:43,237 --> 01:28:44,305 AREAS OF INTEREST WE IDENTIFIED 2116 01:28:44,305 --> 01:28:47,108 FOR THE PURPOSES OF THIS 2117 01:28:47,108 --> 01:28:49,510 PARTICULAR PILOT SOLICITATION IS 2118 01:28:49,510 --> 01:28:51,312 THE USE OF BIOLOGICAL CONTROL 2119 01:28:51,312 --> 01:28:55,416 THEORY AND THE DESIGN AND 2120 01:28:55,416 --> 01:28:56,684 CHARACTERIZATION OF EITHER NEW 2121 01:28:56,684 --> 01:28:58,819 SIN BIO TOOLS AND PARTS AND 2122 01:28:58,819 --> 01:29:00,354 THEIR -- OR THEIR, DOWNSTREAM 2123 01:29:00,354 --> 01:29:01,155 APPLICATION TO TECHNOLOGY 2124 01:29:01,155 --> 01:29:02,990 DEVELOPMENT IN THE BIO MEDICAL 2125 01:29:02,990 --> 01:29:07,328 FIELD THIS IS, IT'S -- IT'S NOT 2126 01:29:07,328 --> 01:29:09,230 ONLY LIMITED TO THESE AREAS 2127 01:29:09,230 --> 01:29:11,165 OUTLINED HERE BUT THE IDEA IS 2128 01:29:11,165 --> 01:29:13,000 THERE SHOULD BE INCLUSION OF 2129 01:29:13,000 --> 01:29:16,337 SOME ASPECT OF CONTROL THEORY 2130 01:29:16,337 --> 01:29:19,306 INTO THESE PROJECTS. AND IT 2131 01:29:19,306 --> 01:29:21,642 COULD INCLUDE GENE CIRCUIT 2132 01:29:21,642 --> 01:29:23,911 DESIGNS FOR ENHANCING 2133 01:29:23,911 --> 01:29:26,647 RELIABILITY, PREDICTABILITY OF 2134 01:29:26,647 --> 01:29:29,950 CURRENT GENE CIRCUIT DESIGNS OR 2135 01:29:29,950 --> 01:29:37,425 NEW STRATEGIES. FOR 2136 01:29:37,425 --> 01:29:38,826 INCORPORATING NOVEL FEEDBACK 2137 01:29:38,826 --> 01:29:39,527 STRATEGIES AND WHATNOT. THESE 2138 01:29:39,527 --> 01:29:40,928 ARE INCLUSIVE BUT NOT LIMITED TO 2139 01:29:40,928 --> 01:29:43,931 THESE BULLET POINTS. NOW FOR 2140 01:29:43,931 --> 01:29:47,301 THE TIMELINE, AGAIN, THE 2141 01:29:47,301 --> 01:29:49,070 SOLICITATION WAS ISSUED SOMETIME 2142 01:29:49,070 --> 01:29:50,071 IN SEPTEMBER OR END OF AUGUST 2143 01:29:50,071 --> 01:29:52,039 AND THE PROPOSALS ARE DUE IN A 2144 01:29:52,039 --> 01:29:54,008 COUPLE OF WEEKS THE REVIEW WILL 2145 01:29:54,008 --> 01:29:56,277 TAKE PLACE IN FEBRUARY/MARCH AND 2146 01:29:56,277 --> 01:29:59,246 THE FIRST AWARDS WILL BE MADE IN 2147 01:29:59,246 --> 01:30:00,381 APRIL/MAY OF NEXT YEAR AND THEN 2148 01:30:00,381 --> 01:30:02,917 THE TRANSITION REVIEW WILL BE 2149 01:30:02,917 --> 01:30:04,585 ROUGHLY 21 MONTHS AFTER THESE 2150 01:30:04,585 --> 01:30:07,588 AWARDS ARE MADE AND THEN AT THE 2151 01:30:07,588 --> 01:30:11,125 24 MONTH MARK, THOSE WHO ARE 2152 01:30:11,125 --> 01:30:12,493 GRANTED PERMISSION TO EXTEND 2153 01:30:12,493 --> 01:30:13,994 INTO PHASE TWO WILL BE AWARDED. 2154 01:30:13,994 --> 01:30:16,564 AND THAT CORRESPONDS TO AGAIN, 2155 01:30:16,564 --> 01:30:19,433 APRIL/MAY 2027. AND THESE ARE 2156 01:30:19,433 --> 01:30:22,136 MY WONDERFUL COLLEAGUES AT THE 2157 01:30:22,136 --> 01:30:23,971 NSF WHO WORKED WITH ME IN 2158 01:30:23,971 --> 01:30:26,507 LAUNCHING THIS PROGRAM SO IF YOU 2159 01:30:26,507 --> 01:30:29,977 HAVE ANY QUESTIONS ABOUT THE 2160 01:30:29,977 --> 01:30:31,846 PROGRAM OR WHAT MIGHT BE A GOOD 2161 01:30:31,846 --> 01:30:35,683 FIT FOR NSF OR NIH FEEL FREE TO 2162 01:30:35,683 --> 01:30:39,320 REACH OUT TO US AND I AM HAPPY 2163 01:30:39,320 --> 01:30:46,260 TO TAKE ANY QUESTIONS. 2164 01:30:46,260 --> 01:30:47,995 >> GIVEN FIRST DEADLINE IS 2165 01:30:47,995 --> 01:30:49,330 COMING UP QUITE SOON WHAT DO YOU 2166 01:30:49,330 --> 01:30:53,968 THINK IS IF THE LIKELIHOOD THAT 2167 01:30:53,968 --> 01:30:55,503 THIS PROGRAM WILL BE RENUED A 2168 01:30:55,503 --> 01:30:58,606 FEW YEARS FROM NOW? 2169 01:30:58,606 --> 01:31:00,775 >> WE TO NOT KNOW. WE DON'T 2170 01:31:00,775 --> 01:31:03,210 KNOW. WE GOT GREAT FEEDBACK 2171 01:31:03,210 --> 01:31:05,112 FROM THE COMMUNITY. 2172 01:31:05,112 --> 01:31:14,622 AS TO, YOU KNOW SH,KNOW, EXCITI 2173 01:31:14,622 --> 01:31:16,056 THOUGHT THE PROGRAM WAS. FOR 2174 01:31:16,056 --> 01:31:18,526 NOW IT'S A PILOT PROGRAM. WE'RE 2175 01:31:18,526 --> 01:31:19,994 TESTING IT OUT AND THE UMBRELLA 2176 01:31:19,994 --> 01:31:23,330 IS THERE SO WE CAN USE THIS FOR 2177 01:31:23,330 --> 01:31:24,064 FUTURE COLLABORATIONS BUT WE 2178 01:31:24,064 --> 01:31:26,100 DON'T KNOW. 2179 01:31:26,100 --> 01:31:27,134 >> AUDIENCE: THIS IS A REALLY 2180 01:31:27,134 --> 01:31:29,470 CLEVER CONCEPT. I LOVE IT. I 2181 01:31:29,470 --> 01:31:32,406 ASSUME THERE'S NO OPPORTUNITY 2182 01:31:32,406 --> 01:31:35,976 FOR A NO COST EXTENSION IN THAT 2183 01:31:35,976 --> 01:31:37,912 PERIOD. YOU NEED TO BE READY IN 2184 01:31:37,912 --> 01:31:40,714 TWO YEARS TO TRANSITION ON. 2185 01:31:40,714 --> 01:31:42,449 >> THIS CAME UP AND MAYBE IS THE 2186 01:31:42,449 --> 01:31:44,585 ANSWER. IT DEPENDS BECAUSE EACH 2187 01:31:44,585 --> 01:31:46,387 AGENCY HAS THEIR OWN POLICIES 2188 01:31:46,387 --> 01:31:47,988 AND PROCEDURES IN PLACE. I 2189 01:31:47,988 --> 01:31:50,324 ACTUALLY CANNOT SPEAK FOR THE 2190 01:31:50,324 --> 01:31:54,461 NSF BUT I KNOW THIS QUESTION 2191 01:31:54,461 --> 01:31:56,664 CAME UP AND WE WILL EVALUATE IT 2192 01:31:56,664 --> 01:31:59,166 ON A CASE-BY-CASE BASIS. SO WE 2193 01:31:59,166 --> 01:32:03,070 DIDN'T RULE IT OUT BUT WE HOPE 2194 01:32:03,070 --> 01:32:06,240 THAT THINGS WILL BE 2195 01:32:06,240 --> 01:32:07,308 TRANSITIONING SMOOTHLY. 2196 01:32:07,308 --> 01:32:09,476 >> ANY OTHER QUESTIONS? ALL 2197 01:32:09,476 --> 01:32:11,312 RIGHT. THANK YOU. 2198 01:32:11,312 --> 01:32:19,920 >> THANK YOU. 2199 01:32:19,920 --> 01:32:22,523 >> NEXT UP JER MONTH CHEN IS 2200 01:32:22,523 --> 01:32:24,625 GOING TO BE TALKING ABOUT THE 2201 01:32:24,625 --> 01:32:27,628 SUMMARY OF THE BIOLOGY WORKSHOP. 2202 01:32:27,628 --> 01:32:29,997 >> THANKS NICOLE. ON BEHALF OF 2203 01:32:29,997 --> 01:32:32,066 THE HEART AND LUNG SYNTHETIC 2204 01:32:32,066 --> 01:32:33,567 BIOLOGY WORKING GROUP I'M GOING 2205 01:32:33,567 --> 01:32:36,670 TO PRESENT A SHORT SUMMARY OF 2206 01:32:36,670 --> 01:32:38,105 THEIR TWO DAY ONLINE WORKSHOP. 2207 01:32:38,105 --> 01:32:40,241 SO JUST LIKE YOU HEARD FROM 2208 01:32:40,241 --> 01:32:42,877 AGING, JUST LIKE YOU HEARD FROM 2209 01:32:42,877 --> 01:32:46,347 CANCER, HEART AND LUNG ALSO 2210 01:32:46,347 --> 01:32:48,849 WANTS TO FUND IN THE SYNTHETIC 2211 01:32:48,849 --> 01:32:50,718 BIOLOGY WORKSHOP SO, AGAIN, IT 2212 01:32:50,718 --> 01:32:55,022 WAS A TWO DAY WORKSHOP THE 2213 01:32:55,022 --> 01:33:00,694 CO-CHAIRS WERE KATIE. AND I'M 2214 01:33:00,694 --> 01:33:02,029 SURE YOU'RE FAMILIAR WITH THEIR 2215 01:33:02,029 --> 01:33:03,564 WORK IN THE SYNTHETIC BIOLOGY 2216 01:33:03,564 --> 01:33:06,700 FIELD SO THE MAIN GOAL HERE WAS 2217 01:33:06,700 --> 01:33:10,371 TO IDENTIFY AND TEAM DEVELOPERS 2218 01:33:10,371 --> 01:33:13,407 AND USERS IN ORDER TO HELP 2219 01:33:13,407 --> 01:33:17,511 HEART, LUNG, BLOOD AND SLEEP. 2220 01:33:17,511 --> 01:33:19,313 LOOK AT THEIR DISEASE RESEARCH. 2221 01:33:19,313 --> 01:33:22,283 SO, AGAIN, IT WAS A TWO DAY 2222 01:33:22,283 --> 01:33:25,019 ONLINE MEETING. AND THEIR GOAL 2223 01:33:25,019 --> 01:33:26,253 IS TO ESTABLISH A WORKSPACE IN 2224 01:33:26,253 --> 01:33:28,622 THIS CASE, YOU CAN SEE THE 2225 01:33:28,622 --> 01:33:31,158 PICTURE. IT'S A SANDBOX WITHIN 2226 01:33:31,158 --> 01:33:33,928 HEART, LUNG, BLOOD INSTITUTE 2227 01:33:33,928 --> 01:33:35,629 WHERE THE TECHNOLOGY 2228 01:33:35,629 --> 01:33:38,899 DEVELOPMENT, FOR SYNTHETIC 2229 01:33:38,899 --> 01:33:41,035 BIOLOGY HAS A HOME. SO THEIR 2230 01:33:41,035 --> 01:33:43,938 GOALS HERE, VERY SIMILAR TO SOME 2231 01:33:43,938 --> 01:33:45,072 OF THE OTHER GOALS THAT THE 2232 01:33:45,072 --> 01:33:49,677 OTHER INSTITUTES LIKE THE NIBIB 2233 01:33:49,677 --> 01:33:53,480 AND AGING GOALS WERE TO FORM 2234 01:33:53,480 --> 01:33:55,683 TEAMS TO PREPARE APPLICATIONS TO 2235 01:33:55,683 --> 01:33:57,384 SUBMIT TO HEART, LUNG AND BLOOD. 2236 01:33:57,384 --> 01:33:59,386 AND WHAT THEY'RE IN THE PROCESS 2237 01:33:59,386 --> 01:34:03,357 OF DOING IS CREATING A 2238 01:34:03,357 --> 01:34:05,092 PUBLICATION FOR RELEASE AND THAT 2239 01:34:05,092 --> 01:34:07,328 WILL BE POSTED ON BOTH THE 2240 01:34:07,328 --> 01:34:10,664 HEART, LUNG AND BLOOD WEBSITE 2241 01:34:10,664 --> 01:34:14,768 ALONG WITH THE NIH SIN BIO 2242 01:34:14,768 --> 01:34:16,303 WEBSITE. SO THESE WERE THE 2243 01:34:16,303 --> 01:34:17,271 GUIDING THOUGHTS OF THE 2244 01:34:17,271 --> 01:34:19,106 WORKSHOP, KIND OF UNDERSTANDING 2245 01:34:19,106 --> 01:34:20,374 THE LANDSCAPE OF WHAT HEART, 2246 01:34:20,374 --> 01:34:23,577 LUNG, BLOOD SLEEP WANTED TO DO. 2247 01:34:23,577 --> 01:34:26,447 AND THE FLASHLIGHT IS SYNTHETIC 2248 01:34:26,447 --> 01:34:28,515 BIOLOGY KIND OF GOING OVER, 2249 01:34:28,515 --> 01:34:30,718 TRYING TO FIT WHERE SYNTHETIC 2250 01:34:30,718 --> 01:34:33,954 BIOLOGY CAN FIT ANY OF THOSE 2251 01:34:33,954 --> 01:34:36,857 CATEGORIES. HOW CAN -- HOW CAN 2252 01:34:36,857 --> 01:34:39,159 THIS -- HOW CAN THEY ADD THIS TO 2253 01:34:39,159 --> 01:34:40,594 TRAINEES THINKING? HOW CAN THEY 2254 01:34:40,594 --> 01:34:42,296 DEVELOP THE NEXT GENERATION OF 2255 01:34:42,296 --> 01:34:44,298 THERAPIES AND DIAGNOSTICS? AND, 2256 01:34:44,298 --> 01:34:49,536 AGAIN, HOW CAN SYNTHETIC BIOLOGY 2257 01:34:49,536 --> 01:34:50,804 AT HEART, LUNG AND BLOOD ENABLE 2258 01:34:50,804 --> 01:34:52,272 THE GOAL THEY WANTED TO CREATE 2259 01:34:52,272 --> 01:34:55,709 WHICH IS COLLABORATIONS GOING 2260 01:34:55,709 --> 01:34:57,144 FORWARD? SO THESE WERE THE 2261 01:34:57,144 --> 01:34:58,979 TAKEAWAYS FROM THE MEETINGS. 2262 01:34:58,979 --> 01:35:01,081 AGAIN, THE VIDEOS WERE RECORDED 2263 01:35:01,081 --> 01:35:02,783 AND AT SOME TIME THEY'LL BE 2264 01:35:02,783 --> 01:35:04,685 POSTED TO THEIR WEBSITES: AGAIN, 2265 01:35:04,685 --> 01:35:07,888 MODEL DEVELOPMENT AND AGING 2266 01:35:07,888 --> 01:35:09,723 EVENTS WITH DISCREET TIMING AND 2267 01:35:09,723 --> 01:35:11,058 SPATIAL DATA. 2268 01:35:11,058 --> 01:35:14,495 ACCESSIBLE TISSUES FOR STUDYING 2269 01:35:14,495 --> 01:35:15,329 DEVELOPMENT. FIBROSIS 2270 01:35:15,329 --> 01:35:17,331 MECHANISMS WITH HEART FAILURE 2271 01:35:17,331 --> 01:35:20,501 AND PULMONARY FIBROSIS AND 2272 01:35:20,501 --> 01:35:22,169 CARDIOTOXICITY YOU CAN SEE THESE 2273 01:35:22,169 --> 01:35:27,041 ARE HEART, LUNG, BLOOD, SLEEP 2274 01:35:27,041 --> 01:35:30,310 CATEGORIES AND WITH THAT, LIKE I 2275 01:35:30,310 --> 01:35:32,112 SAID, THE VIDEOS WILL BE POSTED 2276 01:35:32,112 --> 01:35:33,881 ON THE HEART, LUNG AND BLOOD 2277 01:35:33,881 --> 01:35:36,016 WEBSITES ALONG WITH THEIR 2278 01:35:36,016 --> 01:35:36,917 PUBLISHED REPORT AND THAT WILL 2279 01:35:36,917 --> 01:35:40,387 BE ALSO LINKED ON THE NIH 2280 01:35:40,387 --> 01:35:42,022 CONSORTIUM WEBSITE. SO IF YOU 2281 01:35:42,022 --> 01:35:45,225 HAVE ANY QUESTIONS, I'M NOT SURE 2282 01:35:45,225 --> 01:35:48,195 I CAN ANSWER THEM BUT WE CAN -- 2283 01:35:48,195 --> 01:35:50,631 WE'LL JUST WAIT FOR THE 2284 01:35:50,631 --> 01:35:54,034 PUBLICATION TO BE FINAL IDEAS 2285 01:35:54,034 --> 01:35:56,703 AND POSTED TO THEIR WEBSITE. 2286 01:35:56,703 --> 01:36:03,977 OKAY. THANK YOU VERY MUCH. 2287 01:36:03,977 --> 01:36:07,314 >> AND OUR NEXT SPEAKER IS 2288 01:36:07,314 --> 01:36:15,322 DR. CONNIE SOME HERS AND HAS AN 2289 01:36:15,322 --> 01:36:20,961 UPCOMING WORKSHOP IN VIVO 2290 01:36:20,961 --> 01:36:21,261 ENGINEERING. 2291 01:36:21,261 --> 01:36:22,763 >> THANK YOU FOR STICKING AROUND 2292 01:36:22,763 --> 01:36:24,031 FOR THE LAST WORKSHOP TALK I'M 2293 01:36:24,031 --> 01:36:26,133 GOING TO BE TALKING ABOUT A 2294 01:36:26,133 --> 01:36:34,108 WORKSHOP CALLED INVIVO 2295 01:36:34,108 --> 01:36:35,242 ENGINEERING. AND IT'LL BE HELD 2296 01:36:35,242 --> 01:36:38,679 IN JANUARY 28TH AND 29TH AND BE 2297 01:36:38,679 --> 01:36:40,747 A VIRTUAL WORKSHOP AND I AM 2298 01:36:40,747 --> 01:36:42,549 PRESENTING ON BEHALF OF THE 2299 01:36:42,549 --> 01:36:43,350 PLANNING COMMITTEE LISTED HERE 2300 01:36:43,350 --> 01:36:47,321 SO JUST A BIT OF BACKGROUND, AS 2301 01:36:47,321 --> 01:36:51,625 YOU ALL KNOW, THERE ARE THE 2302 01:36:51,625 --> 01:36:55,996 HISTORIC PILLARS SUCH AS 2303 01:36:55,996 --> 01:36:57,798 CHEMOTHERAPY, MORE RECENTLY 2304 01:36:57,798 --> 01:36:59,299 IMMUNOTHERAPY HAS COME ON THE 2305 01:36:59,299 --> 01:37:01,635 SCENE AND THAT'S BASICALLY MEANS 2306 01:37:01,635 --> 01:37:03,070 TARGETING THE IMMUNE SYSTEM TO 2307 01:37:03,070 --> 01:37:04,438 KILL THE CANCER RATHER THAN 2308 01:37:04,438 --> 01:37:08,075 TARGETING THE TUMOR CELLS 2309 01:37:08,075 --> 01:37:10,077 THEMSELVES. AND THERE ARE THESE 2310 01:37:10,077 --> 01:37:12,079 DIFFERENT KINDS OF 2311 01:37:12,079 --> 01:37:13,180 IMMUNOTHERAPIES LISTED HERE. 2312 01:37:13,180 --> 01:37:15,782 THE MOST NOTABLE ONES RECENTLY 2313 01:37:15,782 --> 01:37:17,951 HAVE BEEN IMMUNE CHECKPOINT 2314 01:37:17,951 --> 01:37:21,822 BLOCKADES LIKE ANTIPD ONE AND 2315 01:37:21,822 --> 01:37:25,592 ANTICT LSHG 4 FOR TREATING 2316 01:37:25,592 --> 01:37:26,326 CANCERS. 2317 01:37:26,326 --> 01:37:28,996 AND ADOPTIVE CELL THERAPIES AND 2318 01:37:28,996 --> 01:37:31,565 THE MOST ADVANCED ARE CAR-T CELL 2319 01:37:31,565 --> 01:37:34,668 THERAPIES SO THAT IS WHAT I WILL 2320 01:37:34,668 --> 01:37:36,803 CONCENTRATE ON TODAY BUT THERE 2321 01:37:36,803 --> 01:37:39,306 ARE OTHER ADOPTIVE CELL 2322 01:37:39,306 --> 01:37:42,109 THERAPIES LIKE MACROPHAGES AND 2323 01:37:42,109 --> 01:37:47,414 DEN DRDRITIC CELLS, ET CETERA. D 2324 01:37:47,414 --> 01:37:50,384 THESE THERAPIES HAVE BEEN USED 2325 01:37:50,384 --> 01:37:54,454 INITIALLY TO TREAT HAEMATOLOGIC 2326 01:37:54,454 --> 01:37:56,590 MALIGNANCIES. THEY ARE SINCE 2327 01:37:56,590 --> 01:37:59,359 FDA APPROVED AND FOR SOLID 2328 01:37:59,359 --> 01:38:01,728 THERAPIES THERE'S ONE ADOPTIVE 2329 01:38:01,728 --> 01:38:03,830 CELL THERAPY APPROVED WHICH IS 2330 01:38:03,830 --> 01:38:07,901 TUMOR INFILTRATED FOR MELANOMA. 2331 01:38:07,901 --> 01:38:10,604 SO A LITTLE BIT MORE ABOUT CAR-T 2332 01:38:10,604 --> 01:38:12,372 CELL THERAPY SO WE'RE ALL ON THE 2333 01:38:12,372 --> 01:38:14,208 SAME PAGE WHAT HAPPENS IS, THAT 2334 01:38:14,208 --> 01:38:16,376 BLOOD IS REMOVED FROM THE 2335 01:38:16,376 --> 01:38:18,579 PATIENT. AND THEN T-CELLS ARE 2336 01:38:18,579 --> 01:38:20,681 PURIFIED FROM THE BLOOD. AND 2337 01:38:20,681 --> 01:38:24,418 THEN THE T-CELLS ARE ENGINEERED. 2338 01:38:24,418 --> 01:38:29,756 SO USUALLY USING A VIRUS, A 2339 01:38:29,756 --> 01:38:31,758 CHIMERIC ANTIGEN RECEPTOR IS 2340 01:38:31,758 --> 01:38:33,961 INSERTED INTO THE T CELLS AND 2341 01:38:33,961 --> 01:38:39,333 THEN IT'S EXPRESSED ON THE YOU 2342 01:38:39,333 --> 01:38:41,735 ARE -- SURFACE AND THEN GOES 2343 01:38:41,735 --> 01:38:43,537 BACK INTO THE PATIENT AND THEY 2344 01:38:43,537 --> 01:38:46,940 GET A LIMB FOE DEPLETING OR 2345 01:38:46,940 --> 01:38:48,508 PRECONDITIONING USUALLY 2346 01:38:48,508 --> 01:38:51,311 CHEMOTHERAPY TO ALLOW SPACE FOR 2347 01:38:51,311 --> 01:38:53,947 THE CAR-T CELLS TO COME AND AND 2348 01:38:53,947 --> 01:38:59,219 START TO EXPAND AND THEN THE 2349 01:38:59,219 --> 01:39:02,122 CHIMERIC ANTIGEN RECEPTOR HONES 2350 01:39:02,122 --> 01:39:03,690 TO THE CANCER CELLS AND IS 2351 01:39:03,690 --> 01:39:06,526 CAPABLE OF KILLING THE CANCER 2352 01:39:06,526 --> 01:39:09,763 CELLS SO THAT'S KIND OF HOW IT 2353 01:39:09,763 --> 01:39:16,837 WORKS. AND IT WORKS WELL AND 2354 01:39:16,837 --> 01:39:20,407 IT'S PRETTY LABORIOUS. THERE'S 2355 01:39:20,407 --> 01:39:21,174 THE EX VIVO MANIPULATION OF 2356 01:39:21,174 --> 01:39:23,277 CELLS SO THAT'S THE GENETIC 2357 01:39:23,277 --> 01:39:25,279 ENGINEERING OF THE CELLS. IT 2358 01:39:25,279 --> 01:39:26,780 REQUIRES HIGHLY SKILLED 2359 01:39:26,780 --> 01:39:30,050 PERSONNEL. IT REQUIRES GMP 2360 01:39:30,050 --> 01:39:30,684 MANUFACTURING AND PRODUCTION. 2361 01:39:30,684 --> 01:39:32,886 AND I ALSO MENTIONED THE LIMB 2362 01:39:32,886 --> 01:39:36,089 FOE DEPLETION THAT THE PATIENTS 2363 01:39:36,089 --> 01:39:37,257 HAVE TO DO. 2364 01:39:37,257 --> 01:39:41,828 AND SO THIS REQUIRES SPECIALIZED 2365 01:39:41,828 --> 01:39:42,663 FACILITIES, SPECIALIZED 2366 01:39:42,663 --> 01:39:46,633 PERSONNEL. IT'S RELATIVELY 2367 01:39:46,633 --> 01:39:47,834 TIME-CONSUMING. SO BETWEEN THE 2368 01:39:47,834 --> 01:39:49,536 TIME THAT THE BLOOD IS COLLECTED 2369 01:39:49,536 --> 01:39:51,038 FROM THE PATIENTS TO THE TIME 2370 01:39:51,038 --> 01:39:53,006 THAT IT'S ADMINISTERED BACK, CAN 2371 01:39:53,006 --> 01:39:55,309 BE A FEW WEEKS AND IF THE 2372 01:39:55,309 --> 01:39:58,845 PATIENTS ARE VERY SICK TO START 2373 01:39:58,845 --> 01:40:00,113 WITH, WHICH, YOU KNOW, WHEN 2374 01:40:00,113 --> 01:40:01,315 YOU'RE BEGINNING A NEW THERAPY, 2375 01:40:01,315 --> 01:40:02,783 YOU'RE GOING TO GET THE PATIENTS 2376 01:40:02,783 --> 01:40:05,319 WHO HAVE FAILED OTHER THERAPIES 2377 01:40:05,319 --> 01:40:07,354 AND ARE VERY SICK. YOU KNOW, 2378 01:40:07,354 --> 01:40:08,689 THAT CAN BE A PROBLEM THAT 2379 01:40:08,689 --> 01:40:12,292 THEY'RE TOO SICK BY THE TIME TO 2380 01:40:12,292 --> 01:40:14,461 GET THE THERAPY. OR EVEN THAT 2381 01:40:14,461 --> 01:40:19,366 THEY HAVE DIED. AND THE COST IS 2382 01:40:19,366 --> 01:40:21,535 ABOUT 500,000 DOLLARS PER SHOT 2383 01:40:21,535 --> 01:40:25,505 SO IT'S VERY EXPENSIVE. NOT 2384 01:40:25,505 --> 01:40:27,307 EVERYONE CAN AFFORD THAT. SO 2385 01:40:27,307 --> 01:40:31,178 THAT MAKES IT, BOTH THE 2386 01:40:31,178 --> 01:40:32,679 SPECIALIZED PROCESSING AND THE 2387 01:40:32,679 --> 01:40:34,414 COST MAKE IT LESS ACCESSIBLE TO 2388 01:40:34,414 --> 01:40:36,483 BROAD PATIENT POPULATIONS. 2389 01:40:36,483 --> 01:40:39,853 THERE'S A COMPLEX REGULATORY 2390 01:40:39,853 --> 01:40:46,626 PROCESS BECAUSE IT'S A LIVING 2391 01:40:46,626 --> 01:40:48,061 CELL PRODUCT NOT A DRUG WHERE 2392 01:40:48,061 --> 01:40:49,830 YOU CAN JUST TAKE A PILL. THERE 2393 01:40:49,830 --> 01:40:51,465 ARE STILL SOME CHALLENGES WITH 2394 01:40:51,465 --> 01:40:54,568 EFFICACY IN TERMS OF PERSISTENCE 2395 01:40:54,568 --> 01:40:56,937 OF THE CAR-T-CELLS AND THERE ARE 2396 01:40:56,937 --> 01:40:59,306 SAFETY CONCERNS BOTH RELATED TO 2397 01:40:59,306 --> 01:41:01,408 PUTTING IN ALL THOSE CELLS THAT 2398 01:41:01,408 --> 01:41:06,546 BECOME ACTIVATED AND ALSO 2399 01:41:06,546 --> 01:41:09,349 CONCERNS FROM THE LIMB FOE 2400 01:41:09,349 --> 01:41:10,951 DEPLETION PROCESS. 2401 01:41:10,951 --> 01:41:14,388 WHICH RENDERS THE PATIENTS 2402 01:41:14,388 --> 01:41:15,322 SUSCEPTIBLE TO INSPECTION BOTH 2403 01:41:15,322 --> 01:41:17,557 WHEN THEY'RE IN THE HOSPITAL AND 2404 01:41:17,557 --> 01:41:21,628 EVEN, YOU KNOW, AFTERWARDS WHILE 2405 01:41:21,628 --> 01:41:24,498 THEY'RE RECOVERING. SO, THIS -- 2406 01:41:24,498 --> 01:41:28,201 IN VIVO ENGINEERING IDEA IS TO 2407 01:41:28,201 --> 01:41:32,272 CUT OUT SOME OF THE THOSE MORE 2408 01:41:32,272 --> 01:41:33,473 PROBLEMATIC PIECES OF THE 2409 01:41:33,473 --> 01:41:36,009 ADOPTIVE CELL THERAPIES. SO 2410 01:41:36,009 --> 01:41:38,545 WITH IN VIVO ENGINEERING, YOU 2411 01:41:38,545 --> 01:41:40,147 REPROGRAM THE IMMUNE CELLS 2412 01:41:40,147 --> 01:41:42,082 INSIDE OF THE BODY RATHER THAN 2413 01:41:42,082 --> 01:41:43,950 TAKING THE CELLS OUT. 2414 01:41:43,950 --> 01:41:47,087 REPROGRAMMING THEM, AND PUTTING 2415 01:41:47,087 --> 01:41:48,822 THEM BACK IN AND I WILL GET INTO 2416 01:41:48,822 --> 01:41:51,324 HOW THAT'S DONE BUT BASICALLY 2417 01:41:51,324 --> 01:41:53,927 THERE'S NO LEUKOPHORESIS 2418 01:41:53,927 --> 01:41:55,195 REQUIRED. NO LIMB FOE DEPLETION 2419 01:41:55,195 --> 01:41:57,998 FOR THE PATIENTS THERE'S NO EX 2420 01:41:57,998 --> 01:41:59,666 VIVO MANIPULATION OF CELLS. 2421 01:41:59,666 --> 01:42:01,201 YOU CAN STILL DO DIFFERENT KINDS 2422 01:42:01,201 --> 01:42:03,336 OF CELLS, DIFFERENT TARGETS, SO 2423 01:42:03,336 --> 01:42:06,006 YOU CAN DO T-CELLS OR YOU CAN DO 2424 01:42:06,006 --> 01:42:08,341 MACROPHAGES. OR OTHER KINDS OF 2425 01:42:08,341 --> 01:42:11,044 CELLS. YOU CAN DO CELLS 2426 01:42:11,044 --> 01:42:12,112 SPECIFIC DELIVERY OF DIFFERENT 2427 01:42:12,112 --> 01:42:14,214 KINDS OF GENETIC MATERIALS AND I 2428 01:42:14,214 --> 01:42:16,583 WILL GET INTO HOW. BUT USUALLY 2429 01:42:16,583 --> 01:42:18,084 THIS IS GOING TO BE THROUGH BIO 2430 01:42:18,084 --> 01:42:26,293 IF HE CAN -- BIO VECTORS OR 2431 01:42:26,293 --> 01:42:26,927 USING LIPID NANOPARTICLES AND 2432 01:42:26,927 --> 01:42:28,462 YOU CAN DELIVER MRNA OR GENE 2433 01:42:28,462 --> 01:42:31,965 EDITING TOOLS OR JUST, YOU KNOW, 2434 01:42:31,965 --> 01:42:34,568 LOTS OF DIFFERENT PAYLOADS AND 2435 01:42:34,568 --> 01:42:36,870 SIN BIO PEOPLE, YOU CAN PROBABLY 2436 01:42:36,870 --> 01:42:37,838 IMAGINE THIS. IT'S LESS 2437 01:42:37,838 --> 01:42:40,740 RESOURCE DEMANDING. IT'S LESS 2438 01:42:40,740 --> 01:42:41,608 COSTLY. TAKES LESS TIME. SO 2439 01:42:41,608 --> 01:42:44,411 THAT MAKES IT MORE EASILY 2440 01:42:44,411 --> 01:42:53,687 ACCESSIBLE TO MANY MORE 2441 01:42:53,687 --> 01:42:55,322 PATIENTS. SO HOW ARE YOU GOING 2442 01:42:55,322 --> 01:42:58,158 TO DELIVER THESE PAYLOADS? 2443 01:42:58,158 --> 01:42:58,792 THERE'S TWO DIFFERENT METHODS 2444 01:42:58,792 --> 01:43:01,761 USING VECTORS AND ASSOCIATED 2445 01:43:01,761 --> 01:43:03,330 VECTORS ARE THE ONES THAT ARE 2446 01:43:03,330 --> 01:43:04,798 COMMONLY BEING USED 2447 01:43:04,798 --> 01:43:07,300 PRECLINICALLY NOW AND THEN THE 2448 01:43:07,300 --> 01:43:10,604 OTHER MAIN TYPE IS SYNTHETIC 2449 01:43:10,604 --> 01:43:12,706 NANO CARRIERS AND THIS THESE CAN 2450 01:43:12,706 --> 01:43:15,809 BE LIPID NANOPARTICLES. 2451 01:43:15,809 --> 01:43:18,078 THEY CAN BEEN NANO VESICALS 2452 01:43:18,078 --> 01:43:21,248 THERE'S A VARIETY OF PARTICLES 2453 01:43:21,248 --> 01:43:30,090 THAT YOU CAN IMAGINE COULD 2454 01:43:30,090 --> 01:43:31,358 COMPLETE THIS GOAL IF TARGETED 2455 01:43:31,358 --> 01:43:34,094 TO THE CORRECT CELLS. SO HERE 2456 01:43:34,094 --> 01:43:36,997 ON THE BOTTOM LEFT IS A PAPER 2457 01:43:36,997 --> 01:43:40,066 FROM JENNIFER'S LAB. USING 2458 01:43:40,066 --> 01:43:43,403 ENVELOPE DELIVERY VEHICLES. AND 2459 01:43:43,403 --> 01:43:48,608 SO THOSE ARE MEMBRANE-LIKE 2460 01:43:48,608 --> 01:43:49,676 VEHICLES BUT THEY HAVE 2461 01:43:49,676 --> 01:43:50,877 ANTIBODIES ON THEIR SURFACE THAT 2462 01:43:50,877 --> 01:43:53,747 HELPS TARGET THEM SO IN THE 2463 01:43:53,747 --> 01:43:55,348 PROOF OF PRINCIPLE EXAMPLE, THEY 2464 01:43:55,348 --> 01:43:59,319 DID IN THIS VERY ELEGANT 2465 01:43:59,319 --> 01:44:03,356 ARTICLE, THEY TARGETED THE EDVS 2466 01:44:03,356 --> 01:44:06,026 TO T-CELLS USING ANTIBODIES AND 2467 01:44:06,026 --> 01:44:07,527 ONCE THEY GET IN, THEY ARE 2468 01:44:07,527 --> 01:44:11,298 DELIVERING CRISPR REAGENTS AND 2469 01:44:11,298 --> 01:44:17,337 THE ANTIGEN RECEPTOR TO CD 19 SO 2470 01:44:17,337 --> 01:44:21,942 THEY'RE ACTUALLY DISRUPTING THE 2471 01:44:21,942 --> 01:44:24,110 T-CELL RECEPTOR AND THE NEW 2472 01:44:24,110 --> 01:44:25,579 CHIMERIC RECEPTOR AND THE T-CELL 2473 01:44:25,579 --> 01:44:29,349 ON A T-CELL SURFACE ARE HOME TO 2474 01:44:29,349 --> 01:44:32,986 THE CD POSITIVE CANCER CELLS AND 2475 01:44:32,986 --> 01:44:36,389 KILL THEM. SO THIS IS ALL 2476 01:44:36,389 --> 01:44:38,358 WORKING, YOU KNOW, MAKING SENSE, 2477 01:44:38,358 --> 01:44:41,294 WORKING IN MICE, IT'S REALLY ON 2478 01:44:41,294 --> 01:44:43,129 THE CUSP OF BEING AVAILABLE FOR 2479 01:44:43,129 --> 01:44:45,832 PATIENTS. SO WE THINK THIS IS A 2480 01:44:45,832 --> 01:44:49,603 NICE TIME FOR THIS WORKSHOP. SO 2481 01:44:49,603 --> 01:44:51,805 THE GOALS ARE TO PRESENT THE 2482 01:44:51,805 --> 01:44:53,807 LATEST RESEARCH ON IN VIVO 2483 01:44:53,807 --> 01:44:55,508 ENGINEERING OF IMMUNE CELLS, 2484 01:44:55,508 --> 01:44:58,111 LOOK AT WHAT ARE THE GAPS. WHAT 2485 01:44:58,111 --> 01:45:00,580 ARE THE OPPORTUNITIES. WHAT ARE 2486 01:45:00,580 --> 01:45:04,484 THE FUTURE DIRECTIONS, THIS IS 2487 01:45:04,484 --> 01:45:05,752 AN EDUCATIONAL OPPORTUNITY FOR 2488 01:45:05,752 --> 01:45:09,990 ANYONE, YOU KNOW, IT'S 2489 01:45:09,990 --> 01:45:10,991 PREREGISTRATION. WE THINK IT'S 2490 01:45:10,991 --> 01:45:14,260 A TIMELY DISCUSSION ON THE 2491 01:45:14,260 --> 01:45:15,328 COMPARISONS BETWEEN EX VIVO AND 2492 01:45:15,328 --> 01:45:18,698 IN VIVO APPROACHES THE IN VIVO 2493 01:45:18,698 --> 01:45:19,366 APPROACHES ARE ALREADY ON GOING, 2494 01:45:19,366 --> 01:45:21,034 ALREADY WORKING WHAT DO WE NEED 2495 01:45:21,034 --> 01:45:22,569 TO DO IN THE EX VIVO FIELD TO 2496 01:45:22,569 --> 01:45:24,938 ACTUALLY BE ABLE TO OFFER THIS 2497 01:45:24,938 --> 01:45:27,307 TO PATIENTS NOW. AND THE 2498 01:45:27,307 --> 01:45:27,941 INFORMATION AND REGISTRATION 2499 01:45:27,941 --> 01:45:29,709 SITE IS LISTED IN THE MIDDLE OF 2500 01:45:29,709 --> 01:45:33,146 THE SLIDE THERE BUT IF YOU JUST 2501 01:45:33,146 --> 01:45:40,053 GOOGLE AND NCI EVENTS, ALMOST 2502 01:45:40,053 --> 01:45:42,022 ANYTHING, ADOPTIVE CELL THERAPY 2503 01:45:42,022 --> 01:45:43,556 THE SITE WILL COME UP AND THAT'S 2504 01:45:43,556 --> 01:45:44,791 WHERE YOU CAN REGISTER. BUT I 2505 01:45:44,791 --> 01:45:46,626 WANT TO JUST BRIEFLY GO THROUGH 2506 01:45:46,626 --> 01:45:48,628 THE FOUR SESSIONS. THAT WE'RE 2507 01:45:48,628 --> 01:45:52,832 GOING TO HAVE IN THE WORKSHOP. 2508 01:45:52,832 --> 01:45:57,437 I'M NOT GOING TO GO THROUGH ALL 2509 01:45:57,437 --> 01:45:59,372 OF THE TALKS BUT THE FIRST 2510 01:45:59,372 --> 01:46:01,307 SESSION IS ON THE DELIVERY 2511 01:46:01,307 --> 01:46:03,343 METHODS I MENTIONED THERE ARE 2512 01:46:03,343 --> 01:46:07,313 VIRAL DELIVERY METS AND THE 2513 01:46:07,313 --> 01:46:08,915 NANOTECHNOLOGY APPROACHES. 2514 01:46:08,915 --> 01:46:10,216 THE TALKS BASICALLY GIVE 2515 01:46:10,216 --> 01:46:11,418 EXAMPLES OF WHAT'S GOING ON IN 2516 01:46:11,418 --> 01:46:14,921 TERMS OF DIFFERENT METHODS OF 2517 01:46:14,921 --> 01:46:17,891 DELIVERY AND WHERE WE ARE WITH 2518 01:46:17,891 --> 01:46:19,993 THAT. THE SECOND SESSION 2519 01:46:19,993 --> 01:46:22,162 BECAUSE GENOME EDITING 2520 01:46:22,162 --> 01:46:25,498 TECHNOLOGY SUCH AS CRISPR ARE 2521 01:46:25,498 --> 01:46:28,268 GOING TO BE SO CRITICAL TO SOME 2522 01:46:28,268 --> 01:46:29,903 OF THESE DELIVERY METHODS WE'RE 2523 01:46:29,903 --> 01:46:33,907 HAVING A SEPARATE SESSION ON 2524 01:46:33,907 --> 01:46:37,610 CRISPR TO GO OVER WHAT ALL THE 2525 01:46:37,610 --> 01:46:39,679 UP-TO-DATE METHODS ARE, HOW THIS 2526 01:46:39,679 --> 01:46:43,783 CAN BE USED FOR INVIVO EDITING 2527 01:46:43,783 --> 01:46:49,589 AND ACTUALLY ONE TALK ON INVIVO 2528 01:46:49,589 --> 01:46:51,891 EPIGENOME EDITING IN THE THIRD 2529 01:46:51,891 --> 01:46:53,727 SESSION WE CALL UPON BEYOND 2530 01:46:53,727 --> 01:46:56,863 T-CELLS FOR REPROGRAMMING AND SO 2531 01:46:56,863 --> 01:46:58,098 THIS WILL BE DIFFERENT PAYLOADS 2532 01:46:58,098 --> 01:47:01,468 AND DIFFERENT KINDS OF CELLS. 2533 01:47:01,468 --> 01:47:02,736 SO DIFFERENT PEOPLE ARE LOOKING 2534 01:47:02,736 --> 01:47:06,906 AT NK CELLS, LOOKING AT 2535 01:47:06,906 --> 01:47:11,311 MACROPHAGES. AND EVEN DENDRITIC 2536 01:47:11,311 --> 01:47:13,246 CELLS AND I THINK THE FOURTH 2537 01:47:13,246 --> 01:47:15,315 SESSION WILL REALLY BRING 2538 01:47:15,315 --> 01:47:17,050 EVERYTHING TOGETHER TO TALK 2539 01:47:17,050 --> 01:47:18,284 ABOUT WHERE WE ARE IN TERMS OF 2540 01:47:18,284 --> 01:47:20,320 GETTING THESE THINGS INTO THE 2541 01:47:20,320 --> 01:47:23,790 CLINIC. AND SO OUR FIRST TALK 2542 01:47:23,790 --> 01:47:25,992 IS GOING TO BE FROM TOM 2543 01:47:25,992 --> 01:47:27,460 WHITEHEAD AND HE'S THE FATHER OF 2544 01:47:27,460 --> 01:47:29,295 EMILY WHITEHEAD I'M NOT SURE IF 2545 01:47:29,295 --> 01:47:32,966 YOU HEARD OF HER BUT SHE'S THE 2546 01:47:32,966 --> 01:47:33,767 FIRST PEDIATRIC PATIENT TO 2547 01:47:33,767 --> 01:47:38,838 RECEIVE CAR-T-CELL THERAPY AND 2548 01:47:38,838 --> 01:47:39,839 WOMEN'S HEALTH SHE WAS SEVEN 2549 01:47:39,839 --> 01:47:43,777 YEARS OLD AND KNEW SHE'S AN AS 2550 01:47:43,777 --> 01:47:45,178 UNDERGRADUATE AT THE UNIVERSITY 2551 01:47:45,178 --> 01:47:47,313 OF PENNSYLVANIA AT THE 2552 01:47:47,313 --> 01:47:49,382 INSTITUTION CONNECTED TO WHERE 2553 01:47:49,382 --> 01:47:51,818 SHE GOT HER CAR-T-CELL THERAPY 2554 01:47:51,818 --> 01:47:54,020 AND HER PARENTS START THIS HAD 2555 01:47:54,020 --> 01:47:55,755 FOUNDATION TO HELP OTHERS. 2556 01:47:55,755 --> 01:47:58,658 AND I HEARD HIM SPEAK HE GETS 2557 01:47:58,658 --> 01:48:02,395 TONS OF LETTERS AND E-MAILS FROM 2558 01:48:02,395 --> 01:48:05,999 PEOPLE ALL AROUND THE WORLD WHO 2559 01:48:05,999 --> 01:48:12,639 ARE DESPERATE TO HAVE THIS 2560 01:48:12,639 --> 01:48:13,907 THERAPY FOR THEIR CHILDREN. 2561 01:48:13,907 --> 01:48:16,309 HE'LL PROVIDE THIS SORT OF 2562 01:48:16,309 --> 01:48:18,111 CONTEXT FOR THE RATIONALE FOR 2563 01:48:18,111 --> 01:48:19,312 TRYING TO MOVE THIS FIELD 2564 01:48:19,312 --> 01:48:21,214 FORWARD AS QUICKLY AS POSSIBLE. 2565 01:48:21,214 --> 01:48:23,583 AND THEN THERE ARE THREE MAJOR 2566 01:48:23,583 --> 01:48:25,652 COMPANIES. WHO ARE TRYING TO 2567 01:48:25,652 --> 01:48:27,954 MOVE THESE INTO THE CLINIC. SO 2568 01:48:27,954 --> 01:48:30,990 THEY'RE EITHER CLOSE OR THEY'RE 2569 01:48:30,990 --> 01:48:35,829 THERE. THOSE ARE THE 2570 01:48:35,829 --> 01:48:40,934 THERAPEUTICS THAT WE'LL HAVE 2571 01:48:40,934 --> 01:48:42,368 REPRESENTATIVES FROM. WE'LL 2572 01:48:42,368 --> 01:48:46,773 HAVE A TALK FROM DARIA. THEY 2573 01:48:46,773 --> 01:48:48,675 HAD A SOLICITATION TO DEVELOP IN 2574 01:48:48,675 --> 01:48:50,877 VIVO CELL THERAPIES SO THAT'S A 2575 01:48:50,877 --> 01:48:51,878 REALLY INTERESTING PROGRAM THAT 2576 01:48:51,878 --> 01:48:54,113 SHE'LL TALK ABOUT. AND THEN 2577 01:48:54,113 --> 01:48:57,884 WE'LL HAVE PETER MARKS FROM THE 2578 01:48:57,884 --> 01:49:00,687 FDA TALK ABOUT REGULATORY 2579 01:49:00,687 --> 01:49:02,722 CONSIDERATIONS AND AT THE END OF 2580 01:49:02,722 --> 01:49:06,092 ALL THE SESSIONS WE'LL HAVE 2581 01:49:06,092 --> 01:49:09,329 PANEL DISCUSSIONS AND HOPEFULLY 2582 01:49:09,329 --> 01:49:12,932 REALLY TRY TO SYNERGIZE AND TALK 2583 01:49:12,932 --> 01:49:15,168 ABOUT HOW TO MOVE THE FIELD 2584 01:49:15,168 --> 01:49:16,035 FORWARD. SO THANK YOU FOR 2585 01:49:16,035 --> 01:49:18,471 HAVING ME HERE TO TALK ABOUT IT. 2586 01:49:18,471 --> 01:49:20,240 AGAIN, THERE'S THE REGISTRATION 2587 01:49:20,240 --> 01:49:23,309 WEBSITE. AND I'M HAPPY TO 2588 01:49:23,309 --> 01:49:30,083 ANSWER ANY QUESTIONS. 2589 01:49:30,083 --> 01:49:32,518 >> ANY QUESTIONS? GREAT. THANK 2590 01:49:32,518 --> 01:49:35,355 YOU VERY MUCH. 2591 01:49:35,355 --> 01:49:43,296 >> YOU'RE WELCOME. 2592 01:49:43,296 --> 01:49:45,365 >> OKAY, THANK YOU TO ALL THE 2593 01:49:45,365 --> 01:49:46,332 SPEAKERS TODAY FOR PRESENTING 2594 01:49:46,332 --> 01:49:49,535 WHAT THE NIH IS INTERESTED IN 2595 01:49:49,535 --> 01:49:53,039 AND TO DR. COHEN FOR WHAT THE 2596 01:49:53,039 --> 01:49:55,074 CHANGES IN THE REVIEW PROCESS. 2597 01:49:55,074 --> 01:49:56,476 SO WHAT I'D LIKE TO DO IS JUST 2598 01:49:56,476 --> 01:49:57,844 WRAP UP I THINK THIS HAS BEEN A 2599 01:49:57,844 --> 01:49:59,212 GREAT SERIES OF TALKS FROM 2600 01:49:59,212 --> 01:50:01,915 WEDNESDAY'S TRAINING SESSIONS TO 2601 01:50:01,915 --> 01:50:04,183 YESTERDAY'S TECHNICAL SESSION TO 2602 01:50:04,183 --> 01:50:05,318 TODAY'S OPPORTUNITY SESSION. 2603 01:50:05,318 --> 01:50:08,054 WHAT I WILL SAY IS THAT THESE 2604 01:50:08,054 --> 01:50:08,721 VIDEOS WILL BE AVAILABLE 2605 01:50:08,721 --> 01:50:10,990 SOMETIME IN THE NEXT WEEK OR SO, 2606 01:50:10,990 --> 01:50:13,393 ARCHIVED ON A VIDEO CAST AND 2607 01:50:13,393 --> 01:50:15,929 THEY'LL BE POSTED ON OUR 2608 01:50:15,929 --> 01:50:17,430 SYNTHETIC BIOLOGY CONSORTIUM 2609 01:50:17,430 --> 01:50:19,933 WEBSITE SO THAT'S ONE WEBSITE I 2610 01:50:19,933 --> 01:50:22,201 WOULD RECOMMEND THAT EVERYONE 2611 01:50:22,201 --> 01:50:23,836 BOOKMARKS BECAUSE WE'LL LINK TO 2612 01:50:23,836 --> 01:50:26,406 OTHER NIH FUNDING OPPORTUNITIES 2613 01:50:26,406 --> 01:50:29,375 ON THE WEBSITES. AGAIN, THANKS 2614 01:50:29,375 --> 01:50:33,947 TO THE NIH CONSORTIUM. THE 2615 01:50:33,947 --> 01:50:35,348 MEMBERS THAT HELPED WITH PUTTING 2616 01:50:35,348 --> 01:50:39,319 THIS ON, THE WORKSHOP STAFF OF 2617 01:50:39,319 --> 01:50:45,925 STRATEGIC RESULTS AND THE 2618 01:50:45,925 --> 01:50:47,093 NEUROSCIENCES FACILITY AND WITH 2619 01:50:47,093 --> 01:50:48,094 THAT I WOULD LIKE TO THANK 2620 01:50:48,094 --> 01:50:50,863 EVERYONE FOR THEIR ATTENDANCE 2621 01:50:50,863 --> 01:50:52,732 AND SAFE TRAVELS BACK. I THINK 2622 01:50:52,732 --> 01:50:54,100 I SAW IT SNOW EARLIER WHICH I'M 2623 01:50:54,100 --> 01:50:57,570 NOT USED TO. OKAY, THANK YOU, 2624 01:50:57,570 --> 01:50:59,038 EVERYONE. OH, ONE LAST THING IF 2625 01:50:59,038 --> 01:51:00,540 YOU HAVEN'T SIGNED OUR POSTER, 2626 01:51:00,540 --> 01:51:02,976 PLEASE SIGN OUR POSTER. THIS IS 2627 01:51:02,976 --> 01:51:06,112 OUR OLD TRADITION THAT WE'RE 2628 01:51:06,112 --> 01:51:16,489 TRYING TO BRING BACK.